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2.4.1	Conduction	abnormalities	Conduction	abnormalities	are	the	most	common	manifestations	of	CS	due	to	the	affinity	of	granulomas	 for	 the	atrioventricular	septum	and	 the	vulnerability	of	 the	conduction	system	to	granulomatous	infiltration	(111).	Yet	another	often	mentioned,	yet	probably	rare	mechanism	for	conduction	disturbances	is	granulomatous	infiltration	of	the	nodal	artery	causing	ischemia	of	the	conduction	system	(112).	Virtually	 any	 kind	 of	 conduction	 abnormality	 is	 possible	 in	 CS	 from	 bundle	 branch	blocks	 to	 AV-blocks	 of	 any	 degree	 (110).	 Different	 conduction	 abnormalities	 are	reported	in	42-65%	of	patients	(5,16,22,77,93,97-99,101,113,114).	Complete	AV-block,	present	 in	 15	 to	 45%	 in	 the	 larger	 studies,	 is	 the	 most	 frequent	 symptomatic	 first	manifestation	in	CS	(5,16,97,115).	AV-block	due	to	sarcoidosis	occurs	at	a	younger	age	compared	to	patients	with	AV-block	of	other	causes	(116).	In	a	Japanese	study,	clinically	or	histologically	verified	CS	was	diagnosed	in	11.2%	of	patients	manifesting	with	high-degree	AV-block	(117).	Bundle	branch	blocks	are	present	in	27-57%,	with	right	bundle	branch	block	(RBBB)	being	the	more	frequent	finding	(113,114).			
2.4.2	Arrhythmias	Active	 inflammation	 may	 lead	 to	 increased	 automaticity	 and	 fibrous	 granulomatous	scars,	promoting	re-entry	substrates	by	creating	slow	conduction	zones	in	myocardium.	Furthermore,	the	variable	involvement	of	LV	and/or	RV	is	a	characteristic	feature	of	CS.	The	 combination	 of	 these	 elements	 makes	 ventricular	 arrhythmias	 in	 CS	 not	 only	common,	 but	 also	 challenging	 to	 treat	 (98,118-120).	 Ventricular	 arrhythmias	 in	 CS	range	from	asymptomatic	ventricular	premature	beats	(VPBs)	to	ventricular	fibrillation	(VF).	As	in	other	types	of	structurally	abnormal	hearts,	the	VTs	usually	result	from	scar-induced	 re-entry	mechanisms,	with	 the	most	 common	mechanism	 likely	 to	be	macro-reentrant	 arrhythmias	 around	 granulomatous	 scars	 (121,122).	 The	 distinguishing	feature	in	CS	is	a	higher	prevalence	of	electrical	storm,	in	which	active	inflammation	can	play	 a	 significant	 role	 (123).	 An	 electrical	 storm	 (defined	 as	 ≥	 3	 appropriate	 ICD	therapies	in	24	hours)	occurred	in	14%	(16/112)	of	CS	patients	in	a	2.4-year	follow-up	after	 an	 ICD	 implantation	 (98).	 Characteristically,	 CS-associated	 VT	 is	 monomorphic	with	 either	 LBBB	 or	 RBBB	 morphology,	 but	 polymorphic	 VTs	 are	 also	 possible	(98,119,124,125).	 Electrophysiological	 studies	 have	 demonstrated	 that	 most	 VTs	originate	 from	confluent	regions	of	RV	and	LV	scarring	with	predilection	to	the	septal	and	 peritricuspid	 areas	 (122,126).	 One	 additional	 possible	 etiology	 for	 VTs	 in	 CS	 is	Purkinje	 fiber-related	 VT,	 due	 to	 conduction	 disturbances	 (118).	 In	 the	 study	 by	McArdle	et	al.	(127),	sustained	VTs	were	associated	with	signs	of	active	inflammation	by	PET,	 while	 Banba	 et	 al.	 (124)	 did	 not	 find	 a	 link	 between	 disease	 activity	 and	arrhythmias.	 In	 patients	 dying	 suddenly	 from	 CS,	 histologic	 lesions	 more	 often	contained	well-formed	granulomas	instead	of	early	inflammatory	cell	lesions	or	healed	collagen-rich	lesions	(87).	 28
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Variable	 ventricular	 tachyarrhythmia	 incidence	 numbers	 of	 11%	 to	 31%	 have	 been	previously	 reported	 based	 on	 autopsy	 and	 clinical	 follow-up	 studies	 in	 CS	(5,16,22,93,97,101).	Recently,	pacemaker	 follow-up	studies	have	yielded	more	precise	incidence	 numbers.	 In	 a	 rather	 selected	 CS	 population	 from	 an	 academic	 center	with	ICDs	implanted	either	for	secondary	prevention	(with	history	of	VT,	VF,	sudden	cardiac	arrest,	 or	 syncope	 of	 unknown	 etiology,	 n=16)	 or	 primary	 prevention	 (without	aforementioned	 history,	 n=29),	 the	 incidence	 of	 appropriate	 ICD	 therapies	 (shock	and/or	 anti-tachycardia	 pacing)	 was	 15%	 per	 year	 and	 there	 was	 no	 significant	difference	 in	 the	 incidence	 rate	 between	 the	 two	 groups	 (128).	 Two	 larger	 studies	presented	corresponding	ICD	therapy	rates	of	36.2%	(85/234)	and	32.1%	(36/112)	in	mean	follow-ups	of	4.2	years	(129)	and	2.4	years	(98).	 In	 these	two	series,	secondary	prevention	patients	had	higher	rates	compared	to	primary	prevention	patients.	Overall,	the	 frequency	 of	 appropriate	 ICD	 therapies	 and	 hence	 ventricular	 arrhythmias	 was	calculated	 to	 be	 annually	 9-15%	 (4),	 being	much	 higher	 than	 in	 landmark	 studies	 of	heart	failure	(88)3.	The	true	incidence	of	sudden	cardiac	death	in	CS	is	not	known,	but	currently	 up	 to	 25%	of	 patients	with	 CS	 are	 estimated	 to	 present	with	 sudden	 death	(16,17,88,113,130).	From	an	electrophysiologist’s	point	of	view,	CS	revealed	 to	be	 the	etiology	 in	 5-28%	 of	 patients	 referred	 to	 electrophysiological	 study	 and/or	 catheter	ablation	 due	 to	 monomorphic	 VT	 of	 unknown	 cause	 (121,126,131).	 CS	 derived	 VTs	were	inducible	in	electrophysiological	studies	in	virtually	all	patients	(119,121,132).	Given	 their	 diverse	 pathophysiology,	 ventricular	 arrhythmias	 may	 manifest	unexpectedly,	 though	 certain	 predisposing	 factors	 have	 been	 identified.	 Logically,	 LV	dysfunction	 was	 the	 strongest	 predictor	 of	 arrhythmias	 in	 all	 studies,	 but	 still	 a	significant	 number	 of	 patients	 with	 appropriate	 therapies	 had	 LV	 ejection	 fraction	(LVEF)	 of	 >35%	 (98,128,129).	 Besides	 reduced	 LVEF,	 male	 gender	 (129),	 history	 of	syncope	(129),	longer	follow-up	(128),	higher	prevalence	of	complete	heart	block	(128),	and	RV	dysfunction	(RVEF≤45%)	predicted	future	VT	events	(98).		A	few	studies	have	addressed	the	usefulness	of	programmed	ventricular	stimulation	in	identifying	 CS	 patients	 with	 a	 risk	 of	 VTs.	 	 Mehta	 et	 al.	 performed	 programmed	ventricular	 stimulation	 in	 76	 patients	 with	 biopsy-proven	 systemic	 sarcoidosis,	 with	evidence	of	CS	in	PET/CMR	but	without	cardiac	symptoms	(133).	Eight	out	of	76	(11%)	were	 inducible	 for	 VTs	 and	 received	 an	 ICD.	 	 Over	 a	median	 follow-up	 period	 of	 five	years,	two	out	of	eight	died	and	four	out	of	eight	had	appropriate	ICD	shocks,	compared	to	no	arrhythmic	events	in	the	non-inducible	patients.	Likewise,	in	a	study	of	Aizer	et	al.,	32	CS	patients	underwent	programmed	ventricular	stimulation	and	patients	with	either	spontaneous	 (n=6),	or	 inducible	 (n=6)	VT	received	an	 ICD	(134).	 In	a	 follow-up,	after	2.7	 years,	 five	 out	 if	 six	 patients	 with	 spontaneous	 VTs	 and	 four	 out	 of	 six	 patients	without	spontaneous	but	with	inducible	VTs	received	appropriate	ICD	therapies.	Thus,	stimulation	identified	patients	with	future	arrhythmic	events	and	no	arrhythmic	deaths	occurred	 in	 these	 patients	with	 either	 spontaneous	 or	 inducible	VT	when	 all	 of	 them	received	an	ICD.	However,	the	electrophysiological	study	was	not	fully	sensitive,	as	two	
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(10%)	 patients	 without	 spontaneous	 or	 inducible	 sustained	 ventricular	 arrhythmia	suffered	 sudden	death	or	 sustained	VT	on	 follow-up.	 Interestingly,	 in	another	 smaller	study	 of	 16	 patients,	 the	 inducibility	 of	 VT/VF	 did	 not	 predict	 future	 ICD	 therapies	(134).	Due	 to	 overlapping	 clinical	 presentation,	 patients	 first	 presenting	 with	 ventricular	arrhythmias	may	be	misdiagnosed	as	ARVC	and	may	even	 fulfill	 the	Task	Force	ARVC	criteria	(121,135-137).	The	distinguishing	features	in	this	respect	are	lack	of	conduction	abnormalities	and	positive	family	history	in	ARVC,	compared	with	more	frequent	septal	involvement	 and	 LV	 dysfunction	 in	 CS	 (138).	 The	 disruption	 of	 desmosomal	 proteins	may	be	a	potential	link	between	these	two	arrhythmogenic	diseases	(65).	Supraventricular	 arrhythmias	 occur	 in	 9-36%	 of	 CS	 patients	 (4,22,101,139-141).	 The	causes	 of	 atrial	 arrhythmias	 are	 diverse,	with	 direct	 atrial	 granulomatous	 infiltration	causing	abnormal	automaticity,	triggered	activity	and	re-entrant	circuits	as	speculated	mechanisms	 (4,123,140).	 Another	 possible	 cause	 for	 atrial	 arrhythmias	 is	 elevated	atrial	 pressure	 due	 to	 ventricular	 dysfunction	 or	 pulmonary	 hypertension	 (140,142).	Atrial	 fibrillation	 is	 the	most	 common	supraventricular	arrhythmia	 in	CS,	 followed	by	atrial	 tachycardia	 and	 atrial	 flutter	 (123,140).	 Left	 atrial	 enlargement	 was	 the	 only	variable	 found	 to	 be	 associated	 with	 supraventricular	 arrhythmias	 in	 CS	 (risk	 ratio,	6.12;	95%	CI,	2.19-17.11)	(137).	
	
2.4.3	Heart	failure	Granulomatous	 infiltration	 of	 the	 myocardium	 with	 the	 resulting	 inflammation	 and	fibrosis	can	lead	to	either	systolic	or	diastolic	dysfunction	or	a	combination	of	the	two.	Diffuse	 cardiac	 involvement	 leads	 to	 global	 dysfunction,	 whereas	 focal	 involvement	produces	 segmental	 hypokinesia	 and	 aneurysms	 independent	 of	 coronary	 circulation	zones	(143,144).	Congestive	heart	failure	with	reduced	LV	systolic	function	is	a	sign	of	a	widely	 advanced	 disease	 state	 (71).	 Besides	 extensive	 myocardial	 infiltration,	 pump	failure	may	result	from	right	ventricular	overload	caused	by	pulmonary	involvement	or	from	 atrioventricular	 valve	 regurgitation	 caused	 by	 papillary	 muscle	 involvement	(145).	Prior	 to	 current	 diagnostic	 methods,	 overt	 heart	 failure	 was	 a	 common	 first	manifestation	of	CS	with	reported	prevalence	varying	 from	25	to	75%	(22,71,97,116).	Today,	as	diagnosis	 is	made	at	earlier	stages,	around	13-18%	of	patients	have	systolic	dysfunction	 at	 diagnosis	 (93,146).	 CS	 is	 frequently	 misdiagnosed	 as	 DCM.	 In	 two	Japanese	studies	with	patients	undergoing	 left	ventriculoplasty	 for	suspected	DCM,	CS	was	 found	 in	3.6-7%	(14/384	and	8/110,	 respectively)	 (100,147).	 In	a	 third	 Japanese	study	 involving	 533	 patients	 with	 non-ischemic	 cardiomyopathy	 undergoing	 cardiac	resynchronization	 therapy	 (CRT),	 4.5%	 (25	 patients)	 had	 CS	 (148).	 The	 evolution	 of	LVEF	during	disease	course	is	highly	variable	and	data	on	its	natural	course	is	lacking.		
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2.4.4	Other	manifestations	Direct	 valve	 involvement	 in	CS	 is	 relatively	uncommon,	 but	 case	 reports	 involving	 all	four	 valves	 have	 been	 reported	 (110,149,150).	 In	 the	 study	 by	 Fleming	 et	 al.	 valve	lesions	were	reported	in	8.4%	of	patients	(22).	The	most	common	valve	dysfunction	in	CS	 is	 mitral	 regurgitation	 secondary	 to	 either	 papillary	 muscle	 infiltration	 or	 LV	dilatation	 (143,151).	 Symptomatic	 pericardial	 involvement	 is	 very	 rare,	 but	 mild	pericardial	 effusion	 has	 been	 reported	 in	 19%	 patients	 (22,152-154).	 Constrictive	pericarditis	as	a	manifestation	of	CS	has	also	been	reported	(155).	Clinical	 involvement	 of	 the	 coronary	 arteries	 is	 possible	 but	 rare	 in	 CS.	 Despite	 this,	granulomas	 have	 been	 detected	within	 atherosclerotic	 plaques	 and	within	 the	media	and	peri-arterial	 tissue	(156).	Thallium	perfusion	scans	have	shown	ischemic	 findings	in	 the	absence	of	 stenoses	 in	coronary	angiographies	 (157,158).	Microvascular	 spasm	has	 been	 speculated	 as	 a	 possible	 explanation	 for	 the	 ischemic	 findings	 (156,159).	Another	 mechanism	 could	 be	 sarcoid	 coronary	 vasculitis	 (160,161).	 ST-segment	elevation	 is	 a	 rare	 finding	 in	 CS	 and	 is	 considered	 to	 be	 due	 to	 the	 presence	 of	myocardial	 inflammation/fibrosis	 and	 abnormal	 wall	 motion,	 including	 ventricular	aneurysm.	 In	 some	 cases	 ST-elevations	 may	 be	 transient	 and	 may	 attenuate	 after	steroid	treatment	(162).	With	sarcoidosis	being	a	systemic	inflammatory	disease,	up	to	over	 half	 of	 all	 CS	 patients	 are	 reported	 to	 experience	 constitutional	 symptoms	 like	fatigue	(101,163).	Finally,	in	its	early	stages	with	minor	myocardial	involvement,	CS	can	be	a	clinically	fully	silent	disease.			
2.4.5	Isolated	cardiac	sarcoidosis	Sarcoidosis	 can	 manifest	 with	 solely	 cardiac	 symptoms.	 Previously,	 there	 was	 a	misunderstanding	that	the	heart	is	mostly	affected	in	widespread	systemic	sarcoidosis.	Yet,	already	in	the	early	autopsy	study	from	Roberts	et	al.,	 the	authors	concluded	that	most	patients	with	CS	have	little	or	no	clinical	evidence	of	dysfunction	of	extracardiac	organ	systems	(109).	Furthermore,	it	was	demonstrated	that	the	extent	of	extracardiac	sarcoidosis	did	not	differ	among	patients	with	mild,	severe	or	no	cardiac	disease	(17).	In	a	more	 recent	 autopsy	 study	 from	 the	U.S.,	 40%	of	25	CS	patients	did	not	have	gross	extracardiac	 involvement	 (87).	On	 the	contrary,	 in	a	 Japanese	autopsy	series	of	42	CS	patients,	 extracardiac	 sarcoidosis	 involvement	 was	 found	 in	 literally	 all	 patients,	involving	 lymph	nodes	 in	 100%,	 lungs	 in	 88%,	 liver	 in	 64%	and	 spleen	 in	 43%	 (16).	Thus,	 even	 in	 autopsy	 studies	 the	 reported	 frequency	 of	 extracardiac	 involvement	 is	highly	variable	and	clinical	 studies	are	even	more	prone	 to	differences,	depending	on	the	 precision	 of	 the	 examination.	 In	 a	 Finnish	 cohort	 of	 nine	 CS	 patients,	 eight	 had	clinically	 isolated	 CS	 and	 one	 developed	 lung	 manifestation	 later	 (119).	 Recently,	Blankstein	et	al.	reported	extracardiac	involvement	defined	as	abnormal	FDG	uptake	in	whole-body	 18F-FDG-PET	 in	 26%	 of	 71	 CS	 patients	 (108).	 In	 contrast,	 Tezuka	 et	 al.	found	 extracadiac	 involvement	 after	 work-up	 including	 chest-computed	 tomography,	
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whole-body	 18F-FDG-PET,	 ophthalmologic	 and	 dermatologic	 examinations	 in	 73%	(30/41)	of	CS	patients	(164).	Similarly,	 in	the	study	from	Kron	et	al.,	94.5%	of	235	CS	patients	 had	 clinically	 and/or	 histologically	 detected	 extracardiac	 sarcoidosis	 (99).	Although	 the	 differences	 in	 the	 proportion	 of	 patients	with	 extracardiac	 involvement	might	partially	result	from	differences	in	genetic	and	environmental	factors,	the	varying	extent	 of	 extracardiac	 work-up	 is	 the	 most	 probable	 explanation	 for	 the	 divergence	(16,49,99,164).	There	are	three	possible	clinical	scenarios	of	isolated	CS:	1)	sarcoid	lesions	appear	first	in	 the	 heart	 and	 involve	 other	 organs	 later	 in	 the	 course	 of	 the	 disease,	 2)	 a	 truly	isolated	cardiac	involvement	exists,	and	3)	sarcoid	lesions	are	present	in	other	organs	but	 are	 undetectable	 by	 standard	 examination	 methods	 (165).	 The	 critical	 issue	 in	isolated	 CS	 is	 the	 difficulty	 of	 its	 diagnosis,	 given	 the	 limited	 sensitivity	 of	 EMB	(2,21,165).	 As	 one	 example,	 isolated	 CS	 may	 present	 clinically	 as	 DCM	 and	distinguishing	them	can	be	problematic.	In	a	study	of	15	patients	with	CS	and	30	with	DCM,	both	with	LVEF	around	30%,	the	disjunctive	features	were	female	predominance	(73%	vs	20%),	high	incidence	of	AV-block	(67%	vs	0%),	RBBB	(57%	vs	17%),	abnormal	wall	thickness	(73%	vs	17%),	and	uneven	wall	motion	abnormalities	in	LV	angiography	(113).	 As	 an	 additional	 detail,	 sometimes	 the	 disease	 course	 of	 CS	 may	 mimic	postpartum	 cardiomyopathy,	 which	 has	 to	 be	 recalled	 in	 differential	 diagnostics	 in	pregnancy	and	postpartum	reckoning	that	CS	commonly	affects	young	females	(31).		
2.4.6	GCM		GCM	is	known	as	a	myocardial	disease	characterized	by	acute	onset,	progressive	heart	failure,	and	has	a	frequently	fatal	outcome	if	untreated.	In	the	two	largest,	multicenter	studies	 of	 63	 and	 73	 GCM	 patients	 from	 overlapping	 groups,	 64-75%	 of	 patients	presented	 with	 congestive	 heart	 failure	 (5,11).	 Other	 first	 manifestations	 in	 these	landmark	 studies	 were	 ventricular	 arrhythmias	 in	 14-32%,	 signs	 and	 symptoms	mimicking	acute	myocardial	infarction	in	6-19%	and	complete	heart	block	in	5-15%.	In	a	 later	 study	of	 the	 same	group,	presentation	with	heart	 failure	was	 less	 common	 (in	45%,	 five	 out	 of	 11)	 and	mean	 LVEF	 at	 baseline	 only	moderately	 reduced	 (44±18%)	(107).	 In	 two	 small	 cohorts	 of	 five	 and	 eight	 patients	 respectively,	 mean	 LVEF	 was	markedly	 reduced,	 37%	 at	 presentation	 (9,63).	 In	 a	 study	 addressing	 long-term	outcome,	during	the	mean	follow-up	of	5.5	years	starting	one	year	after	GCM	diagnosis,	50%	(13	out	of	26)	patients	had	new	or	worsening	episodes	of	heart	failure,	suggesting	disease	 recurrence	 (166).	 During	 the	 course	 of	 the	 disease,	 23-60%	 of	 the	 patients	develop	 ventricular	 arrhythmias	 that	 are	 often	 pleiotropic	 and	 can	 be	 refractory	 to	treatment	 (5,9,11,107,167).	 Follow-up	 ventricular	 arrhythmias	 occur	 primarily	 in	patients	who	initially	presented	with	ventricular	arrhythmias	(166).	AV-block	has	been	reported	 in	 combination	 with	 heart	 failure	 and	 VTs	 (5,9,11),	 but	 also	 as	 the	 sole	manifestation	 of	 GCM	 (8).	 As	 an	 additional	 detail,	 a	 distinct	 clinicopathologic	 entity	involving	only	 the	atria	and	entailing	a	more	 favorable	prognosis	 compared	 to	 classic	
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ventricular	 GCM	has	 been	 described	 (168).	 Finally,	 GCM	 can	 present	 in	 two	 different	forms;	 either	 as	 an	 isolated	myocardial	 disease	 or	more	 rarely	 together	with	 skeletal	muscle	involvement,	called	thymoma-associated	giant	cell	polymyositis	(66,169-171).	The	 presentation	 of	 GCM	 is	 highly	 variable.	 Its	 progression	 is	 often	 rapid,	 with	 time	from	symptoms	onset	to	hospital	admission	ranging	from	two	to	six	weeks	in	the	larger	series	(5,11,63).	Even	so,	the	manifestation	of	GCM	can	vary	widely	from	sudden	death	(27),	 to	a	more	indolent	course	with	mild	DCM	progressing	to	end-stage	in	nine	years	(9,37,172).	Ren	et	al.	described	three	cases	with	a	protracted	disease	course	with	time	from	active	myocarditis	episode	 to	 transplantation	or	death	being	5-10	years	without	immunosuppression	 (8).	 Recently,	 Maleszewski	 et	 al.	 reported	 prolonged	 survival	 of	over	 19	 years	 beyond	 initial	 diagnosis	 with	 immunosuppression	 (166).	 In	 a	 study	comparing	 GCM	 with	 CS,	 presentation	 with	 heart	 failure	 predicted	 GCM	 and	presentation	with	AV-block	or	more	than	nine	weeks	of	symptoms	were	in	favor	of	CS	(5).	Taken	together,	CS	and	GCM	may	present	with	similar	symptoms	and	differentiating	them	 on	 the	 basis	 of	 clinical	 symptoms	 is	 not	 possible	 (5,9).	 The	 distinctions	 in	histology	and	outcome	are	discussed	elsewhere	in	this	thesis.		
	
2.5	Diagnostics	of	CS	and	GCM	An	 unequivocal	 diagnosis	 of	 CS	 is	 based	 on	 a	 clinical	 presentation	 compatible	 with	myocardial	 disease	 associated	 with	 histology	 of	 non-caseating	 granulomatous	inflammation	in	heart	muscle.	A	probable	but	clinically	sufficient	diagnosis	comes	from	extracardiac	histology	of	sarcoidosis	combined	with	clinical	manifestations	and	cardiac	imaging	 indicative	 of	 myocardial	 involvement.	 In	 cases	 of	 clinically	 isolated	 cardiac	involvement,	 the	 diagnosis	 can	 be	 extremely	 difficult	 and	 rest	 on	 a	 high	 index	 of	suspicion.	 Still	 today,	 in	 57-100%	of	 patients	 undergoing	 transplantation	 due	 to	 end-stage	 heart	 failure,	 the	 diagnosis	 is	 missed	 until	 examination	 of	 the	 explanted	 heart	(82,84,173).	 The	 current	 guidelines	 of	 the	 American	 Thoracic	 Society/European	Respiratory	 Society	 recommend	 screening	 for	 asymptomatic	 CS	 in	 patients	 with	sarcoidosis	diagnosis	from	other	organs	(174).	Several	groups	have	published	stepwise	diagnostic	 algorithms	 to	 aid	 clinicians	 in	CS	diagnostics	 (4,28,165,175-177).	Figure	 5	presents	a	simple	recently	published	screening	strategy	(4).	
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Figure	 5.	 Suggested	 study	 algorithm	 of	 patients	 with	 biopsy-verified	 extracardiac	sarcoidosis.	Adapted	from	(4).		
	
2.5.1	Diagnostic	guidelines	and	recommendations	in	CS	In	Japan,	CS	has	long	been	a	target	of	research	and	the	Japanese	Ministry	of	Health	and	
Welfare	(JMHW)	published	guidelines	for	diagnosing	CS	 in	1993	(175),	Table	3.	Since	then,	 the	 JMHW	 criteria	 have	 been	 widely	 applied	 as	 the	 standard	 diagnostic	 tool	against	 which	 other	 diagnostic	 modalities	 have	 been	 compared.	 However,	 these	guidelines	are	not	properly	validated	for	either	clinical	or	research	applications	(13).	In	2006	the	guidelines	were	revised;	histological	confirmation	was	no	 longer	required	 in	“clinical	diagnosis”	group	and	LGE-CMR	was	included	as	a	minor	criterion	(178).	It	is	of	note	 that	 18F-FDG-PET	was	 still	 not	 included.	 It	 has	 become	 evident	 that	 the	 JMHW	guidelines	have	too	low	a	sensitivity	in	detecting	CS,	especially	its	early	manifestations	
Biopsy	proven	extra-cardiac	sarcoidosis	
Cardiac	history,	ECG,	Echocardiogram	
1)	Symptom(s)	positive	(signimicant	palpitations*/pre-syncope/syncope)	2)	Abnormal	ECG¶	3)	Abnormal	Echocardiogram	§	
One	or	more	of	1-3	
Advanced	cardiac	imaging	LGE-CMR	and/or	18F-FDG-PET	
None	of	1-3	
Negative	–>	Low	probability	of	cardiac	sarcoidosis	
*Palpitations	were	defined	as	“prominent	patient	complaint	lasting		>2	weeks”.	¶Abnormal	electrocardiogram	defined	as	complete	left	or	right	bundle	branch	block	and/or	presence	of	unexplained	pathological	Q	waves	in	two	or	more	leads	and/or	sustained	2nd	or	3rd	degree	AV-block	and/or	sustained	or	non-sustained	VT.	
§	Abnormal	echocardiogram	defined	as	LVEF	<40%	and/or	basal	septum	thinning	and/or	regional	wall	motion	abnormality.		
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(1,2).	 Merely	 the	 fact	 that	 JMHW	 guidelines	 emphasize	 abnormal	 electrocardiogram	(ECG)	results,	yet	even	in	patients	with	extensive	myocardial	lesions	in	autopsy,	the	pre-mortem	 ECG	may	 be	 normal	 in	 25%,	makes	 these	 guidelines	 too	 insensitive	 (17,91).	Recent	 advances	 in	 imaging	methods	 highlight	 this	 inaccuracy.	 As	 an	 example,	 in	 the	study	by	Patel	et	al.,	the	JMHW	criteria	found	only	52%	of	sarcoidosis	patients	with	LGE	in	CMR	(92).	 In	some	recent	studies,	patients	with	pulmonary	sarcoidosis	and	cardiac	abnormalities	 in	 LGE-CMR	 have	 been	 defined	 as	 having	 CS	 even	 without	 clear	 CS	symptoms	 (chest	 pain,	 palpitations	 or	 no	 cardiac	 symptoms	 at	 all),	 which	 is	 also	 a	somewhat	problematic	definition	(179).	
Table	3.	Guidelines	for	diagnosing	CS	from	the	Japanese	Ministry	of	Health	and	Welfare	1993	(175).	
1.	Histologic	diagnosis	group		CS	is	confirmed	when	histologic	analysis	of	operative	or	EMB	specimens	demonstrates	epithelioid	granuloma	without	caseating	granuloma.	
2.	Clinical	diagnosis	group	In	patients	with	a	histologic	diagnosis	of	 extracardiac	 sarcoidosis,	CS	is	suspected	when	item	(a)	and	one	or	more	of	items	(b)	through	(e)	are	present:	a) Complete	RBBB,	left	axis	deviation,	AV-block,	VT,	VPBs	(≥	Lown	2*),	or	abnormal	Q	or	ST-T	segment	change	on	the	ECG	or	ambulatory	ECG	b) Abnormal	wall	motion,	regional	wall	thinning	or	dilatation	of	the	LV	c) Perfusion	 defect	 by	 Thallium-201	 myocardial	 scintigraphy	 or	 abnormal	accumulation	by	gallium-67	or	technetium-99m	myocardial	scintigraphy	d) Abnormal	intracardiac	pressure,	low	cardiac	output,	or	abnormal	wall	motion	or	depressed		LVEF	e) Interstitial	 fibrosis	 or	 cellular	 infiltration	 over	 moderate	 grade,	 even	 if	 the	findings	are	nonspecific	
_____________________________________________________________________________________________________CS=	 cardiac	 sarcoidosis,	 EMB	 =	 endomyocardial	 biopsy,	 RBBB=	 right	 bundle	 branch	block,	AV-block=	atrioventricular	block,	VT=	ventricular	tachycardia,	VPB=	ventricular	premature	beat,	*30	or	more	VPBs	per	hour,	ECG=	electrocardiogram,	LV=	left	ventricle,	EF	=ejection	fraction.	In	 2014,	 an	 expert	 group	 of	 the	 Heart	 Rhythm	 Society	 published	 consensus	recommendations	 for	 diagnostic	 criteria,	 diagnostic	 pathways	 in	 different	 clinical	scenarios	 and	 risk	 stratification	 in	 CS	 Table	 4	 (4).	 In	 the	 same	 year,	 the	 World	Association	of	Sarcoidosis	and	Other	Granulomatous	Disorders	updated	an	instrument	based	 on	 expert	 consensus	 for	 assessing	 different	 organ	 involvement	 in	 sarcoidosis	(177).	 The	 tool	 classified	 organ	 involvement	 into	 three	 categories;	 highly	 probable	(>90%	 likelihood),	 probable	 (50-90%	 likelihood),	 and	 possible	 (<50%	 likelihood).	 In	clinical	studies,	considerably	variable	inclusion	criteria	for	CS	have	been	applied.	
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Table	 4.	 Expert	 consensus	 recommendations	 on	 criteria	 for	 the	 diagnosis	 of	 CS.	Adapted	from	(4).	1. Histological	diagnosis	from	myocardial	tissue	CS	 is	 diagnosed	 in	 the	 presence	 of	 non-caseating	 granuloma	 on	 histological	examination	of	myocardial	tissue	with	no	alternative	cause	identified	(including	negative	organismal	stains,	if	applicable).		2. Clinical	diagnosis	from	invasive	and	non-invasive	studies:	It	is	probable*	that	there	is	CS	if:	a) There	is	a	histological	diagnosis	of	extracardiac	sarcoidosis		
and		b) One	or	more	of	following	is	present	-	Steroid	+/-	immunosuppressant	responsive	cardiomyopathy	or	AV-block	-	Unexplained	reduced	LVEF	(<40%)	-	Unexplained	sustained	(spontaneous	or	induced)	VT	-	Mobitz	type	II	2nd	or	3rd	degree	AV-block	-	Patchy	uptake	on	dedicated	cardiac	PET	(in	a	pattern	consistent	with	CS)	-	Late	gadolinium	enhancement	on	CMR	(in	a	pattern	consistent	with	CS)	-	Positive	gallium	uptake	(in	a	pattern	consistent	with	CS)	
and	c) Other	causes	for	the	cardiac	manifestation(s)	have	been	reasonably	excluded		*	 In	 general,	 “probable	 involvement”	 is	 considered	 adequate	 to	 establish	 a	 clinical	diagnosis	of	CS.		
	
2.5.2	Diagnostic	examinations	and	procedures	
2.5.2.1	ECG	and	Holter	monitoring	According	to	Mehta	et	al.,	the	12-lead	ECG	has	a	high	specificity	of	up	to	97%,	but	low	sensitivity	in	detecting	CS	in	patients	with	systemic	sarcoidosis	(93).	In	a	cohort	of	112	biopsy-proven	pulmonary	sarcoidosis	patients	with	symptoms	suggestive	of	CS,	RBBB	was	 found	 in	23%	of	patients	with	cardiac	 involvement	by	modified	 JMHW	criteria	vs	only	in	7%	of	non-CS	patients	(114).	Likewise,	there	was	a	much	higher	prevalence	of	fragmented	 QRS	 complex	 with	 cardiac	 involvement	 (75%	 vs	 34%)	 (146).	 Other	 ECG	findings	 associated	with	CS	 are	 any	degree	 of	AV-block,	 frequent	 atrial	 or	 ventricular	ectopic	 beats,	 and	 pathologic	 Q-wave	 or	 ST-T	 changes	 indicating	 local	 myocardial	infiltration	 (123).	 More	 delicate	 ECG	 tools,	 such	 as	 microvolt	 T	 wave	 alternans	 and	signal-averaged	 ECG,	 are	 more	 sensitive,	 with	 56-75%	 and	 79-96%	 positive	 and	negative	 predictive	 values	 in	 CS	 diagnosed	 by	 JMHW`s	 early	 or	 revised	 criteria	(146,180).	
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In	 studies	 focusing	 on	 screening	 sarcoidosis	 patients	 for	 cardiac	 involvement,	 Holter	monitoring	has	shown	abnormalities	in	50-67%	of	CS	patients	(diagnosed	by	early-	or	revised-,	 or	 modified	 to	 include	 LGE-CMR,	 JMHW	 criteria)	 with	 specificities	 ranging	from	21	to	97%	(93,125,181).	Nevertheless,	the	abnormalities	observed	are	nonspecific	including	VPBs	and	non-sustained	VTs.	Suzuki	et	al.	detected	≥	100	VPBs	in	67%	(8/12)	of	CS	patients,	8%	(2/26)	of	sarcoidosis	patients,	and	in	5%	(3/58)	of	healthy	controls	(181).	 The	 sensitivities	 and	 specificities	 of	 individual	 tests	 in	 three	 studies	 are	presented	in	Table	5.	
Table	5.	Sensitivities	and	specificities	of	diagnostic	studies	and	findings	in	CS.	Adapted	from	(93,125,146).	_____________________________________________________________________________________________	Abnormality	at	baseline	 	 Sensitivity	(%)	 Specificity	(%)			ECG	 	 	 	 	 8	-	26	 	 	 64	-	97		Signal-averaged	ECG		 		 28	–	52	 	 80	-	82	(any	abnormal	domain)		Holter		 	 	 	 50	–	89	 	 21	–	97		EP	study	 	 	 	 40	 	 	 71	_____________________________________________________________________________________________	CS=	cardiac	sarcoidosis,	ECG	=	electrocardiogram,	EP	=electrophysiologic	
	
	
2.5.2.2	Echocardiography	Given	 its	 wide	 availability	 and	 noninvasiveness,	 two-dimensional	 transthoracic	echocardiography	 is	 the	primary	 imaging	screening	 tool	 for	CS,	but	 the	results	can	be	normal	 in	 over	 two-thirds	 of	 patients	 at	 diagnosis	 (93,182).	 More	 specifically,	echocardiography	 commonly	 fails	 to	 detect	 early,	 mild	 or	 localized	 disease	 (1).	Echocardiogaphic	 abnormalities	 are	 nonspecific,	 with	 LV	 systolic	 and	 diastolic	dysfunction,	 wall	 motion	 abnormalities	 in	 a	 non-coronary	 distribution,	 and	 septal	abnormalities	 as	 the	most	 common	 findings	 (93,113,183).	 Septal	 abnormalities,	 both	thickening	due	to	infiltration	or	edema	and	thinning	due	to	scarring,	are	characteristic	of	CS	and	constitute	one	of	the	strongest	predictors	of	cardiac	involvement	in	patients	with	systemic	sarcoidosis	(90)	(Figure	6).		
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Figure	 6.	 Echocardiographic	 image	 of	 CS	 with	 basal	 thinning.	 IVS=interventricular	septum,	 A=	 point	 located	 10mm	 from	 the	 aortic	 annulus,	 i.e.	 basal	 IVS,	 B=	 IVS	 at	 the	standard	level	of	the	mitral	valve	leaflet	tips,	Ao=aorta,	LA=left	atrium,	LV=left	ventricle.	Adapted	from	(184).	Several	studies	examining	patients	with	pulmonary	sarcoidosis	have	demonstrated	that	diastolic	 dysfunction	 and	 subnormal	 systolic	 function	 (evidenced	 by	 tissue	 doppler	measurements,	 isovolumic	 acceleration	 etc.)	 are	 more	 common	 compared	 to	 healthy	controls	 (163,182,185-188).	 These	 findings	 can	 be	 related	 to	 subclinical	 myocardial	involvement	 but	 the	 abnormalities	 are	 subtle	 and	 cannot	 usually	 be	 detected	 by	traditional	 echocardiographic	 methods	 (189).	 As	 the	 conventional	 two-dimensional	echocardiography	 lacks	 sensitivity	 to	 evaluate	 CS,	 new	 more	 sensitive	 methods	 are	needed	 (190).	 Recently,	 speckle-tracking	 imaging	 which	 assesses	 the	 intrinsic	deformation	(strain)	of	the	myocardium,	has	shown	promise	in	this	respect	(80).	 	 In	a	study	 of	 39	 patients,	 3-D	 speckle-tracking	 radial	 strain	 showed	 good	 potential	 to	distinguish	CS	(diagnosed	by	revised	JMHW	criteria)	from	DCM	(191).	Furthermore,	in	a	study	 of	 96	 biopsy-proven	 systemic	 sarcoidosis	 patients	 without	 abnormalities	 in	conventional	 echocardiography,	 the	 LV	 global	 longitudinal	 strains	 were	 lower	compared	 to	 healthy	 controls	 (192).	 Finally,	 in	 a	 study	 of	 100	 systemic	 sarcoidosis	patients	and	100	healthy	controls,	the	average	global	longnitunidal	strain	was	lower	in	sarcoidosis	and	also	a	prognostic	marker	for	future	adverse	cardiac	events	(80).	Echocardiography	has	important	prognostic	value,	as	LV	dysfunction	and	dilatation	are	strong	 prognostic	 markers	 for	 future	 adverse	 cardiac	 events	 (80,97).	 Finally,	echocardiography	 is	 the	 primary	 follow-up	 tool	 for	 assessing	 the	 development	 of	 LV	dysfunction.			
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2.5.2.3	LGE-CMR	LGE-CMR	has	become	the	preferred	imaging	modality	 in	the	diagnosis	of	CS	(1,77,90).		CMR	offers	both	structural	and	functional	 information	without	radiation	exposure	(1).	Even	minor	 areas	 of	 myocardial	 damage	 can	 cause	 LGE	 at	 CMR,	 which	 thus	 enables	early	diagnosis	prior	to	LV	deterioration	(1).	The	structural	abnormalities	encountered	in	CS	include	local	wall	motion	and	thickness	alterations	that	predominantly	involve	the	septum	and	may	sometimes	result	 in	aneurysm	formation	(164,165)	(Figure	 7).	CMR	also	aids	the	precise	assessment	of	LV	function	and	chamber	sizes.	In	CS	diagnostics,	the	sensitivity	and	specificity	of	LGE-CMR	compared	to	moderated	JMHW	guidelines	were	75-100%	and	77-92%,	with	positive	and	negative	predictive	values	of	55%	and	100%,	respectively	 (164,193-195).	 In	 a	 cohort	 of	 115	 CS	 patients	 (with	 cardiac	 biopsy	confirmation	or	extracardiac	biopsy	confirmation	and	electrophysiological	disturbances	compatible	 with	 CS),	 LGE-CMR	 findings	 were	 normal	 in	 14%	 and	 the	 septum	 was	commonly	affected	(129).		
Figure	7.	Short	axis	and	four	chamber	CMR	image	of	CS	with	basal	septal	thinning	and	myocardial	 late	gadolinium	enhancement.	(With	permission	from	Dr.	Miia	Holmström,	HUS	Medical	Imaging	Center,	Radiology,	University	of	Helsinki	and	Helsinki	University	Hospital).		The	 physiological	 mechanism	 of	 myocardial	 LGE	 is	 as	 follows.	 The	 contrast	 agent,	gadolinium	chelate,	 is	a	biologically	 inert	 tracer	 that	distributes	 freely	 to	extracellular	space	 but	 does	 not	 cross	 intact	 cell	 membranes	 (196).	 In	 damaged	myocardium,	 the	combination	 of	 increased	 extracellular	 volume	 due	 to	 edema	 and	 slower	 washout	kinetics	results	in	an	accumulation	of	the	tracer	seen	as	gadolinium	enhancement	(196).	LGE	 imaged	 10-15	 minutes	 after	 contrast	 injection	 is	 the	 cornerstone	 finding	 in	myocarditis	 such	 as	 CS,	 visualizing	 myocyte	 necrosis	 and	 fibrosis	 (197).	 The	 most	typical	LGE	pattern	in	CS	consists	of	multiple,	patchy	mid-myocardial	lesions	in	a	non-
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coronary	 (i.e.,	 sparing	 the	 endocardium	and	 localizing	 independently	 of	 any	 coronary	circulation	area)	distribution	with	septal	and	RV	 involvement	 (91,96).	Yet,	no	specific	pattern	of	LGE	is	pathognomonic	for	CS	(4,195).	Even	subendocardial	enhancement	in	a	coronary	 distribution	 resembling	 ischaemic	 heart	 disease	 has	 rarely	 been	 observed	(90).	It	is	recommended	that	the	CMR	studies	be	interpreted	by	a	specialized	radiologist	and	integrated	with	the	clinical	data	(4).		While	LGE	imaging	can	help	in	distinguishing	patterns	of	myocyte	necrosis	and	fibrosis	from	 ischemic	 injury,	 T2-weighted	 and	 early	 gadolinium	 enhancement	 imaging	(measured	 rapidly	 after	 contrast)	 indicate	 other	 inflammatory	 processes	 such	 as	edema,	 capillary	 leakage	and	hyperemia	 (198).	Active	 sarcoidosis	 lesions	 in	 the	heart	muscle	 are	 characterized	 by	 focal	 wall	 thickening	 due	 to	 infiltration	 and	 edema,	combined	with	wall	motion	 abnormalities,	 increased	 signal	 intensity	 on	 T2-weighted	images,	 and	 early	 gadolinium	 enhancement	 (94,193).	 In	 the	 chronic	 phase,	 wall	thinning	and	delayed	gadolinium	enhancement	are	seen	as	signs	of	scarring	and	fibrosis	(199,200).	 In	 reality,	 these	 two	 phases	 commonly	 overlap	 (145).	 Despite	 its	 high	sensitivity,	 CMR	may	miss	 early	 inflammation	 and	differentiating	 active	 inflammation	from	fibrosis	can	be	problematic	(1,198).	In	addition	to	its	diagnostic	utility,	contrast	CMR	is	a	potent	risk	stratification	tool,	with	increasing	evidence	 from	several	studies	showing	that	 the	presence	and	magnitude	of	LGE	 predict	 future	 adverse	 cardiac	 events	 in	 patients	 with	 systemic	 sarcoidosis	(91,95,96,201)	 and	 in	 patients	 with	 CS	 (202-204).	 Despite	 this,	 one	 recent	 study	involving	mostly	lung	sarcoidosis	patients,	all	without	cardiac	symptoms	and	preserved	LVEF,	 suggested	 the	 contrary	 as	 there	 was	 no	 difference	 in	 cardiac	 events	 in	 LGE	positive	 and	 negative	 groups	 (90).	 Transmural	 LGE	 lesions	 and	 a	 higher	 number	 of	affected	segments	are	associated	with	larger	ventricles	and	lower	LV	ejection	fractions	(96,196,205).	Furthermore,	LGE-CMR	has	been	shown	to	be	useful	in	the	assessment	of	steroid	response	and	targeting	EMB	(1,95,203,206).	As	 CMR	 studies	 are	 booming	 and	 new,	 even	 more	 sensitive	 methods	 such	 as	multicontrast	 late-enhancement	 are	 developed	 (207),	 more	 sarcoidosis	 patients	without	cardiac	symptoms	but	with	positive	CMR	findings	are	likely	to	be	found.	There	is	no	consensus	on	the	treatment	strategy	of	these	patients	(197).		
2.5.2.4	18F-FDG-PET	18F-FDG-PET	is	another	advanced	imaging	method	used	in	the	diagnosis	and	follow-up	of	 CS.	 18F-FDG	 imaging	 is	 based	 on	 the	 fact	 that	 inflammatory	 cells,	 especially	macrophages,	use	glucose	in	their	metabolism.	18F-FDG	is	a	glucose	analog,	which	after	being	 absorbed	 phosphorylates	 and	 thus	 cannot	 be	 released	 from	 the	 cells.	 Under	aerobic	 circumstances,	 healthy	 myocardium	 utilizes	 mainly	 free	 fatty	 acids	 in	 its	metabolism	 (145).	 	 As	 up-regulation	 of	 glucose	 metabolism	 occurs	 at	 sites	 of	
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macrophage-mediated	 inflammation,	 accumulation	 of	 18F-FDG	 suggests	 an	 active	inflammatory	 process	 (208-210).	 18F-FDG-PET	 study	 is	 usually	 combined	 with	myocardial	perfusion	scan	to	detect	associated	scarring	(145,211).	 In	theory,	 the	18F-FDG-PET	findings	can	be	divided	into	three	phases	according	to	the	disease	activity.	In	the	 early	 inflammatory	 stage,	 focal	 or	patchy	FDG	accumulation	prevails.	 In	 the	more	advanced	stage	a	 typical	 finding	 is	a	 “mismatch”	or	 “hot	spot”	with	FDG	accumulation	superimposed	upon	a	perfusion	defect.	At	a	 late	stage	of	CS,	with	permanent	scarring	but	without	ongoing	inflammation,	only	a	perfusion	defect	is	detected	(145).	The	advantage	of	18F-FDG-PET	in	diagnostics	of	CS	 is	 its	high	sensitivity,	being	100%	compared	to	JMHW	1993	guidelines	in	many	studies	(209,212).	A	systematic	review	of	seven	 studies	 that	 evaluated	 the	 accuracy	 of	 18F-FGD-PET	with	 JMHW	 1993	 criteria	yielded	 89%	 sensitivity	 (208).	 The	 specificity	 of	 18F-FDG-PET	 is	 lower,	 ranging	 from	38.5%	to	90%	and	being	78%	 in	 the	pooled	analysis	defined	by	 the	 JMHW	guidelines	(193,208,212,213).	 A	 speculated	 explanation	 for	 this	 might	 be	 that	 18F-FDG	 depicts	early-stage	 sarcoid	 lesions	 before	 patients	 meet	 the	 diagnostic	 criteria	 (193).	 Many	studies	 have	 used	 qualitative	 visual	 analysis	 of	 FDG	 uptake	 in	 the	 heart	 muscle.	Recently,	the	introduction	of	quantitative	assessment	using	standardized	uptake	values	and	FDG	volume-intensity	analysis	has	increased	the	accuracy	of	18F-FDG-PET,	thereby	improving	its	diagnostic	and	prognostic	value	(210,213,214).	In	 addition	 to	 its	 diagnostic	 utility	 in	 CS	 detection,	 18F-FDG-PET	 provides	 functional	information	 of	 inflammatory	 activity	 and	 can	 thus	 help	 evaluate	 disease	 activity	 and	treatment	response	(211-215).	Like	CMR,	18F-FDG-PET	 imaging	also	predicts	adverse	cardiac	 events	 (108,213)	 with	 a	 mismatch	 pattern	 (see	 above)	 and	 right	 ventricular	involvement	being	particularly	strong	signals	of	high	arrhythmia	risk	(213).	Yet	another	benefit	of	18F-FDG-PET	 imaging	 is	 the	possibility	 to	detect	extracardiac	 inflammation	and	 thereby	 targets	 for	 biopsies	 to	 verify	 sarcoidosis	 histology,	 most	 notably	mediastinal	lymph	node	biopsies	(1,213,216)	(Figure	8).										
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Figure	8.	18-F-FDG-PET	whole-body	images.	18-F-FDG	uptake	in	mediastinal	and	hilar	lymph	nodes	and	lungs	(Left	panel)	and	no	abnormal	18-F-FDG	accumulation	after	10	months	of	treatment	(Right	panel).	Adapted	from	(216).		A	 proper	 technical	 imaging	 protocol	 is	 of	 primary	 importance	 in	 acquiring	representative	 diagnostic	 data	 from	 18F-FDG-PET	 (193,210).	 Since	 normal	 myocytes	also	 utilize	 glucose	 in	 metabolism,	 it	 is	 necessary	 to	 suppress	 the	 physiological	 FDG	uptake	 through	 a	 high-fat/low-carbohydrate	 diet,	 overnight	 fasting	 and/or	administration	 of	 unfractioned	 heparin	 (to	 stimulate	 lipoprotein	 lipase	 which	hydrolyzes	triglycerides	to	free	fatty	acids	and	glycerol)	(209,210,212,217).	Finally,	18F-FDG-PET	and	LGE-CMR	can	be	utilized	as	complementary	imaging	methods	(193).	As	discussed,	18F-FDG-PET	is	more	sensitive	and	serves	better	at	assessing	early	inflammatory	 phase	whereas	 CMR	 in	 detecting	 even	 small	 areas	 of	 scars	 (1,26).	 The	sensitivities	and	specificities	of	different	imaging	modalities	vary,	partly	depending	on	which	CS	diagnostic	criteria	are	applied	(Table	6).					
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Table	6.	Approximated	sensitivities	and	specificities	of	imaging	modalities	for	the	detection	of	CS.	Adapted	from	(110).	_____________________________________________________________________________________________	Imaging	modality	 	 Sensitivity	 	 	 Specificity	_____________________________________________________________________________________________		Echocardiography	 	 Low	 	 	 	 Low		TI-201	or	Tc-99m		 	 Moderate	 	 	 Moderate	scintigraphy	 	 	 		Ga-67	scintigraphy	 	 Low	 	 	 	 High		18F-FDG-PET		 	 High		 	 	 	 Moderate	to	high		LGE-CMR	 	 	 Moderate	to	high	 	 High	_____________________________________________________________________________________________	CS=	cardiac	sarcoidosis,	TI-201=	thallium-201,	Tc-99m=	technetium-99m,	Ga-67=	gallium-67,	18F-FDG-PET=	18F-fluorodeoxyglucose	positron	emission	tomography,	LGE-CMR=	late	gadolinium	enhancement	cardiac	magnetic	resonance	imaging.			
2.5.2.5	Other	imaging	studies	in	CS	Various	 radionuclides,	 including	 thallium	 (TI-201),	 technetium-99m	 (Tc-99m)	 and	gallium-67	 (Ga-67)	 have	 been	 used	 in	 myocardial	 scintigraphies	 to	 evaluate	 CS	(1,158,218,219).	 The	 typical	 abnormality	 in	 thallium-201	 and	 technetium-99m	myocardial	 perfusion	 imaging	 is	 “reverse	 distribution”,	 i.e.,	 the	 presence	 of	 a	 focal	perfusion	 defect	 at	 rest	 that	 decreases	 or	 disappears	 under	 stress	 (220).	 The	hypothesized	 explanation	 for	 this	 is	 focal	 reversible	 vasoconstriction	 at	 rest	 in	arterioles	 adjacent	 to	 granulomas	 (1).	 Gallium-67-citrate	 is	 a	 radionuclide	 used	 for	imaging	inflammation	that	was	previously	widely	utilized	in	lung	sarcoidosis	and	in	the	detection	 of	 myocardial	 involvement	 and	 response	 to	 corticosteroids	 (221).	 Positive	gallium-67	 uptake	 is	 still	 included	 in	 the	 revised	 JMHW	 guidelines	 (178).	 Gallium-67	locates	 inflammatory	 areas	 of	myocardium	with	 high	 specificity	 (221,222).	 However,	the	 reported	 sensitivity	 is	 lower	 and	 gallium-67	 may	 miss	 fibrosis	 and	 dormant	 CS	(219,223).	Where	 available,	 18F-FDG-PET	 and	LGE-CMR	have	 replaced	 the	use	 of	 the	other	radionuclide	imaging	studies	(1).		Thoracic	 computed	 tomography	 can	 identify	 mediastinal	 lymphadenopathy	 and	 thus	help	 to	 differentiate	 CS	 from	DCM.	 Otsuka	 et	 al.	 reported	 that	 88%	 (7/8)	 of	 patients	later	 diagnosed	 with	 CS,	 compared	 to	 5%	 (1/20)	 of	 age-matched	 patients	 with	idiopathic	 DCM,	 exhibited	 significant	 mediastinal	 lymph	 node	 swelling	 at	 computed	
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chest	 tomography	 (100).	 It	 is	 notable	 that,	 conventional	 chest	 X-rays	 did	 not	 show	lymphadenopathy	 in	 any	 of	 the	 patients.	 Further,	 computed	 tomography	 can	 help	 to	reveal	sarcoid	pulmonary	and	mediastinal	involvement	and	to	exclude	coronary	artery	disease	in	young	patients	with	low	pretest	probability	(4).	
2.5.2.6	Cardiac	imaging	in	GCM	In	 acute	 GCM,	 a	 typical	 finding	 in	 echocardiography	 is	 reduced	 LVEF	 together	 with	normal	 LV	 dimensions,	 which	 progresses	 to	 further	 LVEF	 deterioration	 and	 LV	dilatation,	 sometimes	 over	 a	 matter	 of	 days	 (224,225).	 Other	 echocardiographic	abnormalities	 in	 GCM	 may	 include	 aneurysms	 and	 wall	 thickness	 abnormalities,	particularly	thickening	caused	by	extensive	inflammatory	cell	infiltrate	(226,227).	Data	on	LGE-CMR	 in	GCM	 is	 very	 limited	because	 the	 largest	GCM	studies	were	 conducted	prior	 to	 the	 golden	 age	 of	 CMR,	 and	many	 patients	 are	 too	 unstable	 to	 undergo	 the	imaging	in	the	acute	phase	(26).	In	case	reports	of	severe	GCM,	CMR	has	shown	multiple	myocardial	 LGE	 areas	 in	 different	 myocardial	 layers,	 but	 the	 findings	 only	 partially	correlated	with	histological	examinations	at	autopsy	or	of	explanted	heart	(228,229).	In	a	 population	 of	 86	 patients	 with	 suspected	 non-ischemic	 cardiomyopathy,	 more	extensive	 LGE	 predicted	 CS	 and	 GCM	 (230).	 Finally,	 CMR	 is	 a	 widely	 studied	 and	established	imaging	method	in	myocarditis,	involving	largely	the	same	pathophysiologic	mechanisms	 including	 edema,	 hyperemia,	 capillary	 leakage,	 necrosis	 and	 fibrosis	 as	GCM	(231-233).	The	data	on	18F-FDG-PET	in	GCM	is	extremely	limited	(230).		
2.5.2.7	Diagnostics	biopsies	A	definite	 diagnosis	 of	 CS	 and	GCM	 requires	 a	 histologic	 confirmation	 from	 the	 heart	(2,4).	The	histological	hallmark	of	sarcoidosis	is	a	non-caseating	granuloma,	as	opposed	to	caseating	granulomas	in	tuberculosis	(5).	The	sarcoid	granulomas	are	histologically	distinct	 from	 interstitial	 rheumatic	 granulomas	 and	 vascular	 lesions	 in	 Wegener`s	granulomatosis	 (27).	Furthermore,	other	 causes	of	 granulomatous	 infiltration	need	 to	be	 excluded	 on	 special	 stains	 (tuberculosis	 on	 Ziehl-Neelsen	 and	 fungal	 infections	 on	Gomorri	methenamine	 silver).	 Sarcoid	 granuloma	 is	 a	 nodus	 containing	mononuclear	phagocytes	(macrophages,	epithelioid	cells	and	giant	cells)	in	the	center,	surrounded	by	T-lymphocytes,	 plasma	 cells	 and	mast	 cells	 and	 circulated	 by	 a	 fibrous	 ring	 (3).	 The	histologic	criteria	 for	GCM	on	the	other	hand,	requires	the	presence	of	multinucleated	giant	 cells,	 myocyte	 necrosis	 and	 lymphocytes	 in	 the	 absence	 of	 well-formed	granulomas,	 although	 sporadic,	 partial	 granulomas	 may	 be	 observed	 (10).	 Besides	necrosis,	 eosinophils	 are	 more	 common	 in	 GCM,	 while	 fibrosis,	 especially	 when	widespread	 and	 well-organized,	 strongly	 favors	 the	 diagnosis	 of	 CS	 (5,10,105).	Disregarding	the	sometimes	problematic	differential	diagnostics	between	CS	and	GCM,	EMB	is	highly	specific	in	these	diseases	(10).		In	 young	 or	 middle-aged	 patients	 with	 2nd	 or	 3rd	 degree	 AV-block,	 new-onset	 heart	failure	 or	 ventricular	 arrhythmias	 without	 ischemic	 heart	 disease,	 the	 current	
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guidelines	 recommend	 EMB	 (4,231,234).	 EMB	 is	 a	 class	 IB	 recommendation	(recommended	 with	 intermediate	 evidence	 of	 usefulness)	 in	 new-onset	 (<2	 weeks)	heart	failure	with	hemodynamic	compromise	(234).	The	same	recommendation	applies	for	 heart	 failure	 of	 two	weeks	 to	 three	months	 in	 duration	with	 dilated	 LV	 and	 new	ventricular	arrhythmias,	or	2nd	or	3rd	degree	AV-block,	or	failure	to	respond	to	normal	care	within	one	 to	 two	weeks	 (234).	 Furthermore,	 EMB	 is	 a	 class	 II	 recommendation	(may	 be	 considered	 with	 conflicting	 evidence)	 in	 heart	 failure	 of	 >3	 months	 or	unexplained	ventricular	arrhythmias	(231,234).	These	recommendations	are	based	on	incremental	 diagnostic,	 prognostic	 and	 therapeutic	 value,	 which	 histological	confirmation	of	CS,	GCM,	eosinophilic	or	other	treatable	myocarditis	signals	(86,234).			Nevertheless,	 due	 to	 the	 heterogeneous,	 patchy	 distribution	 of	 the	 microscopic	granulomas	 in	 myocardium,	 the	 diagnostic	 yield	 of	 EMB	 in	 CS	 is	 poor.	 Sarcoidosis	classically	 involves	 the	 base	 of	 the	 heart,	 leaving	 standard	mid-ventricular	 and	 apical	biopsies	unrevealing	(235).	Different	studies	have	demonstrated	EMB	sensitivity	of	15-30%	in	CS	(2,21,86,91).	The	histologic	diagnostic	rate	 is	dependent	on	the	stage	of	CS	and	the	timing	of	the	biopsies.	The	success	rate	was	36.4%	in	a	DCM-like	clinical	picture	compared	 to	 6.7%	 in	 cases	 with	 conduction	 disturbances	 and	 preserved	 systolic	function	 (2).	 The	 study	 by	 Ardehali	 et	 al.	 suggested	 that	 a	 limited	 cardiac	 sarcoid	involvement	 that	 was	 not	 detected	 by	 EMB,	 predicted	 better	 survival,	 though	 by	 no	means	 freedom	 from	cardiac	death,	 compared	 to	EMB	positive	 cases	 (86).	 In	GCM,	 at	least	in	the	case	of	fulminant	disease,	the	yield	of	EMB	is	higher,	with	a	sensitivity	of	80-85%	(236).	A	greater	number	of	biopsies	increases	the	diagnostic	yield	in	myocarditis	in	general,	but	the	value	of	multiple	and/or	repeated	EMBs	in	CS/GCM	was	previously	undetermined	 (237).	 Conventionally,	 EMBs	 are	 taken	 from	 the	RV	but	 in	 some	 cases,	e.g.,	 in	imaging	findings	concentrating	on	the	left	side,	LV	biopsies	may	be	usefull	with	reported	complication	rates	similar	to	right-sided	procedures	(237,238).	Pre-procedural	 CMR	 and/or	 18F-FDG-PET	 imaging	 is	 recommended	 and	 usually	performed	 in	 clinical	 practice	 (231).	 Biopsies	 targetting	 areas	 with	 detected	inflammation	 has	 raised	 interest,	 but	 there	 are	 no	 prior	 reports	 on	 its	 usefulness	 in	CS/GCM	 and	 the	 utility	 in	 myocarditis	 in	 general	 is	 poorly	 defined	 (231,237).	 Novel	methods	to	improve	the	diagnostic	yield	of	EMBs	are	needed.	Recently,	electroanatomic	mapping-guided	 EMB	 targeting	 low	 voltage	 and	 fragmented	 signal	 areas	 significantly	improved	the	diagnostic	yield	in	suspected	myocarditis	or	CS	(137,235).	Furthermore,	a	recent	 pilot	 study	 utilizing	 three-dimensional	 electroanatomic	 mapping	 with	 the	recording	 electrode	 placed	 at	 the	 tip	 of	 the	 bioptome	 showed	 promise	 for	 better	diagnostic	gain	(239).	Finally,	due	to	the	limited	sensitivity	of	EMB,	histologic	confirmation	of	sarcoidosis	can	be	acquired	from	extracardiac	organs	in	the	case	of	compatible	cardiac	symptoms	and	signs.	The	 recent	expert	 consensus	 statement	 recommended	extracardiac	biopsy	 sites	to	be	targeted	first	because	of	higher	diagnostic	yield	and	lower	procedural	risk	(4,177).	One	small	prior	report	demonstrated	mediastinal	lymphadenopathy	at	chest-computed	
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tomography	in	88%	(7/8)	of	CS	patients	compared	to	5%	(1/20)	of	DCM	patients,	but	did	not	report	lymph	nodes	as	potential	biopsy	targets	(100).	Gene	 expression	 profiling	 of	 EMB	 samples	 is	 a	 promising	 diagnostic	 tool	 for	differentiating	 CS,	 GCM,	 active	 lymphocytic	 myocarditis	 and	 non-inflammatory	myocardial	diseases.	To	date,	two	small	studies	have	demonstrated	that	genes	encoding	regulators	 of	 immune	 response,	 cellular	 receptors	 including	 Toll-like	 receptors,	 and	proteins	of	 the	mitochondrial	energy	metabolism	are	differentially	expressed	 in	 these	conditions	(60,104).	This	is	an	important	target	for	future	research.		
2.5.3	Laboratory	markers	Sarcoidosis	 presents	 with	 a	 weak	 systemic	 immunologic	 response	 despite	 the	associated	extensive	local	inflammation,	and	thus	biomarkers	measured	from	blood	are	not	 of	 notable	 clinical	 use	 (33).	 Granulomas	 produce	 angiotensin-converting	 enzyme	and	 their	 serum	 levels	 are	 elevated	 in	 60%	 of	 patients	 with	 sarcoidosis.	 Still,	 the	diagnostic	 value	 of	 angiotensin-converting	 enzyme	 is	 controversial	 in	 systemic	sarcoidosis,	 let	 alone	 detection	 of	 cardiac	 involvement	 (33).	 Circulating	 lysozyme	 or	calcium	 concentrations	 are	 no	 more	 helpful.	 Elevated	 plasma	 N-terminal	 pro-B-type	natriuretic	propeptide	(NT-proBNP),	a	marker	of	cardiac	overload,	has	been	observed	in	sarcoidosis	patients	with	cardiac	complications	(240).		An	 early	 report	 found	 first-generation	 cardiac	 troponin-T	 measurements	 to	 be	ineffective	 in	 CS	 (240).	 Instead,	 high-sensitivity	 cardiac	 troponin-T	 (hs-cTnT)	measurements	 were	 recently	 shown	 to	 correlate	 with	 18F-FDG-PET	 findings	 in	 CS,	being	abnormally	elevated	in	most	PET-positive	patients	and	normal	in	the	majority	of	PET-negative	 patients	 (241).	 One	 case	 report	 described	 a	 rapid	 decrease	 in	 high-sensitivity	 cardiac	 troponin-I	 (hs-cTnI)	 following	 intravenous	 methylprednisolone	administration	 (242).	 The	 value	 of	 high-sensitivity	 troponins	 in	 the	 detection	 of	myocyte	 injury	and	evaluation	of	disease	activity	remains	 to	be	solved.	Galectin-3	 is	a	promising	biomarker	involved	in	heart	failure,	inflammation	and	fibrosis	that	has	been	studied	in	a	small	cohort	of	six	CS	patients	(179,243).	Galectin-3	was	found	to	be	higher	in	 pulmonary	 sarcoidosis	 patients	 compared	 to	 healthy	 controls,	 but	 did	 not	 differ	between	CS	and	non-CS	groups	(179,243).		
	
2.6	Management	The	 treatment	 of	 CS	 involves	 immunosuppressive	 medication	 for	 sarcoidosis	 and	cardiac-specific	 treatment	 for	heart	 failure,	 conduction	disturbances	and	arrhythmias.	No	international	guidelines	exist	on	the	management	of	CS	and	the	best	available	data	is	based	on	meta-analysis	and	expert	consensus	(197,244).	In	2012	a	consensus	statement	on	 the	 management	 of	 CS,	 based	 on	 responses	 from	 42	 commendable	 sarcoidosis	
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experts	 to	 a	 Delphi	method	 questionnaire,	 was	 published	 in	 the	 U.S.	 (197).	 Although	there	 were	 significant	 differences	 of	 opinion	 among	 the	 experts	 highlighting	 the	difficulties	 in	managing	CS,	 sufficient	 agreement	was	 reached	 to	 formulate	a	proposal	for	best	practice,	Figure	9.	
	
	
	
		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	9.	Proposed	best	practice	for	the	diagnosis	and	treatment	of	CS	based	on	expert	panel	consensus.	Adapted	from	(197).	CS=	cardiac	sarcoidosis,	ECG=	electrocardiogram,	CMR=	cardiac	magnetic	resonance	imaging,	18F-FDG-PET=	18F-fluorodeoxyglucose	positron	emission	tomography,	EP=	electrophysiologic,	LV=left	ventricle,	RV=right	ventricle,	SCD=	sudden	cardiac	death.	
Screening	for	CS		-	Clinical	symptoms	and	physical	exam	-	12-lead	ECG	-	Echocardiography	-	(Holter	monitoring)		
Immunosuppression	therapy	
	-	Prednisone	(30-40mg/day)	-	Methotrexate/	azathioprine	-	Others		
Starting	immunomodulatory	
therapy	-	Positive	18F-FDG-PET			-	LV	dysfunction	-	Conduction	defects	-	Ventricular	arrhythmias	-	(LGE	on	CMR)		
Workup	for	CS		-	12-lead	ECG	-	Echocardiogram	-	Cardiac	CMR	-	Cardiac	18F-FDG-PET	-	Holter	monitoring	-	(EP	evalutation)	
ICD		-	Positive	EP	study	-	Aborted	SCD	event	
Evaluation	of	therapy	
response		-	Symptoms	-	Cardiac	18F-FDG-PET	-	Cardiac	CMR		
Electrophysiologic	
evaltuation		-EP	study	-RV	mapping	
Follow-up	 Positive	
Positive	
Negative	
Negative	
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2.6.1	Corticosteroids	
2.6.1.1	Implementation	The	goal	of	immunosuppressive	treatment	in	CS	is	to	reverse	ongoing	inflammation	and	thereby	 potentially	 prevent	 progression	 to	 fibrosis	 and	 adjacent	 organ	 dysfunction	(197).	 As	 in	 sarcoidosis	 affecting	 other	 organs,	 corticosteroids	 are	 the	 mainstay	 of	therapy	for	cardiac	involvement.	Corticosteroids	function	by	suppressing	multiple	pro-inflammatory	 cytokines	 and	 chemokines	 (245).	However,	 debate	 exists	 as	 to	whether	treatment	 can	 change	 the	outcome	of	 sarcoidosis	 in	 general	 and	 the	 evidence	 is	 even	more	incomplete	in	CS	(29,43).		As	there	are	no	randomized	controlled	trials,	the	choice,	dosage	and	duration	of	therapy	still	 remain	 to	 be	 judged	 by	 clinicians.	 In	 general,	 prednisone	 starting	 dosage	 varies	from	20-60mg/day	or	50-60mg	on	alternate	days.	 	 In	 the	 study	by	Yazaki	et	 al.	 there	was	 no	 difference	 in	 outcome	 in	 low	 (≤	 30mg)	 compared	 to	 high	 (≥40mg)	 initial	prednisone	 daily	 dose	 (97).	 The	 dose	 of	 prednisone	 is	 gradually	 tapered	 down	 to	 a	maintenance	dose	of	5-15mg/day	 (6,97,244).	Controversy	 remains	on	 the	duration	of	the	treatment	(244).	Some	centers	repeat	18F-FDG-PET	scans	or	other	cardiac	imaging	modalities	 to	 guide	 long-term	 steroid	 treatment(197,244).	 Finally,	 after	 stopping	immunosuppressive	 therapy,	 close	 follow-up	 for	 possible	 future	 relapses	 is	recommended	by	the	experts	(244).	
2.6.1.2	Efficacy	Despite	 over	 50	 years	 of	 the	 use	 of	 corticosteroids	 in	 CS,	 there	 still	 is	 no	 proof	 of	survival	benefit	 from	immunosuppressive	treatment	(43,244).	 	 In	the	 largest	study	on	long-term	survival,	 the	 five-year	 survival	 rate	was	only	10%	 in	patients	not	 receiving	steroids	compared	to	75%	in	steroid-treated	patients,	but	since	all	 the	20	non-treated	patients	were	diagnosed	at	autopsy,	no	conclusion	on	the	efficacy	of	steroid	treatment	could	 be	 drawn	 (113).	 The	 same	 dilemma	 applies	 to	 other	 studies	 as	 there	 are	 no	placebo-controlled	treatment	trials.	Kato	et	al.	retrospectively	evaluated	the	survival	of	seven	patients	receiving	corticosteroids	and	13	patients	not	receiving	these	agents	and	found	 that	 in	 the	 untreated	 group,	 two	 patients	 died	 compared	 to	 no	 deaths	 in	 the	treatment	group,	but	the	difference	was	statistically	insignificant	(246).	Likewise,	Nagai	et	 al.	 found	 no	 effect	 on	 cardiac	 deaths	 in	 the	 7.6-year	 follow-up	 in	 67	 patients	with	corticosteroid	treatment	compared	to	16	patients	without	corticosteroids	(reasons	for	withholding	 corticosteroids;	 cardiac	 imaging	 without	 active	 inflammation	 in	 seven,	patient	refusal	in	five,	active	infectious	disease	in	two	and	others	in	two)	(115).	The	data	concerning	the	efficacy	of	corticosteroids	on	LV	function	is	contradictory.	In	a	cohort	 of	 30	 patients	 in	 a	 study	 by	 Takaya	 et	 al.,	 LVEF	 remained	mildly	 reduced	 yet	stabile	over	12	months	of	steroid	treatment	(215).	Conversely,	in	a	cohort	of	10	patients	from	Kudoh	et	al.,	mean	LVEF	improved	from	35%	to	49%	after	six	months	of	steroid	therapy	 (247).	 In	 a	 study	 of	 20	 CS	 patients	with	 AV-block	 and	 initially	 normal	 LVEF,	seven	corticosteroid-treated	patients	demonstrated	no	change	in	LVEF,	compared	to	11	
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out	 of	 13	 non-treated	 patients	 with	 marked	 decline	 in	 LVEF	 over	 a	 mean	 follow-up	period	 of	 79	months	 (246).	 Similarly,	 in	 a	 recent	 study	 by	Nagai	 et	 al.,	 patients	with	corticosteroid	 therapy	 (n=67,	 initial	mean	LVEF	36%),	had	an	 increase	 in	LVEF	 (+8%	±36%)	versus	decrease	 in	LVEF	 (-17	±35%)	 in	non-steroid	 group	 (n=16,	 initial	mean	LVEF	35%)	(115).	Furthermore,	the	difference	in	LVEF	was	emphasized	in	patients	with	baseline	 LVEF	 ≥35%	 and	 steroid-treated	 patients	 also	 had	 fewer	 hospital	 admissions	due	 to	 heart	 failure	 (115).	 Furthermore,	 Chiu	 et	 al.	 demonstrated	 no	 effect	 on	 LVEF	either	 in	 the	 total	 group	of	 43	CS	patients	 or	 in	 patients	with	 severely	 reduced	LVEF	(<30%,	 n=11),	 but	 a	 significant	 improvement	 in	 LVEF	 and	 LV	 end-diastolic	 diameter	(LVEDD)	in	the	group	with	mildly	to	moderately	decreased	LVEF	(30-54%,	n=10)	(6).	A	systematic	review	summarizing	four	studies	(not	including	the	recent	study	from	Nagai	et	 al.)	 concluded	 that	 steroid	 therapy	 seems	 to	maintain	 LV	 function	 in	 patients	with	normal	LVEF	at	diagnosis,	improve	LVEF	in	patients	with	mild	to	moderate	dysfunction,	but	 have	 no	 effect	 in	 patients	 with	 severe	 dysfunction	 (244).	 Anyhow,	 the	 authors	underline	 that	 it	 is	unclear	whether	 the	 improvements	were	due	 to	corticosteroids	or	were	simply	indicative	of	the	natural	course	of	the	disease	(244).		Several	 small	 patient	 series	 have	 shown	 that	 AV-conduction	 blocks	 mainly	 develop	during	 the	 inflammatory	phase	of	CS	and	that	recovery	of	conduction	 is	possible	with	corticosteroid	treatment	(124,246,248).	 In	the	study	by	Yodogawa	et	al.	(2013)	(248),	AV-block	resolved	within	the	first	week	of	steroid	therapy	in	four	of	seven	patients	and	later	(up	to	14	months)	in	the	remaining	three	patients	out	of	a	total	of	15	patients.	The	restoration	of	conduction	was	more	common	in	patients	with	preserved	LVEF	(248).	In	 studies	 with	 CS	 patients	 having	 ventricular	 arrhythmias	 at	 presentation,	 initiating	steroid	 treatment	 has	 shown	 no	 beneficial	 effect	 on	 the	 arrhythmia	 load	 (124,132).		However,	 in	 a	 small	 study	 of	 patients	 without	 presenting	 ventricular	 arrhythmias,	14.3%	 (1/7)	 of	 patients	 treated	 with	 steroids	 compared	 to	 61.5%	 (8/13)	 of	 non-steroid-treated	patients	had	ventricular	 arrhythmias	during	 the	disease	 course	 (246).	The	study	by	Yodogawa	et	al.	 (2011)	showed	a	significant	decrease	 in	VPBs	and	non-sustained	 VTs,	 as	 well	 as	 an	 improvement	 in	 signal-averaged	 ECG	 parameters	 in	patients	with	EF	≥	35%,	but	not	in	patients	with	EF	<	35%	over	a	seven-month	period	of	corticosteroid	 therapy	 (249).	 In	 45	 CS	 patients	 with	 ICD,	 post-implantation	immunosuppression	had	no	effect	on	the	ventricular	arrhythmias	(128).	Several	 18F-FDG-PET	 studies	 have	 demonstrated	 the	 diminution	 or	 disappearance	 of	18F-FDG	 uptake	 in	 CS	 after	 one	 to	 two	 months’	 steroid	 therapy	 (211,214,215).	Likewise,	in	a	scintigraphy	study,	corticosteroids	abolished	gallium-67	uptake	within	six	months	in	all	nine	patients	with	positive	uptake	at	presentation	(124).	In	a	CMR	study	of	12	histologically	verified	patients	with	systemic	sarcoidoisis	and	suspected	CS	based	on	scintigraphy	 results,	 six	 (including	 three	 with	 cardiac	 symptoms)	 received	corticosteroids	with	CMR	showing	cleared	or	improved	findings	in	all	at	the	12-month	follow-up,	 compared	 to	 a	 worsening	 or	 stability	 of	 CMR	 findings	 (signal	 intensity,	contractility	and	myocardial	 thickness)	 in	the	six	non-treated	patients	(206).	Whether	
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the	 reduction	of	myocardial	 inflammation	measured	by	 imaging	 findings	 is	 related	 to	clinical	 improvement	 is	 controversial.	 Osborne	 et	 al.	 found	 a	 significant	 inverse	relationship	with	LVEF	and	standardized	uptake	values	in	PET	(214),	whereas	Takaya	et	al.	demonstrated	resolution	of	18F-FDG	and	gallium-67	scintigraphy	activity	without	any	 improvement	 in	 LVEF	 (215).	 Altogether,	 there	 is	 evidence	 from	 relatively	 small	studies	that	the	corticosteroid	treatment	response	in	CS	might	be	positive	in	the	early	inflammatory	phase	of	disease	but	no	longer	when	myocardial	 fibrosis	and	scars	have	formed	(6,124,215,249).		
2.6.2	Other	immunosuppressants	Long-term	 use	 of	 steroids	 is	 associated	 with	 adverse	 effects	 (diabetes,	 cataract,	osteoporosis,	 weight	 gain,	 gastrointestinal	 bleeding,	 infections,	 etc.),	 and	 alternative	agents	 are	 also	 required	 for	 patients	 refractory	 to	 corticosteroids.	 No	 randomized	comparative	studies	of	steroid-sparing	immunosuppressants	in	CS	exist.	In	a	study	of	17	patients,	a	combination	of	methotrexate	(6mg/week)	and	a	low-dose	(5-15	mg/day)	of	prednisolone	showed	a	tendency	towards	better	outcomes	compared	to	corticosteroids	alone	 (with	 no	 information	 of	maintenance	 dose)	measured	 by	 higher	 LVEF,	 smaller	LVEDD	 and	 lower	 NT-proBNP	 over	 five	 years	 of	 follow-up	 (250).	 In	 a	 Delphi	 study	collecting	 the	 opinions	 of	 sarcoidosis	 experts,	 methotrexate	 was	 the	 second	 most	commonly	 used	 drug,	 followed	 by	 azathioprine,	 mycophenolate	 mofetil,	hydroxycholoquine,	 and	 anti-TNF-α	 agents	 (88,197).	 There	 are	 case	 reports	 showing	that	anti-TNF-α	agent	infliximab	may	be	effective	in	CS	(251,252).	The	use	of	infliximab	is	 theoretically	 supported	 by	 the	 well-known	 role	 of	 TNF-α	 in	 granuloma	 formation	(32,41,42).	 However,	 infliximab	 has	 been	 shown	 to	 worsen	 the	 outcome	 in	 severe	systolic	 heart	 failure	 in	 general	 (253),	 and	 it	 should	 therefore	 be	 used	 with	 great	caution,		particularly	with	advanced	CS.				
2.6.3	Management	of	heart	failure	and	arrhythmias	Besides	 immunosuppression,	 the	 treatment	of	CS	 includes	management	of	ventricular	dysfunction,	 heart	 failure,	 and	 cardiac	 rhythm	 disturbances	 (88).	 Ventricuar	dysfunction	 is	managed	 according	 to	 the	 established	 guidelines	 for	 heart	 failure	with	beta	 blockers,	 angiotensin-converting	 enzyme	 inhibitors,	 and	 mineralocorticoid-receptor	antagonists	(254).	The	treatment	of	ventricular	arrhythmias	is	based	on	both	drugs	 and	 devices	 (see	 below).	 In	 a	 multicenter	 study	 of	 235	 patients,	 the	 most	frequently	 used	 antiarrhythmic	 agents,	 in	 addition	 to	 beta	 blockers,	were	 sotalol	 and	amiodarone	(129).		Class	I	(Vaughan-Williams)	antiarrhythmic	drugs	should	be	avoided	in	 ventricular	 and	 atrial	 arrhythmias	 alike	 due	 to	 their	 potential	 harmfulness	 in	structural	heart	disease	(255).	
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2.6.4	Device	therapy	and	catheter	ablation		Since	 ventricular	 arrhythmias	 in	 CS	 usually	 recur,	 ICD	 therapy	 has	 long	 been	recommended	 for	 patients	 with	 sustained	 VT	 or	 VF	 (132).	 More	 recently,	 ICDs	 have	been	 increasingly	 implanted	 for	 primary	 prevention,	 especially	 in	 patients	with	 non-sustained	 arrhythmias	 on	 ambulatory	 ECG,	 unexplained	 or	 near	 syncope,	 or	 positive	electrophysiological	 study	 in	 the	 setting	 of	 reduced	 EF	 (90,197).	 In	 large	 studies	recently	 published	 in	 the	 U.S.,	 63-74%	 of	 ICDs	 in	 CS	 patients	 were	 implanted	 for	primary	 prevention	 in	 patients	 without	 prior	 significant	 ventricular	 arrhythmias	(98,128,129).	 Besides	 a	 high	 rate	 of	 appropriate	 ICD	 therapies	 (see	 Arrhythmias	section),	 CS	 patients	 are	 also	 reported	 to	 experience	 inappropriate	 shocks	 (13.3-25%)(98,128,129)	 and	 device-related	 complications	 (15.6-18%)	 relatively	 commonly	(99,128,129).	In	the	general	ACC/AHA/HRS	2013	guidelines	for	cardiac	pacing,	CS	was	classified	as	IIA,	level	of	evidence	C	indication	for	ICD,	meaning	that	implantation	should	be	 considered	 (256).	 In	 the	 2013	 ESC/EHRA	 guidelines	 CS	 was	 not	 separately	addressed	 (257).	 An	 expert	 consensus	 statement	 on	 CS	 recommends	 ICD	 for	 all	 CS	patients	with	spontaneous	sustained	VTs	and/or	LVEF	≤	35%,	despite	optimal	medical	therapy	 and	 a	 period	 of	 immunosuppression	 (if	 there	 is	 active	 inflammation)	 (4).	Independent	 of	 LVEF,	 ICD	 implantation	 can	 be	 useful	 in	 cases	 of	 indication	 for	bradycardia	 pacemaker,	 unexplained	 syncope	 or	 near	 syncope	 or	 positive	electrophysiological	 studies	 (4).	 In	 case	 of	 mildly	 to	 moderately	 reduced	 LVEF	 (36-49%)	 and/or	 RVEF	 <40%,	 ICD	 implantation	 may	 be	 considered	 (4).	 If	 none	 of	 the	aforementioned	 symptoms	 or	 findings	 are	 present	 and	 there	 is	 no	 LGE	 on	 CMR,	 ICD	implantation	is	not	recommended,	but	the	patients	should	be	closely	monitored	(4).	As	the	disease-specific	data	on	CRT	in	CS	is	minimal,	general	recommendations	should	be	applied	 (4,257,258).	 In	one	 Japanese	 study,	CS	patients	 (n=25)	 seemed	 to	 respond	less	to	CRT	compared	to	other	non-ischemic	cardiomyopathy	patients	(148)	but	this	has	not	 been	 confirmed.	 CRT	 is	 recommended	 in	 patients	with	 sinus	 rhythm,	 LBBB	with	QRS	 duration	 ≥	 120ms,	 LVEF	 ≤	 35%	 and	 NYHA	 class	 ≥	 II	 despite	 adequate	 medical	treatment	 and	 should/may	 be	 considered	 in	 non-LBBB	 patients	 with	 the	 other	aforementioned	features	(257).	In	patients	with	conventional	pacemakers,	upgrading	to	CRT	should	be	done	according	to	the	aforementioned	indications	(257).	The	evidence	in	patients	 with	 conventional	 indication	 for	 anti-bradycardia	 pacing	 is	 less	 clear,	 but	suggests	that	patients	with	moderate-to-severe	LV	dysfunction	might	benefit	from	CRT	compared	to	RV	pacing	alone	(257).	In	 the	 case	 of	 ventricular	 arrhythmias	 refractory	 to	 drug	 treatment	 or	 frequent	adequate	ICD	therapies,	radiofrequency	catheter	ablation	is	an	option.	In	a	survey	study	from	 2012,	 14.9%	 of	 235	 patients	 with	 ICD	 implantation	 for	 CS	 in	 major	electrophysiology	centers	 in	the	U.S.,	Canada,	and	India,	underwent	VT	ablation	(129).	In	 two	 cohorts	 of	 patients	 with	 multiple	 antiarrhythmic	 medications	 without	 proper	arrhythmia	 control,	 catheter	 ablation	 resulted	 in	 freedom	 of	 VTs	 in	 four	 out	 of	 eight	patients	(121)	and	either	reduced	or	completely	eliminated	VTs	in	four	and	five	out	of	
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nine	 patients,	 respectively	 (122).	 In	 a	 study	 of	 21	 patients	 who	 were	 refractory	 to	medical	 treatment,	 VT	 ablation	was	 successful	 in	 terminating	 ≥	 1	 spontaneous	 VT	 in	90%	and	 in	eliminating	electrical	 storm	 in	78%	of	patients	 (126).	However,	probably	due	 to	 multiple	 arrhythmia	 substrates,	 VT	 recurred	 in	 all	 but	 three	 patients	 after	 a	single	procedure,	and	repeated	procedures	were	needed	to	achieve	better	arrhythmia	control	with	fewer	antiarrhythmic	drugs	(126).	Altogether,	catheter	ablation	appears	to	be	 effective	 in	 treating	 VT	 storm	 in	 CS	 and	 may	 provide	 palliation	 for	 recurring	arrhythmias,	 but	 due	 to	 diffuse	 myocardial	 involvement,	 achieving	 full	 arrhythmia	control	 is	 difficult	 (126).	Data	 concerning	 ablation	 of	 atrial	 tachyarrhythmias	 in	 CS	 is	limited	to	one	study	that	showed	lasting	results	in	seven	of	nine	patients	during	a	mean	follow-up	period	of	1.8	years	(140).	
	
2.6.5	Transplantation	Cardiac	 transplantation	 is	 a	 viable	 treatment	 in	 end-stage	 heart	 failure	 or	uncontrollable	 ventricular	 arrhythmias	 when	 other	 organs	 are	 not	 significantly	damaged.	CS	accounts	for	up	to	2.5%	of	all	cardiac	transplantations	(82-84,173,259).			Sarcoidosis	 has	 been	 reported	 to	 recur	 in	 the	 transplanted	 heart	with	 a	 rate	 ranging	from	0%	(0/19)	to	14.3%	(2/14)	in	approximately	five	years	(82,173).	A	recurrence	can	follow	 the	 tapering	 of	 corticosteroids	 (260)	 and	 is	 often	 treatable	 with	 an	 elevated	corticosteroid	dose	(82,173,261).		The	 data	 concerning	 prognosis	 after	 cardiac	 transplantation	 in	 CS	 is	 somewhat	contradictory.	 The	 largest	 multicenter	 study	 of	 38,230	 transplantations	 with	 65	 CS	patients	 demonstrated	 slightly	 better	 one-year	 survival	 in	 CS	 patients	 compared	 to	patients	 transplanted	 for	 other	 cardiac	 conditions	 (259).	 Conversely,	 a	 single-center	study	of	825	transplantations	including	14	CS	patients	showed	a	trend	towards	higher	mortality	 in	 CS	 patients	 with	 a	 five-year	 post-transplantation	 survival	 rate	 of	 58.9%	compared	to	76.2%	(82).	In	the	latest	study	no	survival	difference	was	observed,	with	five-year	post-transplantation	survival	being	79%	in	19	CS	patients	compared	to	83%	in	1,050	 other	 heart	 transplant	 recipients	 (173).	 A	 case	 of	 possible	 transmission	 of	sarcoidosis	from	a	donor	to	a	recipient	has	been	described	(262).		
2.6.6	Management	of	GCM	The	 only	 trial	 designed	 to	 evaluate	 immunosuppressive	 treatment	 response	 with	placebo	 in	 GCM,	 by	 Cooper	 et	 al.,	 failed	 to	 recruit	 patients	 in	 the	 non-immunosuppression	 arm,	making	 the	 estimation	of	 survival	 benefit	 impossible	 (107).	Nevertheless,	 the	 study	 design	 was	 modified	 to	 examine	 the	 effect	 of	immunosuppressive	therapy	as	such	and	recruited	11	patients	from	17	medical	centers	around	 the	 world.	 EMBs	 controlled	 at	 four	 weeks	 after	 the	 start	 of	 combined	immunosuppressive	 treatment	 showed	 significant	 a	 reduction	 in	 the	 amount	 of	
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inflammatory	 cells	 and	 necrosis.	 Anyhow,	 LVEF	 did	 not	 change	 significantly	 after	 a	month	of	 treatment,	presumably	because	of	 relatively	mild	 cardiac	dysfunction	at	 the	start	 of	 the	 study	 (mean	 44±18%).	 At	 the	 follow-up	 after	 one	 year,	 two	 patients	required	heart	transplantation	and	one	patient	died	of	recurrent	GCM	after	stopping	all	immunosuppressive	medication.	In	addition	to	the	study	by	Cooper	et	al.,	a	small	study	of	 five	GCM	patients	 also	 found	 improvement	 in	histological	 findings	but	no	 effect	 on	LVEF	 after	 six	 months	 of	 immunosuppressive	 therapy	 (9).	 Recently,	 a	 stepwise	histopathologic	 improvement	 with	 multiple	 immunosuppressants	 was	 documented,	from	 fulminant	 myocarditis	 with	 giant	 cells	 to	 a	 myocarditis	 characterized	 by	 a	lymphocytic-eosinophilic	 infiltrate,	 further	 to	 a	 smoldering	 lymphocytic	 myocarditis	and	 lastly	 to	 interstitial	 (mostly	 replacement-type)	 fibrosis	 in	 repeated	 EMBs	 (166).	However,	 in	 the	 same	 study	 the	 degree	 of	 immunosuppression	 during	 the	 first	 year	after	 diagnosis	 did	 not	 predict	 the	 subsequent	 composite	 endpoint	 event	 of	 death,	transplantation,	 first	 ventricular	 arrhythmia	 or	 GCM	 recurrence	 (166).	 Furthermore,	several	 case	 reports	 have	 demonstrated	 dramatic	 clinical	 and	 histological	 recoveries	from	 GCM	 cardiogenic	 shock	 treated	 by	 immunosuppression	 (69,263-265).	 	 Finally,	experimental	 murine	 autoimmune	 myocarditis	 studies	 indicate	 a	 benefit	 from	 T-cell	suppression	therapy	in	GCM	(62).		No	 international	 guidelines	 on	 therapy	 of	 GCM	 exist,	 and	 the	 studies	 addressing	 its	treatment	are	small.	The	immunosuppression	protocol	in	the	GCM	treatment	landmark	study	 involving	 11	 patients	 was	 as	 follows	 (107).	 Intravenous	 methylprednisolone	10mg/kg	was	administered	for	three	days,	followed	by	prednisone	1mg/kg	with	rapid	tapering	 up	 to	 a	 year.	 Additionally,	 cyclosporine	 with	 serum	 target	 levels	 of	 150-300ng/ml	 was	 used.	 Eighty-two	 percent	 of	 the	 patients	 received	 muromonab-CD3	(OKT-3),	a	monoclonal	antibody	against	CD3-T-cells.	In	the	up-to-date	report	of	26	GCM	patients	 from	 Germany	 and	 the	 U.S.,	 the	 majority	 of	 patients	 received	 cyclosporine-based	multiple	 immunosuppression	 after	 diagnosis,	 including	 muromonab-CD	 3	 or	 a	comparable	 antilymphocytic	 agent	 in	 42%	 (166).	 Of	 them,	 27%	 were	 weaned	 onto	corticosteroid-only	therapy	during	the	first	year	and	73%	continued	with	combination	treatment	(166).	At	any	point	in	time,	26	patients	(100%)	received	corticosteroids,	21	(81%)	 cyclosporine,	 10	 (38%)	mycophenolate	mofetil,	 eight	 (31%)	 azathioprine,	 and	eight	 (31%)	 sirolimus.	 Furthermore,	 there	 are	 case	 reports	 of	 tacrolimus,	 anti-thymocyte	 globulin	 and	 alemtuzumab	 (a	 monoclonal	 CD52	 T-cell	 surface	 protein	antagonist)	being	administered	with	success	in	GCM	(26,69,172,265,266).	In	addition	to	immunosuppressants,	the	treatment	of	GCM	encompasses	heart	failure	and	arrhythmia-targeted	therapies	and,	in	patients	with	severe	LV	dysfunction,	inotropic	agents.	Despite	the	moderate	success	of	intensive	immunosuppression,	a	significant	proportion	of	 GCM	patients	 require	 a	 heart	 transplantation,	 sometimes	 urgently	 (7,37,267).	 As	 a	bridge	to	cardiac	transplantation,	mechanical	circulatory	support	with	ventricular	assist	devices,	 intra-aortic	 balloon	 pumps	 and	 extracorporeal	 membrane	 oxygenation	 have	been	used	successfully	in	GCM	(26,37,268).	In	the	GCM	landmark	study,	54%	(34/63)	of	
	 	 	 			 54	
patients	underwent	transplantation	with	a	median	of	six	months	after	symptom	onset.	On	 follow-up	 after	 3.7	 years,	 26%	 (9/34)	 of	 transplanted	 patients	 died	 (11).	 Post-transplant	recurrence	of	GCM	is	more	common	compared	to	CS,	with	26-43%	(9/34	–	3/7)	of	transplanted	patients	having	GCM	findings	in	surveillance	biopsies	an	average	of	three	 years	 (ranging	 from	 three	 weeks	 to	 nine	 years)	 after	 transplantation	 (11,37).	Asymptomatic	 recurrence	 does	 not	 necessarily	 carry	 a	 poor	 prognosis	 and	 usually	resolves	with	temporarily	augmented	immunosuppression	(37).	In	the	study	by	Cooper	et	 al.	 (1997)	 six	 of	 the	 nine	 recurrences	 were	 asymptomatic	 and	 one	 died	 of	 heart	failure	(11).			
2.7	Prognosis	
2.7.1	Prognosis	of	CS		The	survival	data	concerning	CS	is	heterogeneous,	depending	on	the	diagnostic	criteria	used,	the	inclusion	or	exclusion	of	autopsy	and	post-transplantation	diagnoses,	and	the	reported	 survival	 definition	 reported	 (overall-,	 cardiac-	 or	 transplant-free	 cardiac	survival)	(Table	7).	Some	kind	of	treatment	with	a	possible	effect	on	the	disease	course	has	been	used	since	the	early	studies,	thus	there	are	no	reports	strictly	on	the	natural	history	 of	 CS.	 In	 the	 first	 large	 series	 of	 250	CS	 patients,	 in	which	 the	 treatment	was	variable	but	steroids	were	commonly	used,	the	five-year	survival	rate	was	40%	(22).	In	an	 early	 Japanese	 study,	 55%	 (23/42)	 of	 CS	 patients	 died	 within	 one	 year	 from	 the	onset	of	the	cardiac	symptoms	(16).	The	most	widely	cited	survival	rates	are	from	two	series	 from	 the	beginning	of	 the	21st	 century,	with	 five-year	 survival	 rates	of	60-75%	(5,97).	Regarding	 the	 consequence	 of	 cardiac	 involvement	 in	 systemic	 sarcoidosis,	 CS	was	 reported	 to	 cause	 two-thirds	 of	 deaths	 in	 Japanese	 sarcoidosis	 patients,	 but	 less	than	20%	of	deaths	in	Caucasians	(49,269).	
Table	7.	Prognosis	of	CS	in	different	studies.	_____________________________________________________________________________________________	Study,	year	 	 			N	 	 Survival	 	 Comments	_____________________________________________________________________________________________	Chiu	et	al.	2005	(6)	 		43	 	 Overall	 	 No	cardiac	deaths	in	 		 		 	 	 	 	 	 	 patients	with	normal		 	 	 	 	 Lifetime	diagnosis		 LVEF	at	diagnosis	(N=43)			 	 	 	 	 1	year					98%		 	 	 	 	 5	years			90%		 	 	 	 	 10	years	84%	_____________________________________________________________________________________________			
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Okura	et	al.	2003	(5)				42	 	 Transplant-free	 Survival	significantly		 	 	 	 	 	 	 	 better	compared	to	GCM		 	 	 	 	 Lifetime/autopsy/	explant	diagnosis		(N=42)	5	years	61%		 Lifetime	diagnosis		(N=30)	5	years	70%	_____________________________________________________________________________________________	Yazaki	et	al.	2001	(97)	 95	 Overall	 	 Overall	survival	in	 		 	 	 	 	 	 	 	 patients	with	lifetime		 	 	 	 	 Lifetime/autopsy	 diagnosis	and	LVEF	≥		 	 	 	 	 diagnosis	(N=	95)	 50%;	1	year	95%,	5	1	year					85%		 years	89%	and	10	years	5	years			60%		 89%	10	years	44%		 Lifetime	diagnosis		(N=75)	1	year					92%	5	years			75%	10	years	61%	_____________________________________________________________________________________________	Fleming	et	al	1986	(22)	 250	 Overall	 	 Steroid	used	commonly,		 	 	 	 	 	 	 	 otherwise	treatment		 	 	 	 	 Autopsy	diagnosis	 data	nonexistent		 	 	 	 	 5	years			40%		 	 	 	 	 10	years	14%	_____________________________________________________________________________________________	Roberts	et	al.	1977	(109)		 113		 Overall		 	 	 	 	 Autopsy	diagnosis		 	 	 	 	 1	year	27%	_____________________________________________________________________________________________	Matsui	et	al.	1976	(16)		 42	 Overall	 	 *Only	5	(12%)	lifetime		 	 	 	 	 	 	 	 diagnoses		 	 	 	 	 Mostly	autopsy		diagnoses*		 	 	 	 	 1	year			45%		 	 	 	 	 2	years	26%	CS=	cardiac	sarcoidosis,	LVEF=	left	ventricle	ejection	fraction,	GCM=	giant	cell	myocarditis.		
	 	 	 			 56	
All	the	aforementioned	studies	are	retrospective.	Subsequently,	several	small	studies	on	patients	 with	 systemic	 sarcoidosis,	 diagnosed	 with	 CS	 and	 monitored	 prospectively	since,	 have	 shown	 comparable	 survival	 rates.	 Among	 101	 pulmonary	 sarcoidosis	patients	 from	 the	 Netherlands,	 16	 patients	 were	 diagnosed	 with	 symptomatic	 CS	according	 to	 the	modified	 JMWH	 criteria,	 and	 25%	 (4/16)	 of	 them	died	 over	 a	mean	follow-up	 of	 1.7	 years	 (77).	 Similar	 results	 were	 reported	 from	 the	 U.S.,	 with	 19%	(4/21)	of	patients	with	biopsy-proven	extracardiac	sarcoidosis	and	LGE-CMR	findings	compatible	with	CS	suffering	cardiac	death	in	the	mean	follow-up	of	1.8	years	(91).	 In	contrast,	 in	 the	 study	 by	 Mehta	 et	 al.,	 none	 of	 the	 24	 patients	 with	 pulmonary	sarcoidosis	 and	mostly	asymptomatic	CS	diagnosed	based	on	LGE-CMR	and	18F-FDG-PET	imaging	died	during	a	mean	follow-up	period	of	1.8	years	(93).	One	might	speculate	that	 the	 outcome	 with	 modern	 heart	 failure	 treatment	 and	 prophylactic	 use	 of	 ICDs	should	 be	 better.	 Unfortunately,	 the	 recent	 large	 ICD	 follow-up	 studies	 have	 not	reported	survival	numbers	(98,129).	In	the	latest	study	with	survival	data,	15%	(7/47)	of	 patients	 with	 CS	 diagnosed	 according	 to	 the	 JMHW	 2006	 guidelines	 died	 over	 a	median	follow-up	period	of	15	months	(270).		LV	systolic	function	is	the	most	powerful	predictor	of	outcome	in	CS.	 	 In	a	study	of	95	patients,	10-year	survival	was	89%	in	patients	with	preserved	EF	(≥	50%)	compared	to	27%	in	patients	with	reduced	EF	(<50%)	(97).	In	another	study	of	43	patients,	10-year	cardiac	survival	was	100%	in	patients	with	normal	EF	(≥	55%)	but	only	19%	in	those	with	severely	reduced	EF	(<30%)	at	the	start	of	 the	follow-up	(6).	Other	predictors	of	survival	 in	CS	 include	LV	end-diastolic	diameter,	New	York	Heart	Association	 (NYHA)	functional	 class,	 and	 sustained	 VT	 (97).	 Interestingly,	 the	 presence	 of	 pulmonary	involvement	has	been	associated	with	better	survival,	probably	due	to	earlier	detection	of	 cardiac	 involvement	during	 the	 follow-up	of	pulmonary	 lesions	 (97).	Eventually,	 in	recent	 years	 LGE	 in	 CMR	 has	 been	 suggested	 as	 an	 independent	 predictor	 of	 future	adverse	cardiac	events	in	CS	(202-204)	(see	2.5.2.3).	
2.7.2	Prognosis	of	GCM	The	course	of	GCM	 is	often	 fulminant	and	 its	prognosis	 is	 therefore	 in	general	poorer	than	 the	 prognosis	 of	 CS.	 In	 an	 early	 study	 of	 five	 EMB-verified	 patients,	 60%	 (three	patients)	had	died	or	undergone	transplantation	during	a	follow-up	period	of	1.7	years	(9).	 In	 the	multicenter	 landmark	 study	 of	 63	 patients	with	GCM,	 the	 rate	 of	 death	 or	transplantation	was	89%	and	median	 transplant-free	survival	 from	symptom	onset	 in	all	patients	was	5.5	months	(11).	Notably,	a	total	of	25	patients	(39%)	were	identified	and	 included	 only	 after	 autopsy	 or	 from	 explanted	 hearts.	 Combined	immunosuppressive	 treatment	 including	 cyclosporine	 together	 with	 another	immunosuppressant,	but	not	corticosteroids	alone,	prolonged	the	median	survival	from	3.0	 (without	 any	 immunosuppressants)	 to	 12.3	 months.	 However,	 the	 finding	 was	biased	 resulting	 from	 the	 selection	 of	 survivors,	 i.e.,	 those	who	would	 have	 survived	longer	even	without	immunosuppressive	treatment	were	more	likely	to	be	treated	with	immunosuppressive	therapy.	A	later	study	with	a	longer	follow-up	from	the	same	group	
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demonstrated	a	10%	transplant-free	survival	rate	after	five	years	from	symptom	onset	in	 all	 73	 patients	 and	 22%	 five-year	 transplant-free	 survival	 in	 the	 38	 patients	diagnosed	before	death	or	transplantation	and	treated	with	at	least	corticosteroids	(5).	Recently,	Maleszewski	et	al.	examined	the	long-term	outcome	in	26	GCM	patients	who	survived	the	first	year	following	diagnosis	without	transplant	(166).	Over	the	follow-up	period	of	5.5	years	starting	one	year	after	diagnosis,	31%	of	patients	either	died	(n=3)	or	underwent	transplantation	(n=5).	The	factors	leading	to	fulminant	progress	and	poor	prognosis	or	indolent	course	in	GCM	are	unknown.																					
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3	AIMS	OF	THE	STUDY			This	 study	 was	 designed	 to	 assess	 the	 epidemiology,	 characteristics,	 diagnostics	 and	outcome	of	CS	and	GCM	in	Finland.	More	specifically	the	goals	were	the	following:		1.	To	evaluate	the	detection	rate	and	prevalence	of	CS	since	the	turn	of	the	1990s	(I).		2.	To	elucidate	 the	role	of	CS	and	GCM	in	the	etiologic	spectrum	of	AV-block	 in	young								and	middle-aged	adults	(III).		3.	To	assess	the	biopsy	diagnostics	of	CS	clinically	isolated	in	the	heart	(II).	4.	To	examine	the	clinical	manifestations	of	CS	(I).	5.	To	determine	the	prognosis	of	CS	with	modern	treatment	(I).		6.	To	assess	the	clinical	utility	of	hs-cTnT/I	in	CS	(IV).		7.	To	evaluate	the	characteristics	and	outcomes	of	GCM	with	modern	treatment	(V)															
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4	MATERIALS	AND	METHODS			This	work	is	essentially	a	retrospective	study	where	the	data	generated	during	routine	examinations,	 treatment,	 and	 follow-up	 of	 patients	 with	 CS	 and	 GCM	 were	 collected	afterwards	 for	 research	 purposes.	 The	 project	 was	 launched	 by	 the	 real	 life	 clinical	observation	that	there	was	a	remarkable	increase	in	the	amount	of	patients	diagnosed	with	CS,	formerly	considered	an	extremely	rare	myocardial	disease,	in	our	institute.	The	study	 was	 planned	 and	 initiated	 at	 Helsinki	 University	 Hospital	 (HUH)	 and	 further	conducted	 in	 collaboration	 with	 the	 other	 Finnish	 university	 and	 central	 hospitals	treating	 patients	 with	 CS	 and	 GCM.	 During	 this	 project,	 the	 Myocardial	 Diseases	 in	Finland	(MIDFIN)-study	group	was	established,	consisting	of	academic	cardiologists	at	the	 five	 Finnish	 university	 hospitals.	 We	 also	 founded	 an	 internet-based	 national	registry	 of	 CS	 and	 GCM	 to	 help	 with	 the	 collection	 and	 storage	 of	 data	 for	 future	research.		
	
4.1	Study	population			Patients	diagnosed	with	biopsy-proven	CS	(n=229)	and	GCM	(n=49)	in	Finland	between	October	1988	and	 July	2015	were	enlisted	 through	 the	 following	process.	 In	2009,	all	five	Finnish	university	hospitals	and	17	central	hospitals	covering	the	whole	of	Finland,	were	contacted	by	email	and	if	necessary	by	telephone.	Possible	patients	were	screened	from	hospital	discharge	data	registries	using	the	ICD-10	code	I41.8*D86.8	(sarcoidosis	of	 heart)	 and	 the	 code	 D86	 (sarcoidosis)	 combined	 with	 one	 of	 the	 codes	 I42	(cardiomyopathy),	 I44.1-2	(2nd	or	3rd	degree	AV-block),	 I45.3	 (trifascicular	block),	 I46	(cardiac	 arrest),	 I47.2	 (VT),	 I49.0	 (VF),	 I49.3	 (premature	 depolarization),	 I50	 (heart	failure)	 or	 R00.1	 (bradycardia).	 In	 addition,	 colleagues	 in	 different	 hospitals	 treating	cardiomyopathies	were	 asked	 to	 gather	 patients	with	 CS	 and	 GCM	 in	 their	 care.	 The	investigator	 (RK)	personally	 visited	 each	hospital	with	potential	 adult	 (>18	years)	CS	patients	and	scrutinized	the	screening	data.	The	GCM	patients	were	identified	from	HUH	hospital	registries.			
4.1.1	Diagnostic	criteria		For	 inclusion,	 a	histologic	 confirmation	of	 sarcoidosis	was	 required	and	 thus	patients	with	 clinically	 diagnosed	 CS	 were	 excluded.	 Histological	 analysis	 of	 the	 heart	 (EMB,	cardiac	 tissue	 sample	 taken	 during	 open	 heart	 surgery	 or	 heart	 transplantation	 or	 at	autopsy)	 was	 the	 golden	 standard.	 The	 histological	 criteria	 for	 sarcoidosis	 were	 the	presence	of	at	 least	one	non-necrotizing	epithelioid	cell	granuloma	with	no	more	than	solitary	 giant	 cells	 and	 eosinophils	 and	 without	 myocardial	 necrosis	 and	 special	stainings	 to	 rule	 out	 other	 causes	 of	 granulomatous	 inflammation	 if	 considered	pertinent.	 The	 histological	 diagnosis	 of	 GCM	 required	 widespread	 inflammatory	
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infiltrate	including	multinucleated	giant	cells,	eosinophlis,	lymphocytes	and	histiocytes	together	with	 a	 variable	degree	of	myocardial	necrosis	 in	 the	 absence	of	well-formed	granulomas.	 The	 histological	 tissue	 samples	were	 originally	 analyzed	 by	 pathologists	from	 different	 university	 hospitals.	 For	 study	 V,	 the	 GCM	 biopsy	 samples	 were	reanalyzed	by	two	experienced	cardiac	pathologists	in	HUH.	If	well-formed	granulomas	were	detected,	 the	patients	were	excluded	 for	having	CS	according	 to	 the	Multicenter	GCM	Study	Group	criteria	(11).	In	 case	 of	 missing	 cardiac	 tissue	 verification,	 extracardiac	 organ	 histologic	 proof	 of	sarcoidosis	 in	 combination	 with	 both	 clinical	 manifestation	 indicative	 of	 myocardial	disease	 and	 abnormalities	 compatible	 with	 CS	 in	 either	 LGE-CMR,	 18F-FDG-PET	 or	echocardiography	was	required.	The	typical	imaging	findings	compatible	with	CS	were	LGE	in	a	non-coronary	artery	disease	pattern	in	LGE-CMR,	focal	18F-FDG	uptake	with	or	without	 a	 concomitant	 perfusion	 defect	 in	 PET,	 and	 LV	 dysfunction	 and/or	 septal	abnormalities	at	echocardiography.	In	total,	our	inclusion	criteria	adhered	to	the	recent	expert	consensus	guidelines	(4).	Isolated	 CS	 was	 defined	 as	 sarcoidosis	 involving	 the	 heart	 without	 prior	 history	 or	evident	signs	or	symptoms	of	sarcoidosis	outside	the	heart.	The	diagnostic	work-up	for	screening	 extracardiac	 organs	 included	 chest	 X-ray,	 clinical	 examination,	 basic	laboratory	 exams,	 and	 a	 detailed	 medical	 history,	 but	 further	 studies	 such	 as	 chest-computed	tomography	or	ophthalmologic	examinations	were	not	routinely	conducted.	Patients	who	had	18F-FGD	uptake	 in	mediastinal	 lymph	nodes	 in	PET	but	no	signs	of	sarcoidosis	elsewhere	outside	the	heart	were	included	in	the	isolated	CS	group.		
4.1.2	Studies	I-V	-The	 cohort	 in	 study	 I	 constituted	 of	 the	 110	 patients	 diagnosed	 with	 histologically	proven	 CS	 across	 the	 whole	 of	 Finland	 between	 October	 1988	 and	 February	 2012	detected	through	the	aforementioned	conduct.	All	the	patients	in	studies	II-III	and	some	of	the	patients	in	study	IV,	were	subgroups	of	this	cohort.	-The	 cohort	 in	 study	 II	 (conducted	prior	 to	 study	 I)	was	 screened	 from	HUH	medical	records	and	the	EMB	registry.	Between	January	2000	and	December	2010,	576	patients	underwent	diagnostic	EMBs,	excluding	transplant	surveillance	biopsies.	Biopsy-proven	CS	was	diagnosed	 in	 52	patients	 and	33	 of	 them	without	 extracardiac	manifestations	were	included	in	study	II.		-The	 cohort	 in	 study	 III	 (conducted	 prior	 to	 study	 I)	 was	 identified	 from	 the	 HUH	pacemaker	 registry.	 Between	 January	1999	 and	April	 2009	 there	was	 a	 total	 of	 6420	pacemaker	implantations,	of	which	133	were	for	2nd	or	3rd	AV-block	in	patients	aged	18-55	years,	and	these	patients	constituted	the	population	in	study	III.		
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-The	 cohort	 in	 study	 IV	 consisted	of	62	patients	 from	six	Finnish	hospitals	with	new-onset	treatment	naïve	CS	diagnosed	between	December	2010	and	December	2014	with	hs-cTnT/I	measured	before	and	following	the	initiation	of	corticosteroid	treatment.	To	be	 included,	 the	 patients	 had	 to	 have	 estimated	 glomerular	 filtration	 >60	ml/min/1.73m2	by	the	Modification	of	Diet	in	Renal	Disease	(MDRD)	formula.		-The	 cohort	 in	 study	 V	 consisted	 of	 the	 32	 patients	 diagnosed	 with	 histologically	confirmed	 GCM	 and	 seen	 in	 HUH	 between	 January	 1991	 and	 December	 2011.	 The	patients	were	identified	from	HUH	medical	records	and	HUH	pathology	registry.			
4.2	Data	collection	After	patient	 inclusion,	RK	 reviewed	 the	 relevant	hospital	 charts	 for	data	on	patients’	demographics,	 histologic	 findings,	 symptoms,	 initial	 and	 later	 clinical	 manifestations,	results	 of	 imaging	 and	 laboratory	 studies,	 evolution	 of	 LVEF,	 invasive	 procedures,	details	 of	 treatment	with	 drugs	 and	 devices,	 and	 the	 occurrence	 of	 adverse	 outcome	events.	 Since	 the	 initial	 data	 collection	 on-site	 in	 different	 hospitals,	 the	 follow-up	information	on	disease	progression	and	adverse	cardiac	events	was	collected	 through	the	MIDFIN	network.	The	last	CS	patients	were	included	in	February	2012	and	adverse	events	were	recorded	up	to	the	end	of	December	2013	(I).	For	this	thesis,	the	number	of	new	 CS	 and	 GCM	 cases	was	 updated	 until	 July	 2015	 and	 the	 updated	 data	 is	 in	 part	unpublished.	 The	 work	 started	 in	 2008	 and	 data	 collection	 was	 fully	 retrospective	between	1988	 and	 2008	 and	partly	 prospective	 thereafter.	 The	 causes	 of	 death	were	determined	by	hospital	chart	review.	The	mortality	data	was	double-checked	from	the	Finnish	 Population	 Register	 Centre	 in	 January	 2014.	 All	 imaging	 studies	 were	performed	as	part	of	routine	clinical	care.	The	measurements	of	biomarkers	were	taken	and	analyzed	as	part	of	clinical	routine	except	some	of	the	hs-cTnT	measurements	taken	during	 outpatient	 visits	 at	 HUH	 (Study	 IV).	 Detailed	 imaging	 and	 biomarker	 analysis	protocols	are	described	in	the	original	articles.		
4.3	Ethical	aspects	The	 nationwide	 study	 (I)	 had	 the	 approval	 of	 the	 national	 ethical	 review	 board	(STM/1219/2009).	The	other	studies	(II-V)	were	approved	by	the	institutional	review	board	 (Ethics	 Committee,	 Department	 of	Medicine,	 Helsinki	 University	Hospital).	 The	studies	were	conducted	according	to	the	Declaration	of	Helsinki.	The	patients	gave	their	informed,	written	consent	to	data	collection	for	the	national	MIDFIN	registry.			
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4.4	Statistical	analyses		Continuous	variables	were	presented	as	mean	value	±	SD	when	sample	distribution	was	symmetric,	and	median	(min	-	max)	when	sample	distribution	was	skewed.	Categorical	variables	were	presented	as	absolute	numbers	and	percentages.	Comparisons	between	groups	were	 analyzed	using	 the	Chi-square	 test,	 or	 Fisher’s	 exact	 test	when	expected	values	were	less	than	5,	for	categorical	data.	For	continuous	variables,	the	Student’s	t-test,	 Kruskall-Wallis,	 analysis	 of	 variance	 or	 Mann-Whitney	 test	 were	 applied	 as	appropriate.		Within-group	comparisons	were	made	using	Wilcoxon’s	signed	ranks	test	and	 McNemar’s	 test.	 In	 all	 tests,	 a	 2-tailed	 P<0.05	 was	 considered	 statistically	significant.	Survival	analyzes	were	calculated,	first,	from	the	onset	of	symptoms	and,	second,	from	the	 date	 of	 CS	 or	GCM	diagnosis.	 Thus,	 analyses	were	 performed	 for	 total	 population	and	 separately	 after	 excluding	 the	 cases	 diagnosed	 post-mortem	 or	 from	 explanted	hearts.	In	study	I	the	outcome	events	were	presented	separately	for	1)	cardiac	death,	2)	a	 composite	 of	 cardiac	 death	 and	 transplantation,	 whichever	 came	 first,	 and	 3)	 a	composite	 of	 cardiac	 death,	 transplantation,	 and	 aborted	 sudden	 cardiac	 death.	 In	studies	 II-V	 the	 time-dependent	 outcome	 events	 included	 1)	 a	 composite	 of	 cardiac	death	and	cardiac	transplantation	(V),	2)	aborted	sudden	cardiac	death	(VF	treated	by	external	or	internal	defibrillation),	and	sustained	VT	(II,	III),	and	3)	new	high-grade	AV-block,	whichever	came	first	(IV).	Survival	curves	free	of	the	composite	end	point	were	plotted	by	the	Kaplan-Meier	method,	and	factors	influencing	survival	were	analyzed	by	the	 log	 rank	 test	 and	by	Cox	 regression	 analysis.	 The	 analyses	were	performed	using	SPSS	versions	17.0-22.0	for	Windows	(SPSS	Inc.;	Chicago,	IL,	USA).												
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5	RESULTS			
5.1	Incidence	and	prevalence	of	clinical	CS	and	GCM	in	Finland	(I,V)	A	total	of	229	CS	patients	were	diagnosed	 in	Finland	 from	October	1988	through	 July	2015	(studies	I-IV	and	Kandolin	et	al.	unpublished	results).	The	annual	detection	rate	of	CS	was	0.6	per	100	000	adults	(>18	years)	in	the	last	full	2-year	study	period	between	2013	and	2014.	The	geographical	distribution	of	CS	patients	in	Finland	is	presented	in	
Figure	10.	The	prevalence	of	histologically	diagnosed	CS	cases	in	2012	was	2.2	per	100	000	(I).	
	
Figure	10.	Distribution	of	histologically	diagnosed	CS	patients	in	Finland	between	1988	and	2015	by	health	care	districts.	SHP=	sairaanhoitopiiri	(Finnish	for	health	care	district),	HUS=	Helsingin	ja	uudenmaan,	PP=	Pohjois-Pohjanmaan,	PS=	Pohjois-Savon,	P=	Pirkanmaan,	PK=	Pohjois-Karjalan,	VS=	Varsinais-Suomen,	KS=	Keski-Suomen,	EP=	Etelä-Pohjanmaan,	IS=	Itä-Savon,	KP=	Keski-Pohjanmaan,	SAT=	Satakunnan,	EK=	Etelä-Karjalan,	KH=	Kanta-Hämeen,	L=	Lapin,	PH=	Päijät-Hämeen.	
HUS	126	PPSHP	34	PSSHP	19	PSHP	17	PKSHP	10	VSSHP	8	KSSHP	3	EPSHP	2	ISSHP	2	KPSHP	2	SAT(=S)SHP	2	EKSHP	1	KHSHP	1	LSHP1	PHSHP1	___________	=229	
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Over	the	study	period	of	26	years,	the	detection	rate	of	CS	multiplied.	More	specifically,	the	annual	nationwide	detection	 rate	of	0.5	patients	per	year	 in	 the	earliest	 two-year	period	 between	 1988-1989	 increased	 to	 27	 per	 year	 in	 the	 last	 follow-up	 two-year	period	 from	2013-2014	 (Figure	 11).	 Thus	 the	number	of	patients	diagnosed	with	CS	increased	by	more	than	50-fold	during	the	study	period.			
 
 
Figure	 11.	The	number	of	new	CS	cases	diagnosed	 in	 two-year	periods	 from	1988	 to	2014	in	Finland.								
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A	total	of	49	patients	with	histologically	confirmed	GCM	were	seen	at	HUH	during	the	GCM	study	period	between	June	1991	and	December	2014	(study	V	and	Kandolin	et	al.	unpublished	 results).	 HUH	 is	 a	 nationwide	 referral	 center	 for	 cardiac	 transplantation	and	thus	these	GCM	cases	are	likely	to	present	the	majority	of	GCM	cases	diagnosed	in	Finland	 over	 the	 23-year	 range.	 Therefore,	 the	 annual	 detection	 rate	 of	 histologically	verified	GCM	in	Finland	between	2013	and	2014	was	0.13	per	100	000.	Similarly	to	CS,	the	diagnostic	rate	markedly	increased	over	the	study	period,	especially	over	the	latter	half	of	the	study	(Figure	12).		
	
Figure	12.	The	number	of	new	GCM	cases	diagnosed	in	two-year	periods	from	1991	to	2014	in	Finland.		
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5.2	Patient	characteristics	and	associated	disorders	(I)	
5.2.1	CS	The	mean	 age	 of	 the	 110	 CS	 patients	was	 51±	 9	 years,	 ranging	 from	 27	 to	 69	 years.	There	was	a	female	predominance:	65%	(71	patients)	were	women.	Table	8	presents	the	 associated	 illnesses	 in	 CS	 patients	 (Kandolin	 et	 al.,	 unpublished	 results).	 CS	 was	associated	 with	 other	 autoimmune	 diseases	 in	 16%	 of	 cases	 (18	 patients).	 	 The	autoimmune	 disorders	 preceded	 the	 onset	 of	 CS	 in	 all	 cases.	 Thyroid	 disorders	were	most	common	in	12%	(13	patients)	and	were	overrepresented	compared	to	the	general	population	(271).		Seventy-one	 (65%)	 of	 the	 110	 patients	 with	 CS	 underwent	 coronary	 angiography	 or	coronary	computed	tomography.	Coronary	artery	disease	was	diagnosed	in	five	(4.5%)	patients.	 Two	 patients	 had	 mild	 coronary	 stenoses	 and	 were	 treated	 with	pharmacotherapy	alone.	One	patient	underwent	a	percutaneous	coronary	intervention.	Furthermore,	one	patient	who	underwent	several	percutaneous	coronary	interventions	was	 later	 referred	 to	 cardiac	 transplantation	 due	 to	 terminal	 heart	 failure	 and	 the	diagnosis	of	CS	was	 revealed	 from	 the	explanted	heart.	Additionally,	 one	patient	with	pulmonary	sarcoidosis	and	VTs	underwent	coronary	bypass	surgery	and	the	diagnosis	of	 cardiac	 sarcoid	 involvement	 was	 found	 in	 cardiac	 tissue	 samples	 taken	 during	surgery.													
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Table	8.	Associated	disorders	in	110	patients	with	CS	(Kandolin	et	al.,	unpublished	results).		_______________________________________________________	
Autoimmune	disorders	Hypothyroidism	 	 	 11	(10%)	Type	I	diabetes	mellitus	 	 3	(3%)	Rheumatoid	arthritis	 	 1	(1%)	Inflammatory	bowel	disease	 1	(1%)	Coeliac	disease																																							1	(1%)	Multiple	sclerosis																																		1	(1%)	________________________________________________________	
Respiratory	disease	Asthma																																											 10	(9%)	COPD																																																 1	(1%)	________________________________________________________	
Malignancy	Thyroid	cancer																													 2	(2%)	Breast	cancer																																 2	(2%)	Colon	cancer																																	 1	(1%)	Lymphoma																																			 1	(1%)	Thymoma																																						 1	(1%)	Melanoma																																						 1	(1%)	Myeloma																																								 1	(1%)	________________________________________________________	
Other	Hypertension		 	 	 26	(24%)	Dyslipidemia	 	 	 	 17	(15%)	Type	II	diabetes	mellitus	 	 13	(12%)	Coronary	artery	disease	 	 5	(5%)	(2	with	medical	treatment	alone)	Kidney	insufficiency	 	 	 1	(1%)	______________________________________________________			
5.2.2	GCM	(V)	The	mean	 age	 of	 the	 32	 GCM	 patients	was	 52.5	 ±	 12.7	 years,	 ranging	 from	 35	 to	 69	years.	 	 The	majority	 of	 them,	 69%	 (22	patients)	were	 female.	Among	 the	32	patients	with	GCM,	19%	(6	patients)	had	associated	autoimmune	disorders,	 including	 reactive	arthritis,	 iritis,	 and	 thyreoiditis	 (n=1),	 coeliac	 disease	 (n=2),	 psoriasis	 (n=1),	rheumatoid	 arthritis	 (n=1),	 and	 hypothyroidism	 (n=1).	 One	 patient	 with	 vitiligo	 had	thymoma-associated	 orbital	 myositis,	 i.e.,	 symptoms	 compatible	 with	 giant	 cell	polymyositis.	 Furthermore,	 in	 accordance	 with	 genetic	 susceptibility,	 among	 the	 32	patients,	 two	 women	 were	 sisters	 and	 they	 both	 had	 a	 medical	 history	 of	 coeliac	disease.	 These	 two	patients	 had	 a	healthy	brother	 and	 their	 first-degree	 relatives	did	not	have	evidence	of	autoimmune	disease	or	cardiomyopathy.			
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5.3	Presenting	manifestations	(I)	The	first	clinical	manifestations	in	CS	and	GCM	are	presented	in	Table	9.	AV-block	was	the	most	frequent	first	manifestation	in	CS,	presenting	in	48	(44%)	patients.	Following	AV-block	 in	 frequency,	 ventricular	 arrhythmias	 were	 the	 second	 most	 common	manifestation,	presenting	in	33%	patients.	The	third	most	common	manifestation	was	symptomatic	heart	failure,	presenting	in	18%.	The	median	LVEF	at	echocardiography	in	patients	presenting	with	heart	failure	was	30%	(range:	15-47%).	In	 patients	 with	 GCM,	 AV-block	 and	 heart	 failure	 were	 equally	 common	 first	manifestations,	 in	 31%,	 followed	 by	 ventricular	 arrhythmias	 in	 25%.	 First	manifestations	in	GCM	are	described	in	Table	9.	
Table	9.	Modes	of	presentation	in	110	CS	patients	and	32	GCM	patients.	_____________________________________________________________________________________________	First	clinical		 								 All	CS	 	 Clinically	 					CS	with	 	 All	GCM	Manifestation								 patients,	 	isolated																extracardiac	 patients,		 	 								 N=110								 CS,	n=71*														disease,	 	 n=32		 	 	 	 	 																					 					n=39*	_____________________________________________________________________________________________	2nd	or	3rd	 							 48	(44	%)										34	(48%)											14	(36%)	 	 10	(31%)	degree		AV-block	_____________________________________________________________________________________________	VT	or	VF	 					 36	(33%)	 				27	(38%)	 						9	(23%)	 	 8	(25%)		 	 					 VT	31	(28%)			 	 	 	 	 VT	7	(22%)		 	 					 VF	5	(5%)	 	 	 	 	 	 VF	1	(3%)¶	_____________________________________________________________________________________________	Heart	failure		 				 20	(18%)	 				8	(11%)	 						12	(31%)	 	 10	(31%)	_____________________________________________________________________________________________	Others		 				 6	(6%)†	 				2	(3%)	 							4	(10%)	 	 4	(13%)§	_____________________________________________________________________________________________	The	data	presents	numbers	of	patients	and	(%).	CS=	cardiac	sarcoidosis,	GCM=	giant	cell	myocarditis,	AV-block=	atrioventricular	block,	VT=	ventricular	tachycardia,	VF=	ventricular	fibrillation.	*For	 comparison	 between	 clinically	 isolated	 CS	 and	 CS	 with	 extracardiac	 disease,	p=0.016.	¶Out-of-hospital	cardiac	arrest.	†	Multiple	ventricular	premature	beats	(n=4),	mitral	regurgitation	(n=1)	and	pericardial	effusion	(n=1).	§	 Chest	 pain	 and	 ST-segment	 changes	 in	 ECG,	mimicking	 acute	myocardial	 infarction	(n=3)	and	perimyocarditis	(n=1).		
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Manifestations	 from	 outside	 the	 heart	 were	 observed	 in	 39	 (35%)	 CS	 patients.	 The	lungs	were	the	most	commonly	affected	organ	in	23	(21%)	patients,	followed	by	lymph	nodes	(n=8),	skin	(n=7),	central	nervous	system	(n=5),	eyes	(n=4),	and	liver	(n=3).	The	diagnostic	delay,	ie.,	the	median	time	from	first	cardiac	manifestation	to	histologic	CS	 diagnosis,	 was	 9.5	 months	 (range	 0.3-168)	 in	 the	 whole	 group	 of	 CS	 patients	(n=110).	In	case	where	there	was	AV-block	as	the	first	presentation	(n=48),	the	median	diagnostic	 delay	was	 14	months,	 compared	 to	 six	months	 in	 cases	 of	 heart	 failure	 or	VT/VF	as	presenting	manifestations	(p=0.182).		
	
5.3.1	Importance	of	CS	and	GCM	in	idiopathic	AV-block	(III)	A	key	discovery	of	this	work	was	the	significance	of	CS	and	GCM	in	the	causal	spectrum	of	 AV-block	 in	 young	 and	middle-aged	 adults.	 From	 the	HUH	pacemaker	 registry,	we	identified	a	total	of	6420	patients	who	had	undergone	pacemaker	implantation	for	2nd	or	 3rd	 degree	 AV-block	 between	 1999	 and	 2009.	 Patients	 <18	 years	 were	 excluded	because	 of	 the	 high	 proportion	 of	 congenital	 heart	 diseases	 and	 the	 low	 incidence	 of	sarcoidosis	in	this	age	group.	Respectively,	patients	aged	>55	were	excluded	due	to	the	high	 prevalence	 of	 conduction	 tissue	 degeneration.	 	 Consequently,	 there	 were	 113	patients	aged	18-55	years,	and	61	of	them	had	a	known	etiology	of	AV-block	at	the	time	of	pacemaker	implantation.	The	other	etiologies	are	presented	in	Figure	13	(Kandolin	et	al.,	unpublished	results).	The	remaining	72	patients	(with	a	median	age	of	47,	61%	female)	had	unexplained	AV-block	at	the	baseline.	After	diagnostic	studies,	18	of	the	72	(25%,	 95%	 CI	 15-30%)	 patients	 with	 initially	 unexplained	 AV-block	 were	 diagnosed	with	either	CS	(n=14)	or	GCM	(n=4).	Additionally,	four	patients	had	echocardiographic	and	 18F-FDG-PET	 findings	 compatible	 with	 CS,	 but	 due	 to	 the	 lack	 of	 histologic	verification,	 they	were	classified	as	having	 idiopathic	AV-block	and	clinically	probable	CS.	Considering	all	2nd	to	3rd	degree	AV-blocks	in	this	age	group,	CS	and	GCM	explained	14%	 (18	 out	 of	 133)	 and	 including	 the	 non-histologically	 proven	 CS	 cases,	 the	percentage	is	17%	(22	out	of	133).			
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Figure	 13.	 Etiologies	 for	 AV-block	 with	 a	 known	 cause	 at	 the	 time	 of	 pacemaker	implantation	(n=61)	(Kandolin	et	al.,	unpublished	results).		There	were	characteristic	differences	between	the	patients	with	CS	or	GCM	compared	to	the	patients	in	whom	AV-block	remained	idiopathic	after	the	diagnostic	work-up.	First,	89%	of	the	patients	with	CS	or	GCM	were	female,	compared	to	the	52%	in	patients	with	idiopathic	 AV-block	 (p<0.05).	 Other	 characteristic	 differences	 were	 lower	 LVEF	 at	presentation	 (median	 50%	 vs	 61%,	 p<0.05),	 a	 higher	 percentage	 of	 distal	 AV-block	(88%	 vs	 54%,	 p<0.01)	 and	 a	 higher	 proportion	 of	 septal	 abnormalities	 at	echocardiography	 (56%	 vs	 28%,	 p<0.01)	 in	 CS	 and	 GCM	 patients	 compared	 to	idiopathic	 AV-block	 patients.	 None	 of	 these	 characteristics	 differed	 between	 CS	 and	GCM	patients.		
5.3.2	Clinically	isolated	CS	(I)	In	the	total	CS	population	of	study	I,	71	out	of	110	(65%)	had	clinically	isolated	CS	type	(see	 4.1.1).	 The	 remaining	 39	 patients	 (35%)	 had	 extracardiac	manifestations.	 There	were	 marked	 differences	 in	 patients	 with	 isolated	 and	 extracardiac	 disease	 types	(Table	 10).	 First,	 isolated	 CS	was	 associated	with	 female	 predominance.	 Second,	 the	patients	with	 isolated	 disease	 type	 had	 a	 higher	 frequency	 of	 LV	 dysfunction,	 LGE	 at	CMR,	and	septal	abnormalities	indicating	more	widespread	cardiac	involvement.	In	line	with	 this,	 the	 laboratory	 markers	 of	 granulomatous	 inflammation	 were	 higher	 in	patients	with	 extracardiac	 disease	 (see	 5.6).	 Furthermore,	 isolated	 CS	was	 related	 to	worse	 survival	 free	 of	 cardiac	 death,	 transplantation,	 and	 aborted	 sudden	 death	 (see	5.8.2.1).			
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Table	 10.	 Differences	 in	 patient	 characteristics	 in	 clinically	 isolated	 CS	 vs	 CS	 with	extracardiac	manifestations	(I).	_____________________________________________________________________________________________	Characteristic	 Clinically	 	 CS	with	known	 P*	 		 	 	 isolated	CS,	 	 extracardiac		 	 	 n=71	 	 	 disease,	n=39	_____________________________________________________________________________________________	Age,	years		 	 51±9	 	 	 50±9	 	 	 0.463	(mean	±	SD)	_____________________________________________________________________________________________	Gender,	n	of	 	 53	(75%)	 	 18	(46%)	 	 0.003	females	_____________________________________________________________________________________________	Echocardiographic	findings	 	LVEF	<50%	 	 49/71	(69%)	 	 16/39	(41%)	 	 0.004	LV	dilatation	 	 27/64	(42%)	 	 16/38	(42%)	 	 1.000	Septal	thinning	or	 48/70	(69%)	 	 15/39	(38%)	 	 0.002	thickening	_____________________________________________________________________________________________	CMR	findings	Late	gadolinium	enhancement		 36/38	(95%)	 	 13/21	(62%)	 	 0.002	_____________________________________________________________________________________________	18F-FDG-PET	findings	Focal	FDG	uptake	 34/46	(74%)	 	 14/20	(70%)	 	 0.743	Mediastinal	lymph	 22/31	(71%)	 	 8/11	(73%)	 	 1.000	node	FDG	uptake	FDG	uptake	 	 12/30	(40%)	 	 4/9	(44%)	 	 1.000	outside	heart	and	mediastinum	_____________________________________________________________________________________________	CS=	 cardiac	 sarcoidosis,	 LVEF=	 left	 ventricle	 ejection	 fraction,	 LV=	 left	 ventricle,	CMR=cardiac	magnetic	resonance	imaging,	18-FDG-PET=18-fluorodexyglucose	positron	emission	tomography.		
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5.4	Imaging	and	ECG	findings	(I)	
5.4.1	Echocardiography	In	 the	cohort	of	110	CS	patients,	echocardiography	was	performed	at	 least	once	 in	all	patients,	 either	 at	 diagnosis	 or	 in	 case	 of	 post-mortem	 and	 post-transplantation	diagnoses,	 before	 diagnosis.	 At	 baseline,	 65	 out	 of	 110	 (59%)	 patients	 had	 reduced	LVEF	(<50%)	with	median	LVEF	45%	±14%.	LV	was	dilated	(LVEDD>	60	mm	in	men	or	>	 55	 mm	 in	 women)	 in	 43	 out	 of	 102	 (42%).	 Interventricular	 septal	 thinning	 or	thickening	 was	 discovered	 in	 63	 out	 of	 109	 (58%).	 It	 is	 notable,	 that	 not	 all	 these	findings	were	evident	at	 the	 first	performed	echocardiography,	but	 instead	developed	by	 the	 time	 of	 CS	 diagnosis.	 Other	 abnormalities	 detected	 were	 aneurysmatic	 wall	motion,	pericardial	effusion	(usually	mild	but	requiring	fenestration	in	one	patient)	and	mild	to	moderate	mitral	insufficiency.	In	 the	cohort	of	32	patients	with	GCM,	echocardiography	was	performed	 in	all	except	one	 patient	 with	 sudden	 cardiac	 death	 as	 the	 first	 manifestation.	 Initially,	 LVEF	 was	reduced	(<50%)	in	23	out	of	32	(74%)	with	a	median	LVEF	of	38	±13%.	LV	dilatation	was	observed	 in	nine	(28%)	patients.	Septal	 thinning	or	 thickening	was	discovered	 in	21	(68%)	and	LV	aneurysms	in	three	(10%)	patients.			
	
5.4.2	18F-FDG-PET	Of	 the	 110	 CS	 patients,	 66	 (60%)	 underwent	 18F-FDG-PET	 as	 a	 part	 of	 diagnostic	evaluation.	Some	48	(73%)	of	them	had	focally	increased	myocardial	FDG	uptake	and	in	44	 (67%),	 FDG	uptake	was	 superimposable	upon	a	perfusion	defect.	Accumulation	of	FDG	 in	 mediastinal	 lymph	 nodes	 was	 detected	 in	 30	 of	 the	 42	 (71%)	 patients	undergoing	 thoracic	 18F-FDG-PET.	 In	 comparison,	 hilar	 or	 mediastinal	lymphadenopathy	 was	 observed	 in	 15	 (14%)	 patients	 in	 native	 chest	 X-rays.	 In	 18	patients,	 FDG-positive	 mediastinal	 lymph	 nodes	 offered	 a	 biopsy	 target	 in	 case	 of	negative	EMB	and	high	suspicion	of	CS.		Of	the	32	GCM	patients,	12	(38%)	underwent	18F-FDG-PET	revealing	focal	FDG	uptake	in	 10	 (83%)	 and	 involving	 the	 septum	 in	 all.	 A	 concomitant	 perfusion	 defect	 was	observed	in	nine	and	two	patients	had	a	perfusion	defect	without	FDG	accumulation.		
5.4.3	LGE-CMR	Of	 the	 110	 CS	 patients,	 59	 (54%)	 underwent	 LGE-CMR	 as	 part	 of	 diagnostic	 process.	Overall,	LGE	was	observed	in	49	(83%).	Local	wall	thinning	or	thickening	was	detected	in	29	out	of	50	(58%).	Other	findings	perceived	were	ventricular	dysfunction,	dilatation	of	 ventricles,	 and	 aneurysmatic	 wall	 abnormalities.	 In	 the	 32	 GCM	 patients,	 CMR	showed	areas	of	LGE	in	each	of	the	nine	patients	who	underwent	the	study.	
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5.4.4	Electrocardiogram		An	 electrocardiogram	 was	 available	 in	 107	 out	 of	 110	 CS	 patients.	 At	 the	 time	 of	diagnosis	 some	 abnormalities,	 including	 bundle	 branch	 blocks,	 any	 level	 of	atrioventricular	blocks,	pathologic	Q-waves	or	ST-T	changes,	voltage	abnormalities,	or	frequent	VPBs	were	observed	 in	92	 (86%)	patients.	 	AV-block	was	 the	most	 common	finding,	present	in	48	(45%).	RBBB,	observed	in	40	(37%)	patients,	was	almost	twice	as	frequent	as	LBBB,	found	in	22	(21%)	patients.		
5.5	Biopsy	confirmation	(I,II,V)	In	the	national	cohort	of	110	CS	patients,	92	patients	had	undergone	one	or	more	EMBs	of	the	RV,	or	of	both	ventricles	(I).	Ultimately,	the	histologic	confirmation	of	sarcoidosis	was	 obtained	 from	 EMB	 in	 55	 (50%)	 patients.	 In	 47	 cases,	 biopsy	 verification	 was	acquired	 from	 extracardiac	 biopsy	 sites,	 including	 PET-positive	 mediastinal	 lymph	nodes	(n=18),	lungs	(n=11),	peripheral	lymph	nodes	(n=	8),	skin	(n=5),	liver	(n=3),	and	central	nervous	system	(n=2).	In	the	remaining	eight	patients	the	histologic	verification	was	obtained	from	explanted	hearts	at	transplantation	(n=6)	or	at	autopsy	(n=2).	The	value	of	repeated	EMBs	and	mediastinal	lymph	node	biopsies	in	diagnosing	CS	was	analyzed	in	the	cohort	of	55	patients	with	suspected	CS	undergoing	diagnostic	biopsies	at	HUH	between	2000	and	2010	(II).	In	33	patients	(60%),	the	CS	diagnosis	was	finally	verified	by	biopsy,	and	in	22	(40%)	the	histologic	confirmation	remained	unobtainable	despite	 cardiac	 symptoms	 and	 imaging	 results	 compatible	 with	 CS.	 Considering	 the	patients	with	eventual	histological	CS	confirmation,	the	first	EMB	session	revealed	CS	in	10	out	of	31	patients,	resulting	in	a	sensitivity	of	32%.	A	second	and	third	EMB	session	contributed	significantly	to	the	diagnoses,	as	the	cumulative	yield	of	repeated	EMBs	was	55%	 (17	 out	 of	 31).	 In	 one	 patient	 who	 had	 not	 undergone	 diagnostic	 biopsies,	 the	histologic	diagnosis	was	made	from	the	native	heart	removed	at	transplantation.		Due	 to	 the	 poor	 sensitivity	 of	 EMB,	 the	 diagnostic	 strategy	 at	 HUH	was	 upgraded	 in	2006	to	target	18F-FDG-PET-positive,	i.e.,	“hot”	mediastinal	lymph	nodes	in	case	of	high	suspicion	of	CS	despite	negative	EMBs.	Twelve	patients	with	 “hot”	mediastinal	 lymph	nodes	underwent	sampling	of	these	lymph	nodes	at	mediastinoscopy	and	in	11	(92%),	the	 samples	 identified	 sarcoidosis.	 Nevertheless,	 the	 22	 patients	 without	 final	histological	CS	confirmation	underwent	a	total	of	33	EMBs	and	one	mediastinal	lymph	node	biopsy	with	negative	results.		If	these	patients	were	classified	as	having	CS,	in	the	same	way	 as	many	 recent	 studies	 have	 done,	 the	 sensitivity	 of	multiple	 EMBs	 in	 this	cohort	would	be	31.5%	(17	out	of	54).	In	the	total	population	of	biopsied	patients,	the	sensitivity	of	EMB	in	histologically	or	clinically	diagnosed	CS	was	19%	(10	out	of	53)	in	the	first	EMB,	22%	(5	out	of	23)	in	a	second	EMB	and	50%	(2	out	of	4)	in	a	third	EMB.	Over	the	study	period,	the	mean	number	of	right	ventricular	samples	per	biopsy	session	increased	from	5.5	(range	4-7)	during	the	early	half	(from	2000	to	2005)	to	6.2	(range	3-10)	over	the	latter	half	(years	2006-2010).	The	mean	number	of	LV	samples,	acquired	
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only	after	2006	but	with	 increasing	 frequency,	was	5.3	 (range	2-9)	per	 session.	Open	chest	core	needle	biopsies	were	not	performed	in	this	cohort.	The	diagnostic	yield	of	EMB	was	better	in	GCM.	Of	the	32	GCM	patients,	28	(88%)	had	undergone	 one	 or	 several	 EMBs	 (n=28)	 and	 surgical	 biopsies	 (n=3).	 The	 first	 cardiac	biopsy	 session	 revealed	 GCM	 in	 19	 out	 of	 28	 cases,	 resulting	 in	 a	 diagnostic	 yield	 of	68%.	 The	 second	 cardiac	 biopsy	 gave	 diagnosis	 in	 five	 of	 seven	 patients,	 and	 a	 third	cardiac	 biopsy	 in	 two	 of	 two	 patients.	 Therefore,	 the	 cumulative	 yield	 of	 repeated	cardiac	biopsies	was	93%	(26	out	of	28).	The	three	surgical	myocardial	biopsies	were	taken	in	association	with	surgical	procedures	(pericardial	drainage,	ventricle	resection	and	ventricular	assist	device	implantation),	and	the	samples	were	positive	in	all.	Lastly,	of	 the	32	GCM	patients,	 six	 of	whom	 two	had	undergone	EMBs	with	negative	 results,	were	diagnosed	at	autopsy	(n=4)	or	from	explanted	hearts	(n=2).		
5.6	Laboratory	findings	(I,	IV)	Hs-cTnT/I	 were	 repeatedly	 measured	 in	 a	 cohort	 of	 62	 CS	 patients	 with	 new-onset,	treatment-naïve	CS	(IV).	At	enrollment,	hs-cTnT	was	elevated	(>13	ng/l)	in	26	out	of	50	(52%)	 and	 hs-cTnI	 (>0.04	 ng/ml)	 in	 seven	 out	 of	 12	 (58%)	 of	 the	 newly	 diagnosed	patients.	Elevated	hs-cTnT/I	was	associated	with	LV	dysfunction	(p=0.001),	a	tendency	to	 higher	 NT-proBNP	 levels	 (p=0.085),	 and	 a	 tendency	 towards	 more	 heart	 failure	(p=0.064)	and	less	AV-block	as	a	first	manifestation	(p=0.069).	More	specifically,	in	the	new-onset	 CS	 patients,	 LVEF	 averaged	 43±	 14%	 in	 patients	 with	 elevated	 hs-cTnT/I	compared	to	53±	10%	in	patients	with	normal	hs-cTnT/I.		The	 laboratory	markers	of	granulomatous	 inflammation,	 including	ACE,	 lysozyme	and	daily	urinary	calcium	excretion	in	the	110	CS	patients	are	presented	in	Table	11.	The	levels	 of	 these	 markers	 were	 higher	 in	 CS	 patients	 with	 extracardiac	 sarcoidosis	compared	to	clinically	isolated	CS.	 	 	
Table	11.	Laboratory	findings	in	CS	patients	(I).	_____________________________________________________________________________________________	Laboratory	 				All	CS	patients,	 Clinically	isolated	 CS	with	known									P*	finding	 				n=110	 	 CS	patients,		 	 extracardiac		 	 	 	 	 n=71	 	 	 disease,	n=39	_____________________________________________________________________________________________	Elevated	ACE	 				22/90	(24%)	 9/59	(15%)	 	 13/31	(42%)	 							0.005	_____________________________________________________________________________________________	Elevated	LZM					40/74	(54%)	 21/48	(44%)	 	 19/26	(73%)	 							0.016	_____________________________________________________________________________________________	Elevated	dU-Ca			22/45	(49%)	 9/24	(38%)	 	 13/21	(62%)	 							0.029	_____________________________________________________________________________________________	The	 data	 presents	 numbers	 of	 patients	 (%).	 CS=	 cardiac	 sarcoidosis,	 ACE=	 serum	angiotensin-converting	enzyme,	LZM=	serum	lysozyme,	dU-Ca=	daily	urinary	calcium.			*	p-values	for	comparison	between	clinically	isolated	and	extracardiac	disease.	
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5.7	Description	of	management	(I,V)	
5.7.1	Immunosuppressive	treatment	All	 the	 102	 CS	 patients	 diagnosed	 clinically	 before	 death	 or	 cardiac	 transplantation	received	 disease-modifying	 immunosuppressive	 therapy	 (I).	 There	 were	 slight	differences	between	the	hospitals	involved	in	the	study	in	implementing	the	treatment,	but	 the	 therapy	 followed	 same	 main	 principles.	 	 Corticosteroids	 were	 started	 at	diagnosis,	with	the	initial	daily	prednisone-equivalent	dose	ranging	from	30mg	to	80mg.	The	starting	dose	was	<60mg	in	42	and	≥	60mg	in	60	patients.	Corticosteroid	dose	was	decreased	slowly	to	a	prednisone-equivalent	daily	dose	of	approximately	10mg	within	six	 months	 from	 starting	 treatment.	 In	 48	 patients,	 steroids	 were	 used	 continuously	until	 the	 end	 of	 follow-up.	 In	 the	 remaining	 54	 patients,	 steroids	 were	 either	discontinued	or	 used	 intermittently	 due	 to	 fluctuating	disease	 activity	 or	 steroid	 side	effects.	In	patients	with	active	disease	following	corticosteroid	tapering,	steroid-sparing	immunosuppressants	 were	 introduced.	 Azathioprine	 was	 utilized	 in	 50	 patients,	methotrexate	 in	 six	patients,	mycophenolate	mofetil	 in	 three	patients,	 cyclosporine	 in	two	patients	and	infliximab	in	one	patient	during	the	study	period.	 	 	All	 the	 26	 patients	 diagnosed	 with	 GCM	 before	 death	 or	 transplantation	 received	combined	 immunosuppression	with	2-4	drugs	(V).	The	 treatment	 included	steroids	 in	26	 patients,	 azathioprine	 in	 24	 patients,	 cyclosporine	 in	 20	 patients,	 mycophenolate	mofetil	 in	 three	 patients,	 muromonab	 in	 one	 patient,	 gammaglobulin	 in	 one	 patient,	methotrexate	in	one	patient	and	intravenous	methylprednisolone	in	seven	patients.	The	most	 common	 drug	 combination	 therapy	 was	 triple	 immunosuppression	 with	corticosteroid,	azathioprine,	and	cyclosporine	utilized	in	17	(65%)	patients.	Prednisone	was	started	at	approximately	60mg		(or	0.75-1mg/kg)	per	day	and	tapered	to	a	10mg	daily	 dose	 within	 six	 months.	 Prednisone	 was	 discontinued	 if	 the	 patient	 had	 been	stabile	 for	 6-12	months	 or	 in	 the	 case	 of	 intolerable	 side	 effects.	 The	 target	 dose	 of	azathioprine	was	1.5-2mg/kg/day.	The	target	concentration	of	cyclosporine	was	at	the	lower	therapeutic	range	for	post-cardiac-transplantation	(80-120	μg/L).	
5.7.2	Device	and	medical	therapy		During	the	study	period,	a	permanent	pacemaker	was	implanted	in	87	out	of	110	(79%)	of	CS	patients	 (I).	To	prevent	 sudden	cardiac	death	and	 to	manage	malignant	VTs,	 an	ICD	was	implanted	in	59	(54%)	patients.	The	indication	for	ICD	was	primary	prevention	(LVEF	≤	35%)	 in	nine	 (15%)	patients,	 secondary	prevention	(history	of	 sustained	VT,	including	 prior	 cardiac	 arrest)	 in	 41	 (69%),	 and	 other	 indication	 (treating	 clinician`s	judgment)	in	nine	(15%)	patients	(Kandolin	et	al.,	unpublished	results).	A	biventricular	pacemaker	was	implanted	in	17	(15%)	patients.	The	drug	treatment	in	CS	included	beta	blockers	 in	 104	 (95%)	 patients,	 angiotensin-converting	 enzyme	 inhibitors	 or	angiotensin	 receptor	 blockers	 in	 89	 (81%)	 patients,	 diuretics	 in	 48	 (44%),	 and	amiodarone	in	25	(23%)	patients.		
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Of	 the	 32	 GCM	 patients,	 11	 (34%)	 received	 inotropic	 agents	 including	 levosimendan	(n=6),	dopamine,	or	dobutamine	(n=5),	norepinephrine	(n=1),	epinephrine	(n=1),	and	milrinone	 (n=2)	 (Kandolin	 et	 al.,	 unpublished	 results).	 Of	 the	 26	 GCM	 patients	diagnosed	 before	 death	 or	 transplantation,	 25	 (96%)	 received	 beta	 blockers	 and	 19	(73%)	antiarrhythmic	drugs	 (mainly	 amiodarone).	A	pacemaker	was	 implanted	 in	21	(81%)	and	ICD	in	18	(69%)	patients.			
5.8	Outcome	(I,IV,V)	
5.8.1	Observations	during	treatment	and	follow-up	in	CS	
5.8.1.1	Clinical	manifestations	The	cohort	of	110	CS	patients	was	 followed	 for	a	median	of	79	months,	 i.e.,	6.6	years	(range	 12-303	 months)	 from	 first	 symptom	 onset.	 In	 addition	 to	 the	 48	 patients	receiving	a	pacemaker	for	2nd	or	3rd	degree	AV-block	as	part	of	the	early	work-up,	nine	(8%)	 patients	 developed	 a	 new	 2nd	 or	 3rd	 degree	 conduction	 block	 necessitating	pacemaker	implantation	later	during	the	follow-up.	Thus,	a	total	of	52%	of	the	whole	CS	cohort	 had	 significant	 atrioventricular	 conduction	 abnormalities	 during	 the	 course	 of	the	disease.		Furthermore,	15	(14%)	patients	experienced	VF	and	41	(37%)	patients	had	sustained	VT,	either	as	 first	manifestation	or	 later	during	the	disease	course.	During	the	median	follow-up	of	53	months,	i.e.,	4.4	years	(range	0-183	months)	from	ICD	implantation	until	the	 close	 of	 the	 study	 period,	 24	 (41%)	 of	 the	 59	 patients	 with	 ICD	 received	 an	appropriate	 ICD	 therapy	 (shock	 and/or	 anti-tachycardia	 pacing)	 (Kandolin	 et	 al.,	unpublished	results).	Regarding	 systolic	 dysfunction,	 74	 (67%)	 of	 the	 patients	 either	 had	 systolic	 LV	dysfunction	(EF	<50%)	at	diagnosis	(n=65),	or	developed	it	 later	during	the	follow-up	(n=9).			
5.8.1.2	Treatment	effect	evaluation	The	clinical	response	to	corticosteroid	therapy	was	evaluated	from	three	aspects.	First,	initiation	of	 corticosteroids,	 resulted	 in	 the	 recovery	of	 atrioventricular	 conduction	 in	20%	 (7	 of	 the	 35	 patients	 with	 accurate	 pacemaker	 follow-up	 data	 concerning	 the	percentage	 of	 pacing)	 defined	 as	 <10%	 ventricular	 pacing	 on	 follow-up.	 Second,	 LV	function	at	echocardiography	was	analyzed	before	and	12	months	after	the	initiation	of	steroids.	In	the	102	patients	receiving	immunosuppressants,	there	was	no	difference	in	LVEF	 at	 diagnosis	 and	 after	 treatment	 (LVEF	 44.9	 ±	 12%	 vs	 45.4±	 11%)	 (p=0.532).	Nevertheless,	 in	 the	 subgroup	 of	 patients	 with	 severe	 LV	 impairment	 (EF	 <35%)	 at	diagnosis,	 mild	 yet	 significant	 recovery	 of	 LV	 function	 was	 observed	 (LVEF	 before	treatment	 27.9±	 4.1%	 vs	 LVEF	 12	 months	 after	 treatment	 34.1±	 8.3%)	 (p=0.005).	
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However,	no	amelioration	of	LVEF	was	perceived	in	the	subgroups	of	normal	LVEF	(≥	50%)(p=0.145)	or	moderately	impaired	LVEF	(35-49%)(p=0.979).		During	follow-up,	18F-FDG-PET	was	repeated	in	22	(33%)	patients	to	evaluate	steroid	response	and	disease	activity	(Kandolin	et	al.,	unpublished	results).	The	18F-FDG-PET	images	were	analyzed	mostly	qualitatively	and	their	diagnostic	and	prognostic	value	at	follow-up	was	not	 considered	beneficial	 for	 repeated	 studies	with	 the	protocol	 of	 the	time.	 Therefore,	 the	 use	 of	 repeated	 18F-FDG-PET	 studies	 decreased	 until	 the	 end	 of	study	period.	The	early	biochemical	response	to	the	initiation	of	corticosteroid	therapy	was	assessed	in	 the	62	patients	with	new-onset	CS	and	multiple	hs-cTnT/I	measurements	 (IV).	The	initiation	of	treatment	either	decreased	(n=8,	33%)	or	normalised	(n=16,	67%)	the	hs-cTnT/I	 levels	 in	 four	 weeks	 in	 all	 the	 24	 patients	 with	 elevated	 pre-treatment	concentrations	 who	 underwent	 repeated	 measurements	 after	 four	 (±1)	 weeks	 of	steroid	 therapy.	 Hs-cTnT/I	 remained	 normal	 in	 all	 the	 14	 patients	 with	 normal	 pre-treatment	 concentrations	 (p=0.00003).	 Figure	 14	 shows	 the	 hs-cTnT	 response	 to	initiation	 of	 corticosteroid	 therapy	 in	 all	 32	 patients	 who	 underwent	 the	 one-month	repeat	measurement.		
	
Figure	14.	The	early	response	of	hs-cTnT	to	initiation	of	steroid	therapy	(IV).		The	 p-value	 is	 from	 a	Wilcoxon	 signed	 rank	 test	 for	 paired	 comparisons.	 The	 dashed	horizontal	line	signifies	the	upper	limit	of	the	normal	reference	range	(≤13	ng/l).			
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During	 follow-up,	 three	 different	 profiles	 of	 serial	 hs-cTnT/I	measurements	 could	 be	distinguished	 (Kandolin	 et	 al.,	 unpublished	 results).	 First,	 persistent	 hs-cTnT/I	elevation	was	found	in	seven	patients	(11.3	%)	of	whom	four	had	severe	LV	dysfunction	(EF	 ≤35%).	 Second,	 48	 patients	 (77.4%)	 had	 either	 normal	 hs-cTnT/I	 in	 all	measurements	 or	 initially	 elevated	 hs-cTnT/I	 that	 normalised	 and	 remained	 normal	throughout	 the	 follow-up.	 The	 third	 group	 comprised	 of	 seven	 patients	 (11.3%)	 in	whom	 hs-cTnT/I	 was	 initially	 normal,	 or	 normalised	 with	 treatment,	 but	 became	elevated	 later	 during	 follow-up.	 In	 the	 group	 with	 late	 increases	 in	 hs-cTnT/I,	 the	elevations	 were	 frequently	 preceded	 by	 a	 reduction	 in	 the	 intensity	 of	immunosuppression	and	often	responded	to	an	increase	in	the	dose	or	reinstitution	of	prednisone.	 Figure	 15	 illustrates	 a	 case	 example	 of	 hs-cTnT	 evolution	 during	corticosteroid	treatment	(Kandolin	et	al.,	unpublished	results).		
	
Figure	 15.	 Serial	 hs-cTnT	 concentrations	 (lower	 panel)	 and	 daily	 prednisone	 dose	(upper	panel)	during	the	three-year	follow-up	of	a	43-year-old	female	with	chronic	CS.	Hs-cTnT	 was	 elevated	 (>13	 ng/l)	 at	 enrollment,	 and	 there	 were	 two	 additional	 late	increases	 following	 reduction	 of	 the	 daily	 prednisone	 dose	 from	 5mg	 to	 2.5mg	 that	responded	 each	 time	 to	 restoration	 of	 a	 higher	 dose	 (Kandolin	 et	 al.,	 unpublished	results).			Mild	immunosuppressive	treatment	adverse	effects,	most	commonly	insomnia,	edema,	hypokalemia,	 impaired	 glucose	 tolerance	 due	 to	 corticosteroids	 and	 leukopenia,	hepatic/pancreatic	 irritation,	 and	 nausea	 due	 to	 azathioprine,	 were	 commonly	observed.	 Intolerable	 side	 effects	 (severe	myopathy,	 psychosis,	 aseptic	 joint	 necrosis,	and	 severe	 insomnia	 with	 diarrhea	 and	 hypokalemia)	 leading	 to	 permanent	
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discontinuation	 of	 corticosteroids	were	 observed	 in	 four	 patients.	 No	 life-threatening	adverse	events	were	observed.	
5.8.2	Serious	outcome	events	and	survival	in	CS	
Figure	16	presents	the	serious	outcome	events	in	the	cohort	of	110	CS	patients.	A	total	of	 10	 (9%)	 patients	 suffered	 a	 cardiac	 death	 and	 six	 (5%)	 died	 of	 non-cardiac	 cause	during	the	median	follow-up	of	79	months,	 i.e.,	6.6	years	(range	12-303	months)	from	symptom	onset	to	death,	transplantation	or	end	of	follow-up.	Of	the	10	cardiac	deaths,	nine	were	sudden	deaths	(in	two	cases	diagnosis	was	not	made	until	autopsy)	and	one	due	 to	 terminal	 heart	 failure.	 The	 cardiac	 1-,	 5-,	 and	 10-year	 Kaplan-Meier	 survival	probabilities	are	presented	in	Table	12	for	the	total	population	and	for	the	102	patients	diagnosed	 clinically	 before	 death	 or	 transplantation	 and	 thus	 receiving	immunosuppressive	treatment.		During	 the	 follow-up	11	 (10%)	patients	 underwent	 a	 cardiac	 transplantation.	 Two	of	the	 transplanted	 patients	 died	 within	 one	 month	 of	 postoperative	 complications	(multiple	 organ	 failure	 and	 intra-cerebral	 hemorrhage).	 Another	 two	 patients	 died	 of	graft	 failure,	 without	 signs	 of	 sarcoidosis	 recurrence,	 three	 and	 five	 years	 post-transplantation.	 The	 remaining	 seven	 transplanted	 CS	 patients	 were	 alive	 without	recurrence	 at	 the	 end	 of	 follow-up,	 median	 60	 months	 (range	 22-249)	 from	transplantation.	Consequently,	at	the	end	of	median	6.6-year	total	follow-up	from	symptom	onset,	a	total	of	 20	 out	 of	 110	 (18%)	patients	 had	died	 and	 seven	 (6%)	patients	were	 alive	with	 a	transplanted	heart.	The	 cardiac	 survival	 free	of	 transplantation	 is	presented	 in	Table	
12.	 Additionally,	 two	 patients	 were	 awaiting	 transplantation,	 one	 with	 a	 ventricular	assist	 device,	 at	 the	 close	 of	 follow-up.	 The	 main	 indication	 for	 transplantation	 was	terminal	 heart	 failure	 in	 11	 listed	 and	 transplanted	 patients,	 and	 incontrollable	ventricular	 arrhythmias	 in	 two,	 both	 of	whom	both	 also	 had	 severe	 heart	 failure	 (EF	<35%).	 The	 time	 from	 symptom	 onset	 to	 transplantation	 ranged	 from	 five	 to	 89	months,	with	a	median	of	59	months.	
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Furthermore,	11	(10%)	other	patients	experienced	an	aborted	sudden	death	as	a	 first	outcome	 event.	 Eight	 of	 them	 were	 resuscitated	 from	 VF	 and	 three	 received	 an	 ICD	shock	 for	 VF.	 Thus,	 a	 total	 of	 32	 out	 of	 110	 (29%)	 patients	 suffered	 cardiac	 death,	transplantation	 or	 aborted	 sudden	 death.	 Table	 12	 also	 presents	 the	 survival	 rates	without	 the	 composite	 event	 of	 cardiac	 death,	 transplantation	 and	 aborted	 sudden	death.		
	
	
	
	
			
	
	
	
Figure	16.	Serious	outcome	events	in	110	CS	patients	(I).	
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Table	12.	Survival	free	of	major	cardiac	outcome	events	in	all	the	110	CS	patients	and	in	the	102	patients	diagnosed	prior	to	autopsy	and	transplantation	(I).	_____________________________________________________________________________________________		 	 												1-year	survival,	%							5-year	survival,	%			10-year	survival,	%	_____________________________________________________________________________________________	Cardiac	survival	n=110		 	 	99	(94-100)	 	 94	(87-97)		 	 89	(82-94)	n=102		 	 100	(96-100)		 97	(91-99)	 	 93	(85-97)	_____________________________________________________________________________________________	Cardiac		transplantation-free	survival	n=110		 	 	97	(92-99)	 	 90	(82-95)	 	 83	(75-89)	n=102		 	 	99	(94-100)	 	 95	(88-98)	 	 91	(83-95)		Patients	with	heart	 	 	 	 	 	failure	as	first	manifestation,	n=20	 90	(67-98)	 	 75	(51-90)	 	 53	(30-74)	_____________________________________________________________________________________________	Cardiac,		transplantation-	free	and	aborted	sudden		death-free	survival	n=110		 	 89	(81-94)	 	 78	(69-85)	 	 70	(61-79)	n=102		 	 89	(81-94)	 	 82	(73-89)	 	 77	(68-85)	_____________________________________________________________________________________________	CS=	cardiac	sarcoidosis.		
5.8.2.1	Predictors	of	outcome	Heart	 failure	 as	 a	 primary	 manifestation	 was	 associated	 with	 worse	 transplant-free	cardiac	survival,	and	this	applied	across	the	total	population	(n=110)	as	well	as	in	the	clinically	diagnosed	(n=102)	patients	(log	rank	p=0.0001	and	p=0.023,	respectively).	In	the	patients	presenting	with	heart	failure	signs	and	symptoms,	the	5-year	Kaplan-Meier	survival	 estimate	was	 75%	 (95%	CI,	 50.6-	 90.4	%)	 compared	 to	 90%	 (95%	CI,	 82.4-	94.6%)	 in	 the	 total	 population	 (Table	 12).	 On	 the	 other	 hand,	 AV-block	 as	 a	 first	manifestation	 was	 associated	 with	 better	 outcome	 compared	 to	 other	 first	manifestations	 (in	 the	 102	 patients,	 log	 rank	 p=0.037).	 Other	 predictors	 of	 cardiac	survival	free	of	transplantation	in	the	total	population	of	110	patients	were	initial	LVEF	(p=0.006	by	Cox	regression	and	p=0.011	by	log	rank)	and	NYHA	class	at	diagnosis	(log	rank	 p=0.023).	 On	 the	 contrary,	 the	 outcome	was	 not	 related	 to	 age	 (Cox	 regression	
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p=0.469),	sex	(log	rank	p=0.163),	or	the	type	of	CS	(isolated	vs	extracardiac)	(log	rank	p=0.132).	We	 also	 analyzed	 characteristics	 associated	with	 survival	 free	 of	 transplantation	 and	aborted	sudden	death.	In	the	total	CS	cohort	of	110	patients,	LVEF	was	associated	with	survival	 free	 of	 this	 composite	 outcome	 event	 (by	 log	 rank	 p=0.046	 and	 by	 Cox	regression	p=0.017).	Instead,	survival	free	of	transplantation	and	aborted	sudden	death	was	independent	of	age,	sex,	and	heart	 failure	as	the	first	manifestation.	Furthermore,	isolated	CS	type	was	related	to	worse	survival	 free	of	 this	composite	adverse	event	 in	the	total	population	(n=110)	and	in	the	clinically	diagnosed	(n=102)	patients	(log	rank	p=0.005	 and	 0.015,	 respectively).	 This	 could	 be	 explained	 by	 the	 higher	 frequency	 of	presentation	 with	 ventricular	 arrhythmias	 in	 isolated	 CS	 (see	 Table	 9)	 and	 thus	clustering	of	early	aborted	sudden	deaths	in	this	patient	group.	Implementing	 prednisone	 treatment	 with	 a	 high	 (≥	 60mg/day)	 versus	 low	(<60mg/day)	 initial	 prednisone	 dose	 did	 not	 effect	 survival	 free	 of	 cardiac	 death	 or	transplantation	 (log	 rank	 p=0.561).	 Neither	 did	 the	 treatment	 delay	 from	 symptom	onset	 to	 starting	 corticosteroids	 (<6	 months	 vs	 ≥6	 months)	 (log	 rank	 p=0.867).	Furthermore,	 to	 evaluate	 the	 effect	 of	 corticosteroid	 in	 the	 subgroup	of	 patients	with	AV-block	 as	 a	 first	manifestation,	 we	 scrutinized	 the	 adverse	 cardiac	 events	 (cardiac	death,	 aborted	 sudden	 death,	 sustained	 VT,	 new	 systolic	 LV	 dysfunction	 and	transplantation)	on	follow-up	in	patients	with	early	CS	diagnosis	and	thus	initiation	of	steroid	 treatment	 (<3	 months	 from	 pacemaker	 implantation)	 compared	 to	 late	diagnosis	and	initiation	of	steroid	treatment	(≥3	months	from	pacemaker	implantation).	During	the	follow-up	of	a	median	of	6.6	years,	50%	(9	out	of	18)	in	the	early	diagnosis	group	 compared	 to	 63%	 (17	 out	 of	 27)	 in	 the	 late	 diagnosis	 group	 had	 an	 adverse	cardiac	 event,	 but	 the	 difference	 was	 not	 statistically	 significant	 (log	 rank	 p=0.821)	(Kandolin	et	al.,	ESC	Congress	2015	abstract	83429).	 	In	the	cohort	of	62	newly	diagnosed	CS	patients	and	serial	hs-cTnT/I	measurements	at	diagnosis	 and	 during	 follow-up	 (IV),	 there	 was	 a	 trend	 towards	 poorer	 prognosis	 in	patients	 with	 elevated	 hs-cTnT/I	 at	 baseline	 (log	 rank	 p=0.068).	 More	 specifically,	during	the	median	follow-up	of	17	months	(1-48	months),	a	total	of	16	out	of	62	(26%)	patients	 suffered	 a	 cardiac	 adverse	 event,	 including	 sudden	 cardiac	 death	 (n=2),	aborted	 sudden	 cardiac	 death	 (n=5),	 symptomatic	 sustained	 VT	 (n=8),	 and	 new	complete	 AV-block	 (n=1).	 In	 the	 group	with	 elevated	 hs-cTnT/I,	 11	 out	 of	 33	 (33%)	patients	 had	 an	 adverse	 event,	 compared	 to	 five	 out	 of	 29	 (17%)	 in	 the	 group	 with	normal	hs-cTnT/I	at	baseline.	
5.8.3	Outcome	in	GCM	(V)	The	cohort	of	32	GCM	patients	was	followed	for	a	median	of	15	months	(range	0.3-90.3	months)	from	symptom	onset	to	death,	transplantation	or	end	of	follow-up.	During	the	follow-up,	a	total	of	15	(47%)	patients	suffered	cardiac	death	(n=5,	16%)	or	underwent	cardiac	transplantation	(n=10,	31%).	All	the	five	fatalities	were	arrhythmic	and	four	of	
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five	 patients	 who	 died	 were	 diagnosed	 post-mortem.	 The	 Kaplan-Meier	 estimates	 of	transplant-free	 survival	 are	 presented	 in	 Table	 13.	 In	 the	 subgroup	 of	 26	 patients	diagnosed	 clinically	 before	 death	 or	 transplantation	 and	 thus	 receiving	immunosuppressive	 therapy,	 one	 suffered	 cardiac	 death	 and	 eight	 underwent	transplantation.	Their	transplant-free	survival	from	diagnosis	is	also	presented	in	Table	
13.	
Table	13.	Survival	free	of	major	cardiac	outcome	events	in	all	the	32	GCM	patients	and	in	the	26	patients	diagnosed	prior	to	autopsy	and	transplantation	(V).	_____________________________________________________________________________________________	Cardiac*	transplantation-free	 1-year	survival,	%	 5-year	survival,	%	survival	 		n=32	 	 	 	 	 69%	(50-83%)	 52%	(34-70%)	n=26	 	 	 	 	 77%	(56-90%)	 63%	(42-81%)	_____________________________________________________________________________________________	*	Same	as	transplantation-free	survival.	GCM=	giant	cell	myocarditis.		All	 the	 eight	 patients	 with	 known	 pre-transplant	 diagnosis	 of	 GCM,	 were	 listed	 for	transplantation	within	nine	months	 from	the	diagnosis	and	 the	 transplantations	were	accomplished	 within	 one	 year	 of	 diagnosis	 in	 seven	 of	 the	 eight	 patients.	 Of	 the	 10	transplanted	GCM	patients,	three	died	within	six	weeks	of	postoperative	complications	(large	 intracardiac	 thrombus	 (n=1),	 bleeding	 (n=1)	 and	multiple	organ	 failure	 (n=1)).	The	 remaining	 seven	 transplanted	 GCM	patients	were	 alive	 at	 the	 close	 of	 follow-up.	One	 patient	 had	 a	 recurrence	 of	 GCM	 in	 the	 graft,	 presenting	 as	 symptomatic	 heart	failure	4.8	years	post-transplantation,	which	ensued	from	discontinuing	corticosteroid	and	was	resolved	with	augmented	immunosuppression.	The	majority	 of	 GCM	 patients	 had	 ventricular	 arrhythmias.	 The	 aforementioned	 four	patients	suffered	sudden	arrhythmic	death	and	were	diagnosed	only	at	autopsy.	Of	the	two	 patients	 diagnosed	 at	 transplantation,	 one	 had	 sustained	 VTs.	 Of	 the	 26	 patients	diagnosed	 before	 death	 and	 transplantation,	 17	 (65%)	 had	 sustained	 VTs,	 one	 was	successfully	resuscitated	from	VF,	and	one	died	of	VF	two	weeks	after	diagnostic	EMB.	In	total,	24	out	of	32	(75%)	of	GCM	patients	experienced	sudden	cardiac	death,	aborted	sudden	cardiac	death	or	sustained	VT	during	the	disease	course.	In	the	18	GCM	patients	with	 ICD,	 eight	 (44%)	 received	 an	 appropriate	 ICD	 therapy	 (shock	 and/or	 anti-tachycardia	 pacing).	 In	 the	 subgroup	 of	 17	 transplant-free	 survivors,	 10	 (59%)	 had	sustained	VTs	during	follow-up	and	three	received	ICD	shocks.		Considering	 systolic	 dysfunction	 in	 GCM,	 28	 out	 of	 31	 (90%)	 patients	 who	 had	undergone	echocardiography	either	had	reduced	LVEF	(<50%)	at	diagnosis	(n=23)	or	developed	systolic	dysfunction	during	the	disease	course	(n=5).	Symptomatic	(NYHA	II-IV)	heart	failure,	with	LVEF	ranging	from	20%	to	40%,	was	observed	in	seven	out	of	26	patients	 with	 pre-transplant	 and	 pre-mortem	 GCM	 diagnosis.	 Six	 of	 them	 required	
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transplantation	 and	 one	 stabilized	 with	 medical	 therapy.	 Out	 of	 the	 four	 autopsy	diagnosed	 patients,	 two	 had	 severe	 heart	 failure	 (EF	 ≤35%),	 one	 had	 normal	echocardiography	a	year	before	sudden	cardiac	death,	and	one	suffered	sudden	death	without	 previous	 echocardiography.	 Both	 patients	 diagnosed	 at	 transplantation	 had	severe	 systolic	 heart	 failure	 (EF	 <20%).	 Second	 or	 3rd	 degree	 AV-block	 was	 present	from	the	symptom	onset	in	11	(34%)	patients	(of	whom	in	one	the	presenting	symptom	was	 classified	 as	 VT	 according	 to	 the	 principal	 symptom).	 None	 of	 the	 GCM	 patients	developed	a	new	AV-block	during	the	study	period.	Age,	sex	or	presenting	symptoms	were	not	predictive	of	outcome	in	GCM.	Initial	LVEF	was	 not	 statistically	 significantly	 associated	 with	 survival	 free	 of	 transplantation.	Instead,	 at	 follow-up	 LVEF	 was	 higher	 in	 the	 transplant-free	 survivors	 (45±11%),	compared	to	the	patients	who	died	or	underwent	transplantation	(26±7%)	(p=0.003).			
6	DISCUSSION			
6.1	Methodological	considerations	
6.1.1	Study	population	This	study	is	a	retrospective	analysis	of	CS	and	GCM	patients	in	Finland.	The	CS	patients	were	enlisted	by	contacting	all	the	Finnish	university	and	central	hospitals.	All	the	five	university	 hospitals	 and	 six	 out	 of	 17	 central	 hospitals	 responded	 and	 screened	 the	possible	 CS	 patients	 from	 their	 registries	 by	 using	 the	 given	 ICD-10	 codes.	 The	 vast	majority	 of	 diagnosed	 CS	 patients	 in	 Finland	 are	 treated	 and	 followed	 in	 university	hospitals	 or	 have	 at	 least	 undergone	 diagnostic	 procedures	 in	 them	 during	 the	diagnostic	 work-up.	 Thus	 the	 screening	 should	 have	 been	 comprehensive,	 yet	 some	patients	may	have	been	missed	due	to	deficiencies	in	hospital	registries.	Moreover,	the	ICD-10	classification	was	introduced	in	Finland	in	1996,	and	therefore	sporadic	patients	diagnosed	 between	 1988	 and	 1996	 who	 were	 lost	 during	 follow-up	 may	 have	 been	dismissed.		There	were	differences	in	the	prevalence	of	diagnosed	CS	between	different	health	care	districts	(Figure	10).	Although	geographical	divergence	cannot	be	excluded,	differences	in	diagnostic	practices	are	the	most	likely	cause.	The	diagnostic	biopsy	policy	in	patients	with	suspected	inflammatory	or	other	cardiomyopathy	was	particularly	active	in	HUH,	which	is	a	national	cardiac	transplantation	center,	compared	to	other	MIDFIN	network	hospitals.	 Of	 the	 110	 patients,	 50%	 were	 from	 the	 HUH	 area,	 whereas	 the	 referral	population	 of	 HUH	 represents	 roughly	 one-quarter	 of	 the	 total	 Finnish	 population.	Outside	HUH,	 patients	were	more	 often	 diagnosed	 clinically	with	 CS	 and	 also	 treated	without	 histopathological	 proof.	 Yet	 another	 limitation	 of	 the	 present	 study	 is	 that	 it	was	 hospital-based	 and	 therefore	 sudden	 death	 in	 the	 community	 as	 a	 first	manifestation	 of	 CS	 remained	 outside	 its	 scope.	 Finally,	 as	 a	 result	 of	 the	 active	
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diagnostic	strategy,	the	proportion	of	autopsy	and	post-transplantation	diagnoses	(7%)	was	 significantly	 lower	 than	 earlier	 studies	 (21-29%)	 (5,97)	 which	 results	 in	differences	in	disease	course.	The	strict	inclusion	criteria	requiring	histologic	verification	of	CS	entails	pros	and	cons.	The	 inclusion	 policy	 applied	 results	 in	 diagnostic	 specificity	 as	 the	 patients	 included	most	 definitely	 have	 CS.	 In	 contrast,	 a	 selection	 bias	 towards	 a	 more	 severe	 disease	course	might	pursue,	 as	 the	patients	with	 a	more	 severe	disease	 are	more	 rigorously	examined	and	subsequently	included	in	the	study.		Four	facts	suggest	that	the	true	frequency	of	CS	is	probably	higher	than	reported	in	this	study.	First,	we	did	not	 include	 clinically	diagnosed	CS	patients,	 the	number	of	which	might	 be	 double	 the	 number	 of	 histologically	 verified	 cases	 (272).	 The	 sensitivity	 of	multiple	 EMBs	 in	 the	 HUH	 cohort	 was	 31.5%	 (II)	 which	 is	 low	 but	 representative	(2,21,86,91).	 Thus	 a	 considerable	 number	 of	 patients	 with	 suspect	 CS	 with	 negative	EMBs	or	totally	without	histologic	biopsies	during	the	study	period	were	left	out	of	the	scope	of	this	study.	Second,	previous	data	show	that	symptomatic	CS	is	just	the	tip	of	the	iceberg	(16,17,90,91,96,109)	and	that	20-30%	of	patients	with	extracardiac	sarcoidosis	have	asymptomatic	cardiac	involvement	(17,91,96).	During	the	study	period,	systematic	cardiac	screening	of	patients	with	extracardiac	sarcoidosis	was	not	practiced	in	Finland.	Therefore,	 in	the	epidemiologic	sense	a	deficiency	of	this	study	is	that	 it	only	 involves	the	 patients	 with	 symptomatic	 CS.	 Third,	 as	 indicated	 above,	 patients	 with	 outside-hospital	sudden	cardiac	death	as	first	a	manifestation	of	CS	could	not	be	included.	In	the	earlier	 autopsy	 series	 up	 to	 35%	 of	 patients	 suffered	 cardiac	 death	 as	 a	 first	manifestation	 of	 CS	 (16,17).	 However,	 with	 today’s	 modern	 health	 care	 system	 the	figure	is	likely	to	be	lower.	Fourth,	as	the	response	rate	of	the	central	hospitals	was	only	35%,	some	CS	cases	may	have	been	missed.	Anyhow,	it	is	likely	that	the	hospitals	that	failed	 to	 reply	 did	 not	 treat	 known	 CS	 cases	 and	 diagnosed	 cases	 from	 the	corresponding	areas	were	discovered	from	the	university	hospital	records.		In	respect	to	GCM,	the	data	collection	may	have	been	incomplete	as	no	specific	ICD-10	code	exits	for	GCM.	Additionally,	the	fact	that	50%	(16	out	of	32)	of	GCM	patients	were	referred	to	HUH	from	other	hospitals	and	50%	were	from	the	HUH	area,	which	covers	approximately	 one-quarter	 of	 the	 Finnish	 population,	 also	 suggests	 that	 the	 true	incidence	 of	 GCM	 in	 Finland	 is	 higher	 than	 presented	 in	 this	 study.	 Compared	 to	previous	 studies,	 a	 significantly	 higher	 portion	 of	 GCM	 patients	 were	 diagnosed	 at	biopsy	before	death	or	transplantation	(81%	vs	0-56%)(5,37).	The	higher	percentage	of	lifetime	 diagnoses	was	 probably	 a	 consequence	 of	 the	 active	 EMB	policy	 at	HUH	 and	further	 reflects	 on	 differences	 in	 the	 clinical	 picture	 and	 prognosis	 compared	 to	previous	works.	
6.1.2	Diagnostics		Diagnosing	 CS	 is	 challenging	 and	 can	 be	 pursued	 in	 three	 ways.	 Firstly,	 the	 golden	standard	 and	 only	 absolute	 proof	 of	 CS	 is	 histologic	 confirmation	 of	 granulomatous	
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inflammation	from	the	heart	with	other	causes	of	granulomas	excluded.	However,	EMB	more	often	misses	than	hits	the	patchy	granulomatous	infiltrates	with	a	sensitivity	that	is	 no	 better	 than	15-30%	 in	 previous	 studies	 (2,21,86,91)	 and	31.5%	 in	 our	 study.	A	second	approach	to	CS	diagnosis	is	by	confirming	histology	from	an	extracardiac	organ,	e.g.,	 lungs	 or	 lymph	 nodes	 together	with	 symptoms	 and	 imaging	 findings	 compatible	with	CS.		Third,	a	combination	of	typical	imaging	findings	and	symptoms	together	with	clinically	 diagnosed	 extracardiac	 sarcoidois	 but	 without	 histologic	 confirmation	 has	been	 considered	 to	warrant	 diagnosis	 of	 CS	 (178).	 Anyhow,	 in	 this	 study	 a	 histologic	verification	 either	 from	 the	 heart	 or	 an	 extracardiac	 organ	was	 required,	which	 is	 in	accordance	with	 the	 recently	 released	 CS	 guidelines	 (4).	 There	 are	 strong	 arguments	pointing	 towards	 the	 fact	 that	 the	 confirmation	 of	 CS	 should	 be	 undisputed;	 the	diagnosis	 triggers	 long-term	 immunosuppression	 with	 its	 potential	 side	 effects,	commonly	 leads	 to	 ICD	 implantation,	 and	 portends	 a	 potentially	 life-threatening	diagnosis	 in	 often	 otherwise	 healthy	 young	 individuals.	 Despite	 this,	 the	 initiation	 of	treatment	after	repeated	negative	biopsies	but	strong	clinical	grounds	could	be	justified	on	the	basis	that	not	treating	might	lead	to	permanent	myocardial	damage	and	potential	fatality.	In	 terms	of	diagnosing	CS	 from	clinical	perspective,	 there	are	 three	main	scenarios	of	presentation.	 The	 first	 scenario	 comprises	 of	 patients	 presenting	 with	 cardiac	conditions	(mainly	2nd	to	3rd	degree	AV-block,	ventricular	arrhythmias	or	unexplained	heart	 failure	 usually	 together	with	 conduction	 disturbances	 or	 VTs)	without	 signs	 or	symptoms	 of	 sarcoidosis	 from	 other	 organs.	 This	 used	 to	 be	 considered	 a	 rare	presentation,	 but	 cumulating	 evidence	 from	 this	 study	 and	 others	 (108)	 shows	 that	sarcoidosis	often	involves	the	heart	without	clinically	apparent	extracardiac	disease.	In	this	 clinical	 setting,	after	 ruling	out	 coronary	artery	disease,	a	great	deal	of	 caution	 is	needed	 to	 pursue	 the	 CS	 diagnosis,	 often	 with	 multiple	 EMBs	 and	 sometimes	 with	targeting	FDG-positive	mediastinal	 lymph	nodes	 for	biopsy	 confirmation.	 It	 is	notable	that	markers	of	granulomatous	inflammation,	including	angiotensin-converting	enzyme,	lysozyme,	and	daily	urinary	calcium	excretion	were	not	of	significant	help	in	detecting	CS.	A	second	clinical	scenario	encompasses	patients	with	biopsy-confirmed	extracardiac	sarcoidosis	with	 symptoms	 of	 possibly	 cardiac	 origin.	 Given	 the	 positive	 histology	 in	these	cases,	typical	abnormalities	 in	echocardiography,	LGE-CMR,	or	cardiac	18F-FDG-PET	 confirm	 the	 CS	 diagnosis	 with	 sufficient	 certainty.	 	 	 A	 third	 scenario	 involves	patients	 with	 biopsy-confirmed	 extracardiac	 sarcoidosis	 without	 cardiac	 symptoms.	These	patients	should	undergo	medical	history	checks,	a	physical	examination,	and	an	ECG.	 Echocardiography	may	 be	 considered	 but	 lacks	 sensitivity	 and	 is	 recommended	mainly	if	one	of	the	aforementioned	screening	tests	is	positive	(88,197).	Measuring	hs-cTnT/I	and	NT-proBNP	might	be	useful	in	guiding	diagnostic	decisions.	The	 diagnostic	 path	 in	 this	 study	 was	 different	 from	 the	 earlier	 reports	 in	 that	 the	proportion	 of	 patients	 diagnosed	 at	 autopsy	 or	 from	 the	 transplanted	heart	 (8	 out	 of	110)	was	smaller	(5,97).	As	mentioned	previously,	 the	explanation	of	the	difference	is	
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probably	the	active	screening	of	young	patients	with	AV-block	and	active	EMB	policy	in	unexplained	 cardiomyopathy	 with	 conduction	 abnormalities	 or	 arrhythmias	 at	 our	institution.	 Furthermore,	 this	was,	 to	 our	 knowledge,	 the	 first	 study	 to	 systematically	utilize	 mediastinal	 lymph	 node	 biopsy	 in	 patients	 with	 negative	 EMB(s)	 and	 a	 high	suspicion	of	CS.		CS	 biopsy	 findings	 were	 collected	 from	 hospital	 registries.	 Because	 histologic	confirmation	is	the	only	absolute	means	of	differentiating	between	GCM	and	CS	(5),	the	GCM	 tissue	 samples	 were	 re-examined	 by	 cardiac	 pathologists	 for	 purposes	 of	 this	study	to	ascertain	accurate	GCM	diagnosis.	In	four	cases	the	initial	histologic	diagnosis	was	 converted	 from	 GCM	 to	 CS,	 which	 demonstrates	 the	 pitfalls	 in	 pathological	diagnostics.	 On	 the	 other	 hand,	 the	 original	 histologic	 CS	 samples	 all	 contained	granulomas	and	thus	they	were	considered	specific	for	CS.	
6.1.3	Data	The	 data	 including	 patient	 characteristics,	 imaging	 and	 laboratory	 results,	 outcome	events,	 etc.,	 was	 principally	 collected	 from	 hospital	 charts	 and	 registries	 with	 a	 few	exceptions.		First,	the	ECGs	were	reanalyzed	by	the	investigator	when	available.	Second,	the	 results	 of	 hs-cTnT/I	 measurements	 from	 other	 hospitals	 outside	 HUH	 were	collected	 using	 questionnaires.	 The	 retrospective	 study	 design	 inherently	 causes	deficiencies,	 such	 as	 lack	 of	 systematic	 diagnostic	 work-up	 and	 incompleteness	 of	follow-up	data.	Anyhow,	 the	potential	 deficiencies	 in	 clinical	 data	were	minimized	by	using	 complementary	 data	 collection	 systems	 (hospital	 discharge	 registries,	 the	 HUH	pathology	registry,	the	HUH	pacemaker	registry	and	the	,	Centre).	Notably,	we	double-checked	the	most	important	outcome	data	(i.e.	mortality)	from	the	Population	Register	Centre.	 Furthermore,	 a	 single	 investigator	 (RK)	 scrutinized	 the	 patient	 data,	 thus	enabling	uniformity	 in	data	handling.	Reporting	 the	outcome,	we	 focused	on	 the	hard	end-points	(death,	 transplantation,	VF,	VT,	AV-block).	Thus,	we	eluded	the	difficult-to-define	end-points	such	as	heart	failure,	which	are	problematic,	especially	in	the	case	of	retrospective	study	design.	All	the	echocardiographic	data	in	this	study	was	measured	as	a	part	of	clinical	work-up	by	 various	 cardiology	 physicians,	 and	 a	 standardized	 echocardiography	 protocol	was	not	 applied.	 LVEF	was	defined	by	 Simpson’s	method,	M-mode	 and	 visual	 assessment.	Echocardiographic	 analysis	 is	 known	 to	 be	 prone	 to	 inter-observer	 differences	 and	incomplete	reproducibility.		As	 to	 the	 diagnosis	 of	 isolated	 CS,	 screening	 for	 extracardiac	 sarcoidosis,	 such	 as	ophthalmological	and	dermatological	consultations,	were	not	routinely	conducted.	Most	importantly,	chest	(high-resolution)	computed	tomography	was	rarely	performed.	As	a	result,	 although	 these	 patients	 have	 isolated	 CS	 from	 the	 cardiologist’s	 perspective,	some	of	them	probably	have	clinically	silent	extracardiac	involvement.	Although	the	nature	of	this	study	was	purely	observational,	the	information	gained	over	
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the	 years	 was	 acknowledged	 by	 the	 treating	 physicians	 and	 has	 thus	 influenced	 the	patient	 care.	 This	 particularly	 applies	 to	 the	 hs-cTnT/I	 study,	 where	 modulations	 of	immunosuppressive	treatment	were	conducted	based	on	hs-cTnT/I	alterations.	
6.1.4	Analyses	The	series	of	110	CS	patients	is	among	the	largest	worldwide	to	date,	and	the	series	of	32	 GCM	 patients	 is	 the	 largest	 involving	 pre-mortem	 diagnoses.	 Anyhow,	 from	 a	statistical	 perspective	 the	 patient	 numbers	 and	 the	 numbers	 of	 outcome	 events	 are	small,	 limiting	 the	 statistical	 power.	 All	 the	 studies	 were	 uncontrolled,	 thus	 making	conclusions	 about	 treatment	 effect	 impossible.	 Furthermore,	 in	 respect	 to	 the	sensitivity	 of	 diagnostic	 biopsies	 and	 imaging	 studies,	 the	 diagnoses	 of	 patients	with	negative	results	and	thus	the	number	of	false-negative	studies	remained	unknown.	The	outcome	of	these	patients	should	be	evaluated	in	further	investigations.	
6.2	Comparison	with	previous	studies	
6.2.1	Epidemiology	of	CS	and	GCM	Our	 study	 presents	 the	 first,	 yet	 limited	 population-based	 nationwide	 data	 on	 the	prevalence	and	incidence	of	lifetime	symptomatic	CS.	Until	now,	epidemiologic	data	on	the	 prevalence	 of	 CS	 has	 been	 based	 on	 studies	 of	 lung	 sarcoidosis	 with	 cardiac	involvement	(31,77,79),	and	autopsy	studies	(16,17,49,109).	We	found	that	despite	the	marked	increase	in	the	detection	rate	over	the	25-year	period,	CS	still	remained	a	very	rare	 condition	 in	 Finland.	The	 annual	 detection	 rate	 of	 symptomatic	 CS	 confirmed	by	biopsy	 was	 0.6	 per	 100	 000	 adults	 and	 the	 prevalence	 2.2	 per	 100	 000	 in	 2012.	Nevertheless,	 as	 discussed	 in	 the	 Methodological	 considerations	 section,	 the	 true	prevalence	of	CS	including	clinically	mild	disease	is	likely	to	be	significantly	higher.		The	most	striking	result	to	emerge	from	this	study	was	the	over	50-fold	increase	in	the	detection	rate	of	CS	over	26	years	in	Finland.	This	increase	is	likely	to	be	explained	by	growing	awareness	of	CS	and	advances	in	diagnostic	methods.	The	fact	that	the	largest	increase	 in	 detection	 rate	was	 dated	 over	 the	 years	with	 the	 implementation	 of	 LGE-CMR	 and	 18F-FDG-PET	 in	 clinical	 practice	 supports	 this	 theory.	 Despite	 this,	 a	 true	increase	 in	 the	 incidence	of	CS,	possibly	due	 to	an	environmental	or	 infectious	 factor,	cannot	 be	 ruled	 out.	 Previous	 epidemiologic	 data	 on	 lung	 sarcoidosis	 showed	 similar	incidence	numbers	in	Finns	compared	to	other	white	populations	(74-76).	Hence	it	can	be	assumed	that	our	data	is	representable	in	other	white	populations,	yet	caution	must	be	applied	in	generalizing	these	findings	to	other	ethnic	groups.		GCM	 is	 an	 even	 rarer	 myocardial	 disease,	 demonstrated	 by	 the	 fact	 that	 largest	multicenter	 collaboration,	 collecting	data	 from	almost	40	 centers	worldwide	between	1982	 and	1997,	 could	 come	up	with	 no	more	 than	73	GCM	patients	 (5).	 The	 present	GCM	cohort	of	study	V	consisted	of	32	patients,	which	is	thus	far	the	largest	published	single-center	 study	 (and	 our	 unpublished	 results	 add	 17	 new	 patients	 until	 end	 of	2014).	Of	 the	32	GCM	diagnoses,	 29	were	made	over	 the	 latter	10	 years	 of	 the	 study	
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period,	 with	 an	 annual	 detection	 rate	 of	 approximately	 0.1	 per	 100	 000.	 No	 prior	epidemiologic	 lifetime	 data	 exists	 for	 comparison.	 Earlier	 autopsy	 studies	 reported	incidences	 of	 6.6-23.4	 per	 100	 000	 autopsies	 (25,102),	 but	 these	 figures	 might	 be	overestimates	 since	 autopsies	 are	 usually	 performed	 in	 patients	 who	 have	 suffered	unexpected	death.	On	the	other	hand,	it	is	possible	that	a	clinically	more	benign	form	of	GCM	exists	and	 its	prevalence	 is	higher	than	what	 is	detected	by	EMBs	and	autopsies.	The	heterogeneity	of	disease	manifestations	observed	 in	this	study,	as	 in	the	previous	works	(8,37),	supports	this	theory.	
6.2.2	Patient	characteristics	and	disease	manifestations		 	In	 general,	 our	 findings	 considering	 patient	 characteristics	 in	 CS	 are	 consistent	 with	earlier	observations.	We	found	a	female	predominance	of	65%	and	a	mean	age	of	51±	9	years,	 in	 line	 with	 previous	 studies	 (5,113).	 Moreover,	 this	 study	 confirms	 the	association	of	CS	and	GCM	with	autoimmune	diseases.	In	line	with	previous	studies,	we	found	 associated	 autoimmune	 disorders	 in	 16%	 of	 CS	 patients	 and	 in	 19%	 of	 GCM	patients,	which	is	higher	than	the		5-10%	in	the	general	population	(273).			
6.2.2.1	AV-block	One	of	the	most	significant	observations	from	this	study	is	the	high	prevalence	(25%)	of	CS	and	GCM	as	causes	of	AV-blocks	in	adults	aged	<55	years.	Thus,	CS	and	GCM	cause	a	far	 greater	 proportion	 of	AV-blocks	 in	 young	 and	middle-aged	 adults	 than	previously	thought.	This	result	was	later	endorsed	by	a	Canadian	group	that	found	CS	in	34%	(11	out	 of	 32)	 patients	 with	 initially	 unexplained	 AV-block	 in	 patients	 aged	 18-60	 years	(274).	Furthermore,	like	us,	Nery	et	al.	found	that	the	patients	with	AV-block	due	to	CS	had	 more	 severe	 cardiac	 events	 on	 follow-up	 compared	 to	 those	 in	 whom	 AV-block	remained	 idiopathic	 (274).	Consequently,	 it	 is	 important	 for	 the	clinicians	 to	consider	the	possibility	of	CS	in	all	patients	under	55-60	years	with	unexplained	AV-block,	even	without	arrhythmias	or	LV	dysfunction	at	presentation.	The	diagnostic	work-up	of	these	patients	should	include	LGE-CMR	and/or	18F-FDG-PET.			
6.2.2.2	Isolated	CS	Even	 though	CS	without	apparent	extracardiac	 involvement	has	been	reported	before	(5,16,22,87,109),	our	study	was	the	first	to	discuss	isolated	CS	as	a	clinical	entity.	In	our	nationwide	 cohort,	 two-thirds	 of	 patients	 had	 no	 apparent	 extracardiac	 involvement,	which	 is	consistent	with	a	previous	multicenter	study	(5).	However,	silent	sarcoidosis	outside	the	heart	was	not	uncommonly	detected	in	18F-FDG-PET.	Still,	about	one-third	of	patients	undergoing	whole-body	18F-FDG-PET	scans	did	not	have	any	extracardiac	FDG	accumulation.		 	Since	our	study	was	published,	isolated	CS	has	attracted	attention	and	variable	frequencies	of	5.5%-74%	in	CS	have	been	presented	(99,108,137,164,274).	The	 highly	 variable	 percentages	 are	 likely	 due	 to	 different	 screening	 methods	 with	
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many	centers	 routinely	using	whole-body	18F-FDG-PET,	 chest-computed	 tomography,	ophthalmologic	examination	and	close	 inspection	of	 the	skin	 in	clinical	work-up	of	CS	and	 also	 actively	 screening	 patients	 with	 extracardiac	 sarcoidosis	 (164,274).	 In	 the	largest	 multicenter	 CS	 study	 of	 235	 patients,	 chest-computed	 tomography	 was	frequently	 performed	 and	 no	 less	 than	 83.8%	 of	 patients	 had	 pulmonary	 sarcoidosis	(129).		It	is	possible	that	on	a	microscopical	level,	all	sarcoidosis	patients	have	lesions	in	extracardiac	organs,	but	 from	a	cardiologist’s	perspective,	 it	 is	 important	 to	recognize	the	 clinical	 entity	 of	 CS,	 as	 it	 makes	 diagnosis	 much	more	 challenging.	 There	 are	 no	sensitive	 biomarkers	 thus	 far	 to	 help	 in	 the	 detection	 of	 cardiac	 involvement	 in	sarcoidosis,	and	further	investigation	is	needed	to	assess	the	value	of	hs-cTnT/I	in	this	respect.		In	our	cohort,	more	severe	LV	involvement	and	the	female	gender	were	associated	with	isolated	 CS.	 Recently,	 Tezuka	 et	 al.	 also	 found	 a	 correlation	 between	 lower	 LVEF	 and	isolated	 CS	 (164).	 The	 female	 predominance	might	 be	 explained	 by	 different	 disease	manifestations	between	genders	in	myocarditis	and	cardiomyopathy	(275).	We	found	a	worse	 event-free	 survival	 in	 isolated	 CS	 patients	 compared	 to	 systemic	 CS	 patients	when	aborted	sudden	death	was	included	as	an	outcome	event.	This	might	be	because	of	 higher	 frequency	 of	 ventricular	 arrhythmias	 as	 the	 presenting	 manifestation	 in	isolated	 CS.	 Although	 the	 reason	 for	 the	 VT	 proneness	 is	 unknown,	 similarly	 to	 our	finding	a	recent	large	study	of	CS	patients	with	ICD	demonstrated	69%	of	patients	with	isolated	 CS	 receiving	 appropriate	 ICD	 therapies	 compared	 to	 34%	 of	 patients	 with	systemic	CS	(99).	Finally,	 the	overall	clinical	consequences	of	 isolated	CS	remain	to	be	elucidated	in	larger	studies.		
6.2.2.3	GCM	and	comparison	with	CS	In	GCM,	the	mean	age	of	53	±	13	years	in	our	cohort	was	slightly	higher	than	in	previous	studies,	with	 a	mean	 age	 of	 42-48	 years	 (5,9,11,63).	 This	might	 have	 implications	 on	prognosis,	 since	 young	 age	 is	 possibly	 linked	 to	 worse	 outcome	 in	 myocarditis	(11,64,105).	The	GCM	patients	 in	our	 study	were	 female	 in	69%,	whereas	 the	 largest	patient	 series	 showed	 no	 gender	 difference	 (5,11).	 It	 has	 been	 speculated	 that	 sex	differences	might	play	a	role	in	myocarditis,	with	testosterone	promoting	more	severe	disease	in	men,	but	this	theory	has	not	been	confirmed	(275).	In	GCM	patients,	LVEF	at	diagnosis	 was	 reduced	 in	 74%	with	 a	 median	 of	 38	 ±13%,	 which	 is	 consistent	 with	earlier	 reports	 (9,11,63).	 Moreover,	 we	 discovered	 some	 support	 for	 the	 genetic	predisposition	 speculated	 in	 earlier	 studies	 (11,26,60),	 as	 two	patients	with	as	 rare	a	disorder	as	GCM	were	siblings.	GCM	is	associated	with	fulminant	onset	and	frequently	fatal	outcome	(5,11),	although	a	latent	and	prolonged	clinical	course	has	been	described	(5,8,37).	Our	study	confirms	the	heterogenic	 nature	 of	 the	 disease.	 The	 presenting	 manifestations,	 including	 heart	failure,	 ventricular	 arrhythmias,	 sudden	 death	 and	 conduction	 disturbances,	 were	
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comparable	 with	 previous	 studies,	 but	 their	 frequency	 was	 somewhat	 different.	 We	found	AV-block	as	 the	 first	manifestation	 in	31%	of	cases,	which	 is	higher	than	the	5-15%	reported	in	prior	multicenter	studies	(5,11).	This	difference	might	be	explained	by	differences	in	diagnostic	protocols	between	the	earlier	studies	and	ours,	given	that	we	applied	an	exceptionally	proactive	work-up	in	patients	with	AV-block.		Thus,	in	contrast	to	 earlier	 data	 (5),	 our	 finding	 implies	 that	 presentation	 with	 AV-block	 does	 not	differentiate	GCM	from	CS,	although	AV-block	is	more	common	in	CS.			Previous	 data	 indicates	 that	 GCM	 and	 CS	 have	 many	 resemblances	 in	 etiology,	pathophysiology	 and	 clinical	 picture,	 although	 they	 are	 distinctive	 clinicopathologic	entities	 (5,7,26,27).	 Our	 findings	 on	 clinical	 manifestations	 and	 outcome	 support	 the	previous	concept	that	despite	overlapping	features,	GCM	and	CS	are	separate	diseases.	More	specifically,	we	observed	a	shorter	median	time	from	first	cardiac	manifestation	to	diagnosis	 of	 three	months	 (range	 0-16)	 in	 GCM,	 compared	 to	 9.5	months	 (range	 0.3-168)	 in	 CS,	 pointing	 towards	 a	 more	 rapid	 clinical	 course	 in	 GCM.	 At	 diagnosis,	 the	patients	with	GCM	had	only	slightly	lower	LVEF	of	38	±13%,	in	comparison	with	45%	±14	 in	CS,	but	during	 the	disease	course,	GCM	patients	more	often	developed	systolic	heart	failure	(90%	vs	67%).	Consistently,	severe	heart	failure	leading	to	transplantation	was	 more	 common	 in	 GCM	 (31%	 vs	 10%),	 and	 the	 arrhythmia	 burden	 was	 higher.	Finally,	 the	 marked	 differences	 in	 survival	 rates	 discussed	 below	 are	 in	 line	 with	previous	works.			
6.2.3	Disease	course	and	the	effect	of	treatment	in	CS	
6.2.3.1	LV	function	In	line	with	other	large	studies	(77,97,99,129),	the	median	LVEF	at	the	time	of	diagnosis	was	mildly	reduced	(45%	±14%)	and	patient	series	with	both	lower	(115)		and	higher	(6)	 initial	 EF	 exist.	 During	 the	 disease	 course,	 two-thirds	 of	 our	 patients	 had	 systolic	dysfunction	(defined	as	EF	<50%)	but	data	for	comparison	are	lacking.	Prior	to	clinical	awareness	and	modern	diagnostic	methods,	CS	commonly	manifested	as	symptomatic	heart	 failure	 (19),	 but	 in	 our	 study	 as	 in	 other	 recent	 studies	 (93,146),	 overt	 heart	failure	was	more	rare.	Similarly	to	other	types	of	cardiomyopathies,	ours	and	other	CS	studies	 (6,97,98,129)	 show	 that	 LVEF	 is	 an	 important	 prognostic	 factor	 in	 CS.	 In	 our	study,	the	outcome	was	worst	 in	patients	with	severe	systolic	dysfunction	(EF	<35%),	but	the	difference	was	small	between	the	patients	with	mildly	reduced	(EF	35-50%)	and	normal	(>50%)	EF.	Furthermore,	RV	dysfunction	has	recently	been	reported	to	be	not	only	 common	 but	 also	 predisposing	 to	 ventricular	 arrhythmias	 in	 CS	 (98).	 However,	since	 evaluating	 RV	 function	 by	 echocardiography	 is	 challenging	 and	 not	 routinely	quantified,	we	did	not	analyze	it.	
6.2.3.2	AV-block	Overall,	the	high	frequency	of	AV-conduction	disturbances	of	52%	observed	during	the	disease	course	of	CS	was	comparable	with	previous	reports	(5,16,77,97).	In	small	series	
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of	up	to	12	patients,	the	number	of	patients	whose	AV-conduction	recovered	in	time	or	with	corticosteroids	was	reported	to	be	33-75%	(124,246,248)	 in	comparison	to	20%	in	our	study.	Besides	small	sample	sizes,	 these	differences	might	result	 from	different	definitions	 of	 AV-recovery,	 as	 in	 our	 study	 it	 was	 roughly	 estimated	 by	 <10%	 of	ventricular	pacing	and	in	the	studies	focusing	on	assessing	conduction,	more	specifically	examined	by	Holter	monitorings	and	ECGs.			
6.2.3.3.	Arrhythmias	CS	 presented	 as	 ventricular	 arrhythmias	 in	 33%	 of	 patients,	 which	 is	 in	 line	 with	previous	 and	 preceding	 studies	 (5,93,97,128,129).	 ICD	 was	 implanted	 in	 54%	 of	patients	and	the	indication	was	secondary	prevention	in	two-thirds	of	them,	whereas	in	the	 recent	 studies	 from	 the	 U.S.	 over	 two-thirds	 of	 ICDs	were	 implanted	 for	 primary	prevention	 (98,128,129).	 After	 the	 study	 period,	 with	 accumulating	 information,	 the	implantation	 protocol	 in	 Finland	 has	 changed	 towards	 a	 more	 active	 primary	prevention	strategy.	At	the	median	follow-up	of	4.4	years	from	ICD	implantation,	41%	of	the	 59	 Finnish	 CS	 patients	 with	 ICD	 received	 an	 appropriate	 ICD	 therapy,	 which	corresponds	to	the	therapy	rate	in	recent	studies	(98,129).	Furthermore,	the	increase	in	non-sustained	 VT	 frequency	 on	 follow-up	 should	 be	 regarded	 as	 a	 sign	 of	 potential	disease	activation.	
	 	 	
6.2.3.4	Assessment	of	immunosuppressive	treatment	response	All	the	published	clinical	series	suggest	that	corticosteroid	therapy	modifies	the	clinical	course	 in	 CS	 (5,6,97,115,124,246,248,249).	 If	 treatment	 is	 initiated	 early	 on,	 systolic	heart	 failure	seems	to	develop	rarely,	whereas	those	with	reduced	LV	function	have	a	poor	 prognosis	 despite	 initiation	 of	 treatment	 (6,97).	 The	 corticosteroid	 treatment	protocol	in	our	study	was	not	uniform	but	similar	to	older	studies	(6,97,244).	Our	study	confirms	 that	 reduced	 LVEF	 is	 associated	 with	 worse	 prognosis	 despite	immunosuppressive	treatment.	However,	 in	contrast	to	earlier	findings	demonstrating	benefit	from	corticosteroids	in	mild	to	moderate	systolic	heart	failure	(6,115)	our	data	demonstrated	 a	 small	 yet	 significant	 improvement	 in	 LVEF	 in	 patients	 with	 severely	reduced	 LVEF	 (<35%),	 but	 no	 change	 in	 normal	 or	moderately	 depressed	 LVEF.	 The	deficiency	 in	 our	 study	 as	 in	 others	 is	 that	 we	 do	 not	 know	 how	 LVEF	 would	 have	resulted	in	the	absence	of	corticosteroid	treatment.	Furthermore,	the	echocardiographic	evaluation	 of	 LVEF	 is	 prone	 to	 divergence	 between	 operators,	 notably	 when	 LV	 is	dilated.	 Similarly	 to	 earlier	 studies,	 no	 conclusions	 on	 survival	 benefit	 from	immunosuppressants	could	be	drawn,	since	all	the	patients	diagnosed	before	death	or	transplantation	 received	 immunomodulatory	 treatment	 and	 respectively	 the	 ones	without	treatment	were	diagnosed	at	death	or	transplantation.		
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Concerning	 steroid-sparing	agents,	methotrexate	 is	 the	most	widely	 studied	and	used	antimetabolite	in	sarcoidosis	treatment	(29,276).	In	contrast,	in	our	cohort	azathioprine	was	significantly	more	commonly	used	(50	vs	six	patients).	There	are	differences	in	the	side-effect	 profile	 between	 the	 two	 drugs.	 Azathioprine	 is	 associated	 with	 more	infections,	 leading	to	discontinuation	of	the	drug,	 leucopenia,	nausea,	and	pancreatitis,	whereas	methotrexate	involves	more	frequent	hepatotoxic	effects	(276).	An	important	aspect	 in	 choosing	drug	 treatment	 is	 clinicians’	user	experience.	For	example,	 at	HUH	azathioprine	has	been	used	for	a	long	time	in	treating	cardiac	transplant	patients.	
	
6.2.4	Serious	outcome	events	and	survival	
6.2.4.1	In	CS	Prior	knowledge	on	CS	prognosis	is	based	on	retrospective	series	and	small	prospective	studies	 (5,16,22,97,109)	 mostly	 involving	 patients	 with	 extracardiac	 sarcoidosis	screened	 for	 cardiac	 involvement	 (91,93,96).	 In	 the	 largest	 retrospective	multicenter	study	by	Yazaki	et	al.	from	Japan,	the	overall	survival	rate	in	CS	was	60%	at	five	years	in	all	 95	 patients	 and	 75%	 in	 patients	 diagnosed	 before	 death	 (97).	 Similarly,	 the	international	collaboration	study	from	Okura	et	al.	reported	transplant-free	survival	of	60%	at	 five	years	 in	all	42	patients	and	70%	in	patients	diagnosed	at	EMB	(5).	 In	our	cohort,	 the	 five-year	 transplant-free	 cardiac	 survival	was	90%	 in	all	110	patients	and	95%	in	102	patients	diagnosed	prior	to	death	or	transplantation.	Although	these	figures	cannot	 be	 directly	 compared	 since	 our	 numbers	 denote	 cardiac	 survival	 and	 the	previous	studies	included	non-cardiac	deaths,	the	outcome	seems	more	favorable	in	the	present	study.	The	possible	reasons	for	better	survival	could	be	earlier	diagnosis	with	shorter	delay	from	symptom	onset	to	diagnosis	in	our	study	(median	9.5	months,	range	0.3-168	vs	mean	29.7	±	53.3	in	the	study	of	Okura	et	al.)(5).	Alternatively,	compared	to	the	 earlier	 studies,	 the	 immunosuppressive	 treatment	 has	 not	 changed	markedly	 but	there	has	been	development	in	respect	to	arrhythmia	treatment.	In	our	study	ICD	was	implanted	in	54%	vs	24%	in	the	study	by	Okura	et	al.	The	high	frequency	of	ventricular	arrhythmias	 and	particularly	 the	high	number	of	 aborted	 sudden	deaths	 in	our	 study	supports	 this	 theory.	 Lastly,	 differences	 in	 genetic	 backgrounds	 between	 the	populations	might	have	an	impact	on	the	outcome	(49,75,277).			
6.2.4.2	In	GCM		Considering	the	outcome	of	GCM	instead,	our	results	suggest	improved	prognosis	with	combined	 immunosuppressive	 treatment.	Previous	data	on	 the	natural	course	of	GCM	demonstrated	a	grim	prognosis,	with	a	median	transplant-free	survival	of	three	months	from	 symptom	 onset	 but	 a	 significant	 survival	 benefit	 with	 a	 combination	 of	immunosuppression	therapy	including	cyclosporine	(11).	Comparably,	an	international	multicenter	study	demonstrated	a	five-year	transplant-free	survival	probability	of	10%	in	 all	 73	 patients	 and	 22%	 transplant-free	 survival	 in	 38	 patients	 diagnosed	 before	
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death	or	transplantation	and	treated	with	at	 least	corticosteroids	(5).	In	our	study	the	corresponding	 five-year	 survival	probabilities	of	 transplant-free	 survival	were	higher;	52%	in	all	32	patients	and	63%	in	26	patients	receiving	 immunosuppressive	 therapy,	respectively.	 Besides	 active	 and	 potent	 drug	 treatment	 with	 multiple	immunosuppressants,	the	promptness	in	diagnostics	and	possibly	demographic	factors	might	explain	the	ameliorated	survival	rates	in	our	study.	Furthermore,	similarly	to	CS,	the	increased	frequency	of	ICDs	might	have	improved	the	survival	of	GCM	patients.		
6.3	Clinical	implications	and	future	directions		The	results	of	this	work	could	have	an	impact	on	the	diagnostics	and	management	of	CS	and	 GCM	patients	 in	 clinical	 practice.	Most	 importantly,	 the	 finding	 that	 CS	 and	 GCM	together	cause	25%	of	initially	unexplained	AV-blocks	in	young	to	middle-aged	patients	(II)	 has	 been	 acknowledged	 by	 the	 authors	 of	 the	 AHA/ACCF/ESC	 EMB	 guidelines	(234,278).	 Based	 on	 our	 results,	 they	 stated	 that	 EMB	 should	 probably	 be	 a	 class	 2A	recommendation	 (a	 reasonable	procedure)	 in	AV-block	patients	with	a	 similar	 risk	 to	CS/GCM	 (depending	 on	 age,	 ethnicity	 and	 exclusion	 of	 more	 common	 causes)	 (278).	Second,	 in	 case	 of	 high	 suspicion	 of	 CS,	 imaging-guided	 biopsies	 of	 the	 heart	 or	mediastinal	lymph	nodes,	repeated	if	necessary,	can	be	useful	as	they	markedly	increase	the	 diagnostic	 yield	 (I,II).	 Sampling	 “hot”	 18F-FDG-PET	 positive	 lymph	 nodes	 in	mediastinoscopy	has	become	clinical	practice	at	HUH,	since	our	findings	demonstrated	the	 high	 (close	 to	 100%)	 sensitivity	 of	 this	 approach	 (279).	 Third,	 hs-cTnT/I	 have	emerged	as	sensitive	and	easily	repeatable	markers	that	are	routinely	used	at	HUH	as	additional	tools	in	assessing	disease	activity	and	treatment	modifications	in	the	follow-up	 of	 CS.	 Fourth,	 referring	 to	 our	 study	 (V),	 the	 2015	 ESC	 guidelines	 for	 the	management	 of	 ventricular	 arrhythmias	 stated	 that	 the	 presence	 of	 malignant	ventricular	 arrhythmias	 or	 heart	 block	 in	 GCM	 or	 CS	 might	 warrant	 earlier	consideration	of	an	ICD	due	to	the	known	high	risk	of	arrhythmic	death	or	the	need	for	transplantation	(280).	An	 important	 aspect	 of	 this	 study	 lies	 in	 raising	 awareness	 and	 diagnostic	 activity	towards	 CS	 and	 GCM.	 At	 best,	 increased	 knowledge	 enables	 earlier	 diagnosis	 and	treatment	prior	 to	LV	dysfunction,	which	 in	 turn	 is	 likely	 to	 result	 in	better	outcome.	Although	rare	diseases,	CS	and	GCM	should	be	kept	in	mind	in	cases	with	unexplained	DCM,	 ventricular	 arrhythmias	 and	 AV-block,	 particularly	 in	 young	 to	 middle-aged	adults.	Further	 research	 on	 CS	 and	 GCM	 is	 needed	 to	 elucidate	 the	 underlying	 mechanisms	behind	these	enigmatic	diseases	and	ultimately	to	 improve	the	outcome.	 In	enhancing	diagnostic	accuracy,	new	imaging	methods,	such	as	T1	mapping	CMR	(281)	and	novel	PET	 isotopes	 (282)	 offer	 interesting	 targets.	 Moreover,	 more	 sensitive	 EMBs,	 using	immunohistochemistry	and	molecularbiology	methods	(gene	sequencing,	RNA	profiling	etc.)	 are	 highly	 expected.	 Considering	 the	 treatment,	 assessing	 optimal	 drug	 regimen	
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and	 combinations	 should	 be	 studied.	 Possibly	 a	 similar	 treatment	 approach	 as	 in	rheumatoid	 arthritis,	 involving	 rapid	 reductions	 in	 corticosteroid	 doses	 and	 a	 low	threshold	 for	 monoclonal	 antibodies	 in	 treatment	 resistant	 cases,	 could	 be	 applied.	However,	 the	 best	 regimen	 should	 be	 tested	 in	 randomized	 controlled	 trials.	 Large	prospective	multicenter	registries	are	needed	for	the	implication	of	the	studies	in	both	CS	and	GCM.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 	 	 			 96	
7	CONCLUSIONS		The	present	 study	was	 initiated	by	 the	 clinical	 observation	 that	 the	number	of	 young	people	contracting	CS,	a	disease	with	indeterminate	etiology,	diagnostics	and	outcome,	was	increasing	at	our	institution.	We	found	that:	1.	The	detection	rate	of	CS	 increased	over	50-fold	over	the	26-year	study	period	from	1988	to	2014.	The	annual	detection	rate	of	biopsy-confirmed	CS	was	0.6	per	100	000	adults	 (>18	 years)	 in	 the	 last	 two-year	 study	 period	 between	 2012	 and	 2014.	 The	prevalence	of	CS	in	2012	was	2.2	per	100	000.		2.	CS	and	GCM	together	explain	25%	of	2nd	to	3rd	degree	AV-blocks	in	adults	aged	18-55	years	in	whom	the	etiology	of	AV-block	is	unknown	at	presentation.	3.	 Repeated,	 imaging-guided	 EMBs	 improve	 the	 diagnostic	 accuracy	 in	 CS.	 The	sensitivity	 of	 first	 EMB	 was	 31%,	 but	 second	 and	 third	 EMB	 sessions	 increased	 the	sensitivity	to	55%.	4.	 Sarcoidosis	 can	 manifest	 as	 a	 clinically	 isolated	 cardiac	 disorder	 without	 signs	 or	symptoms	 from	 extracardiac	 organs.	 Two-thirds	 of	 CS	 patients	 had	 solely	 cardiac	manifestations.	Clinically	isolated	CS	was	characterized	by	more	severe	LV	dysfunction	and	female	predominance.	5.	 The	 outcome	 of	 CS	 with	 current	 diagnostics	 and	 treatment	 appears	 better	 than	previously	reported.	 In	CS	patients	diagnosed	before	death	or	transplantation,	 the	10-year	cardiac	transplant-free	survival	was	91%.	6.	Hs-cTnT/I	are	 frequently	elevated	 in	new-onset	CS.	The	concentrations	rapidly	and	consistently	decrease	with	corticosteroid	treatment.		7.	 The	 prognosis	 of	 GCM	 with	 current	 diagnostics	 and	 treatment	 appears	 better	compared	to	older	studies.	In	GCM	patients	diagnosed	before	death	or	transplantation,	the	five-year	cardiac	transplant	free	survival	was	63%.							
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